WO2004020591A2 - Methodes d'utilisation de nouveaux polypeptides humains codes par des polynucleotides - Google Patents

Methodes d'utilisation de nouveaux polypeptides humains codes par des polynucleotides Download PDF

Info

Publication number
WO2004020591A2
WO2004020591A2 PCT/US2003/026864 US0326864W WO2004020591A2 WO 2004020591 A2 WO2004020591 A2 WO 2004020591A2 US 0326864 W US0326864 W US 0326864W WO 2004020591 A2 WO2004020591 A2 WO 2004020591A2
Authority
WO
WIPO (PCT)
Prior art keywords
cell
antibody
polypeptide
protein
proteins
Prior art date
Application number
PCT/US2003/026864
Other languages
English (en)
Other versions
WO2004020591A3 (fr
Inventor
Lewis T. Williams
Keting Chu
Ernestine Lee
Kevin Hestir
Pierre Alvaro Beaurang
Dirk Behrens
Robert Forgan Halenbeck
Min Mei Huang
Srinivas Kothakota
Lin Haishan
Thomas Linnemann
Kristen Pierce
Yan Wang
Justin G. P. Wong
Ge Wu
Hongbing Zhang
Original Assignee
Five Prime Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics, Inc. filed Critical Five Prime Therapeutics, Inc.
Priority to AU2003265787A priority Critical patent/AU2003265787A1/en
Publication of WO2004020591A2 publication Critical patent/WO2004020591A2/fr
Publication of WO2004020591A3 publication Critical patent/WO2004020591A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • the present invention is related generally to novel polynucleotides and novel polypeptides encoded thereby, their compositions, antibodies directed thereto, and other agonists or antagonists thereto.
  • the polynucleotides and polypeptides are useful in diagnostic, prophylactic, and therapeutic applications for a variety of diseases, disorders, syndromes and conditions, as well as in discovering new diagnostics, prophylactics, and therapeutics for such diseases, disorders, syndromes, and conditions (hereinafter disorders).
  • the present invention also relates to methods of modulating biological activities through the use of the novel polynucleotides and novel polypeptides of the invention and through the use of agonists and antagonists, such as antibodies, thereto.
  • This application further relates to the field of polypeptides that are associated with regulating cell growth and differentiation, that are over-expressed in cancer, and/or that can be associated with proliferation or inhibition of cancer growth, including hematopoietic cancers such as leukemias, lymphomas, and solid cancers such as lung cancer, for example, adenocarcinomas and/or squamous cell carcinomas.
  • hematopoietic cancers such as leukemias, lymphomas, and solid cancers such as lung cancer, for example, adenocarcinomas and/or squamous cell carcinomas.
  • These polypeptides may also be associated with other conditions, such as inflammatory, immune, and metabolic disorders, as well as microbial infections, including viral, bacterial, fungal, and parasitic diseases, disorders, syndromes, or conditions.
  • This application further relates to modulators of biological activity that can specifically bind to these polynucleotides or polypeptides, or otherwise specifically modulate their activity. For example, they can directly or indirectly induce antibody-dependent cellular cytotoxicity (ADCC), complement- dependent cytotoxicity (CDC), endocytosis, apoptosis, or recruitment of other cells to effect cell activation, cell inactivation, cell growth or differentiation or inhibition thereof, and cell killing.
  • ADCC antibody-dependent cellular cytotoxicity
  • CDC complement- dependent cytotoxicity
  • endocytosis endocytosis
  • apoptosis or recruitment of other cells to effect cell activation, cell inactivation, cell growth or differentiation or inhibition thereof, and cell killing.
  • sequences of the invention encompass a variety of different types of nucleic acids and polypeptides with different structures and functions. They can encode or comprise polypeptides belonging to different protein families ("Pfam").
  • the "Pfam” system is an organization of protein sequence classification and analysis, based on conserved protein domains; it can be publicly accessed in a number of ways, for example, at http://pfam.wustl.edu.
  • Protein domains are portions of proteins that have a tertiary structure and sometimes have enzymatic or binding activities; multiple domains can be connected by flexible polypeptide regions within a protein.
  • Pfam domains can comprise the N-terminus or the C-terminus of a protein, or can be situated at any point in between.
  • the Pfam system identifies protein families based on these domains and provides an annotated, searchable database that classifies proteins into families (Bateman et al., 2002).
  • Sequences of the invention can encode or be comprised of more than one Pfam. Sequences encompassed by the invention include, but are not limited to, the polypeptide and polynucleotide sequences of the molecules shown in the Sequence Listing and corresponding molecular sequences found at all developmental stages of an organism. Sequences of the invention can comprise genes or gene segments designated by the Sequence Listing, and their gene products, i.e., RNA and polypeptides.
  • variants of those presented in the Sequence Listing that are present in the normal physiological state, e.g., variant alleles such as SNPs, splice variants, as well as variants that are affected in pathological states, such as disease-related mutations or sequences with alterations that lead to pathology, and variants with conservative amino acid changes.
  • Sequences of the invention are categorized below; any given sequence can belong to one or more than one category.
  • Secreted proteins also referred to as secreted factors, include proteins that are produced by cells and exported extracellularly, extracellular fragments of transmembrane proteins that are proteolytically cleaved, and extracellular fragments of cell surface receptors, which fragments may be soluble.
  • An example of a secreted protein is keratinocyte growth factor (KGF), which stimulates the growth of keratinocytes, and is useful for repairing tissue after chemotherapy or radiotherapy.
  • KGF keratinocyte growth factor
  • compositions of the present invention will have in common the ability to act as ligands for binding to receptors on cell surfaces in ligand/receptor interactions, to trigger certain intracellular responses, such as inducing signal transduction to activate cells or inhibit cellular activity, to induce cellular growth, proliferation, or differentiation, or to induce the production of other factors that, in turn, mediate such activities.
  • the cell types having cell surface receptors responsive to secreted proteins are various, including, for example, stem cells; progenitor cells; and precursor cells and mature cells of the hematopoietic, hepatic, neural, lung, heart, thymic, splenic, epithelial, pancreatic, adipose, gastrointestinal, colonic, optic, olfactory, bone and musculoskeletal lineages.
  • the hematopoietic cells can be red blood cells or white blood cells, including cells of the B lymphocytic (B cell), T lymphocytic (T cell), dendritic, megakaryocytic, natural killer (NK), macrophagic, eosinophilic, and basophilic lineages.
  • B cell B lymphocytic
  • T cell T lymphocytic
  • NK natural killer
  • macrophagic eosinophilic
  • basophilic lineages eosinophilic lineages.
  • the cell types responsive to secreted proteins also include normal cells or cells implicated in disease, disorders, syndromes, or other pathological conditions.
  • certain of the secreted proteins of the present invention can stimulate T or B cell growth or differentiation by interacting with precursor T or B cells or hematopoietic progenitor cells, or bone marrow stem cells.
  • certain secreted proteins of the present invention can maintain stem cells, progenitor cells or precursor cells in an undifferentiated state.
  • certain secreted proteins of the present invention can regulate bone growth by stimulation or inhibition thereof, secretion of insulin, glucose metabolism, cell proliferation, response to microbial infection, and regeneration of tissues including neural, muscular, and epithelial.
  • certain secreted proteins of the present invention can induce apoptosis such as in cancer cells or inflammatory cells.
  • Certain of the secreted proteins of the present invention are useful for diagnosis, prophylaxis, or treatment of disorders in subjects that are deficient in such secreted proteins or require regeneration of certain tissues, the proliferation of which is dependent on such secreted proteins, or requires an inhibition or activation of growth that is dependent on such secreted proteins.
  • disorders include cancer, such as bone cancer, brain tumors, breast and ovarian cancer, Burkitt's lymphoma, chronic myeloid leukemia, colon cancer, endocrine system cancers, gastrointestinal cancers, gynecological cancers, head and neck cancers, leukemia, lung cancer, lymphomas, malignant melanoma, metastases, multiple endocrine neoplasia, myelomas, neurofibromatosis, pancreatic cancer, pediatric cancers, penile cancer, prostate cancer, disorders related to the Ras oncogene, retinoblastoma (RB), sarcomas, skin cancers, testicular cancer, thyroid cancer, urinary tract cancers, and von Hippel-Lindau syndrome.
  • cancer such as bone cancer, brain tumors, breast and ovarian cancer, Burkitt's lymphoma, chronic myeloid leukemia, colon cancer, endocrine system cancers, gastrointestinal cancers, gynecological cancers
  • Certain of the secreted proteins herein can be used for diagnosis, prophylaxis, and treatment of disorders of hematopoeisis, including thrombosis; bleeding; anemias, e.g., iron deficiency and other hypoproliferative anemias, megaloblastic anemias, hemolytic anemias, acute blood loss, and aplastic anemia; hemoglobinopathies; disorders of granulocytes and monocytes; myelodysplasias and related bone marrow failure syndromes; polycythemias, e.g., polycythemia vera; acute and chronic myeloid leukemia, and other myeloproliferative diseases, e.g., malignancies of lymphoid cells; stimulation of replacement cell growth following irradiation or chemotherapy; and plasma cell disorders.
  • anemias e.g., iron deficiency and other hypoproliferative anemias, megaloblastic anemias, hemolytic anemias, acute blood loss,
  • Certain of the secreted proteins herein can be used for diagnosis, prophylaxis, and treatment of disorders of hemostasis, such as disorders of the platelet and vessel wall, disorders of coagulation and thrombosis, and anticoagulant, fibrinolytic and antiplatelet therapies.
  • Certain of the secreted proteins herein can be used for diagnosis, prophylaxis, and treatment of disorders of the cardiovascular system including disorders of the heart, such as heart failure; congenital heart disease; rheumatic fever; cor pulmonale; cardiomyopathies e.g., myocarditis; pericardial disease; cardiac tumors; cardiac manifestations of systemic diseases; and vascular diseases, such as acute myocardial infarction, ischemic heart disease, hypertensive vascular disease, diseases of the aorta, and vascular diseases of the extremities.
  • disorders of the heart such as heart failure; congenital heart disease; rheumatic fever; cor pulmonale; cardiomyopathies e.g., myocarditis; pericardial disease; cardiac tumors; cardiac manifestations of systemic diseases; and vascular diseases, such as acute myocardial infarction, ischemic heart disease, hypertensive vascular disease, diseases of the aorta, and vascular diseases of the extremities
  • Certain of the secreted proteins herein can be used for diagnosis, prophylaxis, and treatment of disorders of the respiratory system, such as asthma, hypersensitivity pneumonitis, e.g., with pulmonary infiltration, pneumonia, necrotizing pulmonary infections, bronchiectasis, cystic fibrosis, chronic bronchitis, emphysema and airway obstruction, interstitial lung diseases, primary pulmonary hypertension, pulmonary thromboembolism, disorders of the pleura, mediastinum, and diaphragm, disorders of ventilation, sleep apnea, and acute respiratory distress syndrome.
  • disorders of the respiratory system such as asthma, hypersensitivity pneumonitis, e.g., with pulmonary infiltration, pneumonia, necrotizing pulmonary infections, bronchiectasis, cystic fibrosis, chronic bronchitis, emphysema and airway obstruction, interstitial lung diseases, primary pulmonary hypertension, pulmonary thromboembolism, disorders of the
  • Certain of the secreted proteins herein can be used for diagnosis, prophylaxis, and treatment of disorders of the kidney and urinary tract, such as, for example, chronic renal failure and glomerulopathies.
  • Certain of the secreted proteins herein can be used for diagnosis, prophylaxis, and treatment of disorders of the gastrointestinal system, including disorders of the alimentary tract, such as, for example, peptic ulcer disease and related disorders, inflammatory bowel disease, irritable bowel syndrome; disorders of the liver and biliary tract, such as, for example, hyperbilirubinemias, acute viral hepatitis, chronic hepatitis, and cirrhosis; and disorders of the pancreas, such as acute or chronic pancreatitis.
  • Certain of the secreted proteins herein can be used for diagnosis, prophylaxis, and treatment of disorders of the immune system, connective tissue, and joints, including, for example, autoimmune diseases, primary immune deficiency diseases, human immunodeficiency virus diseases, allergies, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, Sjogren's syndrome, ankylosing spondylitis, reactive arthritis, vasculitis, sarcoidosis, amyloidosis, osteoarthritis, gout, psoriatic, and other arthritis.
  • Certain of the secreted proteins herein can be used for diagnosis, prophylaxis, and treatment of disorders of the endocrine system, including, for example, disorders of the pituitary, hypothalamus, neurohypophysis, thyroid gland, adrenal cortex, testes, ovary, and other organs of the female reproductive system, such as breast; as well as pheochromocytoma, diabetes mellitus, and hypoglycemia.
  • Certain of the secreted proteins herein can be used for diagnosis, prophylaxis, and treatment of disorders of bone and mineral metabolism, and other metabolic processes, including, for example, diseases of the parathyroid gland and other hyper- and hypocalcemic disorders, osteoporosis, Paget's disease and other dysplasia of bone, disorders of lipoprotein metabolism, hemochromatosis, porphyries, disorders of purine and pyrimidine metabolism, Wilson's disease, lysosomal storage diseases, glycogen storage diseases, lipodystrophies, and other primary disorders of adipose tissue.
  • Certain of the secreted proteins herein can be used for diagnosis, prophylaxis, and treatment of disorders of the central nervous system, including, for example, seizures and epilepsy, cerebrovascular diseases, Alzheimer's disease and other extrapyramidal disorders, ataxic disorders, amylotrophic lateral sclerosis and other motor neuron diseases, disorders of the autonomic nervous system, diseases of the spinal cord, including spinal cord injury, primary and metastatic tumors of the nervous system, multiple sclerosis, and other demyelinating diseases, as well as chronic and recurrent meningitis.
  • disorders of the central nervous system including, for example, seizures and epilepsy, cerebrovascular diseases, Alzheimer's disease and other extrapyramidal disorders, ataxic disorders, amylotrophic lateral sclerosis and other motor neuron diseases, disorders of the autonomic nervous system, diseases of the spinal cord, including spinal cord injury, primary and metastatic tumors of the nervous system, multiple sclerosis, and other demyelinating diseases, as well as chronic and recurrent
  • Certain of the secreted proteins herein can be used for diagnosis, prophylaxis, and treatment of disorders of nerves or muscle, including, for example, Guillain-Barre Syndrome, myasthenia gravis and other diseases of the neuromuscular junction, polymyositis, dermatomyositis, muscular dystrophies, and other muscle diseases.
  • Certain of the secreted proteins herein can be used for diagnosis, prophylaxis, and treatment of disorders of the skin, including, for example, eczema, psoriasis, cutaneous infections, acne, and other common skin disorders, and immunologically mediated skin diseases.
  • the agonists or antagonists of the secreted proteins herein or fragments thereof can be useful in treating elevated levels of such proteins in ny of the disorders above, and including angina, anoxia, arrhythmias, asthma, atherosclerosis, benign prostatic hyperplasia, Buerger's Disease, cardiac arrest, cardiogenic shock, cerebral trauma, Crohn's Disease, congenital heart disease, mild congestive heart failure (CHF), severe congestive heart failure, cerebral ischemia, cerebral infarction, cerebral vasospasm, cirrhosis, diabetes, dilated cardiomyopathy, endotoxic shock, gastric mucosal damage, glaucoma, head injury, hemodialysis, hemorrhagic shock, hypertension (essential), hypertension (malignant), hypertension (pulmonary), hypertension (e.g., pulmonary, after bypass), hypoglycemia, inflammatory arthritis, ischemic bowel disease, ischemic disease, male penile erectile dysfunction, malignant hemangio
  • TPR tetratricopeptide repeat
  • Secreted protein-related sequences e.g., cholesteryl ester transfer protein and phospholipid transfer protein
  • the inventors herein have identified novel secreted proteins using an algorithm that is constructed on the basis of a number of attributes including hydrophobicity, two-dimensional structure, prediction of signal sequence cleavage site, and other parameters. Based on such algorithm, a sequence that has a secreted tree vote of 0.5 — 1.0, preferably, 0.6 - 1.0, is believed to be a secreted protein.
  • Transmembrane proteins extend into or through the cell membrane's lipid bilayer; they can span the membrane once, or more than once. Transmembrane proteins that span the membrane once are “single transmembrane proteins” (STM), and transmembrane proteins that span the membrane more than once are “multiple transmembrane proteins” (MTM). Examples of transmembrane proteins include the insulin receptor, adenylate cyclase, and intestinal brush border esterase. [030] A single transmembrane protein typically has one transmembrane (TM) domain, spanning a series of consecutive amino acid residues, numbered on the basis of distance from the N-terminus, with the first amino acid residue at the N- terminus as number 1. A multi-transmembrane protein typically has more than one TM domain, each spanning a series of consecutive amino acid residues, numbered in the same way as the STM protein.
  • STM single transmembrane
  • MTM multiple transmembrane proteins
  • Transmembrane proteins having part of their molecules on either side of the bilayers, have many and widely variant biological functions. They transport molecules, e.g., ions or proteins across membranes, transduce signals across membranes, act as receptors, and function as antigens. Transmembrane proteins are often involved in cell signaling events; they can comprise signaling molecules, or can interact with signaling molecules.
  • tyrosine kinases can be transmembrane receptor proteins. Abnormalities of receptor tyrosine kinases are associated with human cancers; tumor cells are known to use receptor tyrosine kinases in transduction pathways to achieve tumor growth, angiogenesis and metastasis. Therefore, receptor tyrosine kinases represent pivotal targets in cancer therapy. It would be similarly advantageous to discover novel transmembrane proteins or polypeptides, and their corresponding polynucleotides that have additional medical utility.
  • transmembrane polypeptides of the invention like the secreted polypeptides, also have many different functional domains, and belong to a wide variety of Pfam families.
  • Transmembrane protein-related sequences can also possess or interact with domains designated as differentially expressed in neoplastic vs. normal cells "DENN" domains, which are involved in signal transduction.
  • MAP mitogen-activated protein
  • ACBP acyl coA binding protein
  • Transmembrane proteins that are differentially expressed on the surface of cancer cells are desirable targets for production of antibodies, e.g., diagnostic antibodies or therapeutic antibodies, such as antibodies that mediate ADCC or CDC to effect tumor cell killing.
  • Transmembrane proteins with extracellular fragments that can be cleaved can be useful as secreted proteins to effect ligand/receptor binding so as to mediate intracellular responses, such as signal transduction.
  • Transmembrane proteins that act as receptors, and possess a ligand binding extracellular portion exposed on a cell surface and an intracellular portion that interacts with other cellular components upon activation can be also be useful as transmembrane proteins to mediate intracellular responses, such as signal transduction.
  • a kinase is an enzyme that catalyzes the transfer of phosphate groups from phosphate donors to acceptor substrates.
  • Kinase substrates include, but are not limited to, proteins and lipids. Sequences of the invention that phosphorylate protein substrates are designated "Pkinases.” Examples of kinase-related sequences include calcium, calmodulin-dependent protein kinase II, myosin light chain kinase, and phosphatidlyinositol kinase.
  • Kinases and phosphatases are counteracting: kinases add phosphate groups and phosphatases liberate phosphate groups.
  • kinases and phosphatases provide cells with a "switch" that can turn on or turn off the function of various proteins.
  • the activity of any protein regulated by phosphorylation depends on the balance, at any given time, between the activities of the kinase(s) that phosphorylate it, and the phosphatase(s) that dephosphorylate it.
  • Phosphorylation plays a important role in intercellular communication during development, homeostasis, and the function of major bodily systems, including the immune system.
  • kinases control such diverse and essential cellular processes as transcription, cell division, cell cycle progression, differentiation, cytoskeletal function, apoptosis, receptor function, learning and memory, hematopoeisis, fertilization, neural transmission, muscle contraction, non- muscle motor function, glycogen metabolism, and hormone secretion.
  • kinases act within a network of kinases and other signaling effectors, and are modulated by autophosphorylation and phosphorylation by other kinases (Manning et al., 2002). Intracellular signaling involves a multitude of diverse mechanisms that combine to modulate the activity of individual proteins in response to different biological inputs.
  • Defects in cell signal transduction pathways are responsible for a number of disorders, including the majority of cancers, immune disorders, and many inflammatory conditions, including, but not limited to, Crohn's disease (Geffen and Man, 2002; Nan Den Blink et al., 2002; Lodish 1999).
  • Over-expression and/or structural alteration of kinases for example, receptor tyrosine kinase family members, is often associated with human cancers.
  • tumor cells are known to use receptor tyrosine kinases in transduction pathways to achieve tumor growth, angiogenesis and metastasis. Therefore, receptor tyrosine kinases represent pivotal targets in cancer therapy.
  • a number of small molecule receptor tyrosine kinase inhibitors have been synthesized, are in clinical trials, are being analyzed in animal models, or have been marketed.
  • Inhibitory mechanisms include ligand-dependent down regulation, e.g., by the adaptor Cbl (Brunelleschi et al., 2002).
  • kinases by virtue of their participation in many and varied intracellular activities, are useful as targets of therapeutic intervention such as, for example, in cancer and inflammation.
  • Cells transfected with cDNA encoding a kinase can be used in screening for small molecule agonists or antagonists, for example.
  • Ligases are enzymes that join together, or ligate, two molecules.
  • Ligase substrates include nucleic acids and proteins.
  • DNA ligases link two DNA molecules together; they play a role in DNA repair and replication.
  • DNA ligases also are involved in the rearrangement of immunoglobulin gene segments, such as those responsible for the generation of antibody diversity.
  • protein ligases include ubiquitin protein ligases, which add an ubiquitin molecule to an amino acid residue, typically as part of a peptide or polypeptide.
  • nucleic acid ligases include DNA ligase I, DNA ligase III alpha, and T4 RNA ligase 2.
  • GCL glutamate-cysteine ligase
  • GCL glutamate-cysteine ligase
  • Polymorphisms of human GCL account for differences in sensitivity to environmental toxicants and chemotherapeutic agents in human cancer cell lines (Walsh et al., 2001).
  • glutamate- ammonia ligase, or glutamine synthetase (GS) is expressed at a higher than normal level in human primary liver cancer, and may be involved in hepatocyte transformation (Christa et al., 1994).
  • 2_5_ligase 2 ',5' RNA ligase domains
  • ligases are also useful as targets for identification of agonists and antagonists, such as small molecule drugs.
  • Receptor-Related Sequences including Nuclear Hormone and T-Cell Receptors
  • a receptor is a polypeptide that binds to a specific signaling molecule and initiates a cellular response.
  • Receptors can be present on the cell surface or inside the cell.
  • Example of receptor types include G-protein-linked receptors, ion channel-linked receptors, enzyme-linked receptors, T-cell receptors, thyroid hormone receptors, retinoid receptors, nuclear hormone receptors, and the related category of steroid hormone receptors, e.g., cortisol receptors (Alberts et al., 1994).
  • G-protein-linked receptors transduce extracellular signals into intracellular responses by interacting with guanine nucleotide binding proteins.
  • the same ligand can activate many different G-protein-linked receptors.
  • G-protein-linked receptors mediate cellular responses to a diverse range of signaling molecules, including hormones, neurotransmitters, and local mediators, which are varied in structure and function, and encompass proteins and small peptides, as well as amino acids and their derivatives, and fatty acids and their derivatives. Many signaling molecules are active at low concentrations, and their receptors often bind with high affinity. Examples of G-protein-linked receptors include, but are not limited to, rhodopsins, olfactory receptors, and ⁇ -adrenergic receptors.
  • Ion channel-linked receptors are involved in synaptic signaling.
  • ion channel-linked receptors regulate ion channels, to which they are linked. Some respond to signals from neurotransmitters, e.g., acetylcholine, serotonin, GABA, and glycine.
  • a common mechanism of action for ion channel-linked receptors is to transiently open or close their respective ion channel, transiently changing the permeability of the membrane in which they reside to a specific ion or ions.
  • Enzyme-linked receptors can be linked to enzymes or can function as enzymes. Their ligand binding site is commonly on one side of the membrane, e.g., an extracellular domain, and the catalytic site is on the other, e.g., a cytoplasmic domain.
  • Transmembrane tyrosine-specific protein kinase receptors for growth and differentiation factors are enzyme-linked receptors; examples include receptors for epidermal growth factor (EGF), platelet-derived growth factor (PDGF), fibroblast growth factors (FGFs), hepatocyte growth factors (HGF), insulin, insulin like growth factor-1 (IGF-1), nerve growth factor (NGF), vascular endothelial growth factor (VEGF), and macrophage colony stimulating factor (M-CSF).
  • EGF epidermal growth factor
  • PDGF platelet-derived growth factor
  • FGFs fibroblast growth factors
  • HGF hepatocyte growth factors
  • IGF-1 insulin like growth factor-1
  • NGF nerve growth factor
  • VEGF vascular endothelial growth factor
  • M-CSF macrophage colony stimulating factor
  • Nuclear hormone receptors generally function by crossing the plasma membrane of target cells and binding to intracellular protein ligands. Ligand binding activates these receptors in some instances, exposing a DNA binding domain which regulates the transcription of specific genes. Generally, nuclear hormone receptors bind to specific DNA sequences adjacent to or in the vicinity of the genes regulated by their ligand. A host of cell type-specific regulatory proteins can collaborate with the nuclear hormone receptor to influence the transcription of specific genes or sets of genes (Alberts et al., 1994).
  • nuclear hormone receptors examples include estrogen-related receptors, such as hERRl, which modulates the estrogen receptor-mediated response of the lactoferrin gene promoter (Yang et al., 1996), and is a transcriptional regulator of the human medium chain acyl coenzyme A dehydrogenase gene (Sladek et al., 1997).
  • nuclear hormone receptors also include photoreceptor-specific nuclear receptors, such as NR2E3, which are part of a large family of nuclear receptor transcription factors involved in signaling pathways. NR2E3 plays a role in cone function and human retinal photoreceptor differentiation and degeneration (Milam et al., 2002; Kobayashi et al., 1999).
  • T-cell receptors are membrane proteins comprised of two disulfide-linked polypeptide chains, each with two immunoglobulin-like domains. They display a similarity to antibodies in that they have a variable amino-terminal region and a constant carboxyl-terminal region which is coded for by variable, joining, and constant region genes (Wei et al., 1997; Alberts et al., 1994). Rearrangement of T-cell receptor genes have been associated with human T-cell leukemias (Fisch et al., 1993).
  • Receptors are involved in cellular processes that regulate growth and differentiation. Their dysregulation can lead to hyperproliferative conditions, and they are common therapeutic targets.
  • the EGF receptor is aberrantly activated in neoplasia, especially in tumors of epithelial origin. EGF receptor antagonists can successfully treat some of these tumors, either alone or in combination with chemotherapy or ionizing radiation (Kari et al., 2003).
  • the progesterone receptor an intracellular steroid hormone receptor, plays a role in the development and function of the mammary gland, the uterus, and the ovary. Mutation or aberrant expression of the progesterone receptor, or its regulatory molecules, can affect its normal function and lead to cancer (Gao and Nawaz, 2002).
  • Receptors are also involved in cellular processes that regulate inflammation and immunity.
  • members of the type 1 interleukin-1 receptor family mediate immune and inflammatory responses, and function in host defense.
  • Their activation can lead to the activation of signaling cascades, e.g., pathways involving transcription factors and protein kinases, resulting in an inflammatory response (O'Neill, 2002).
  • Another mechanism by which receptors regulate inflammation and immunity is by their selective expression, at discrete stages of differentiation, by cells involved in the inflammatory response.
  • triggering receptor expressed on myeloid cells TERT-1
  • myeloid DAP12-associating lectin MDL-1
  • Receptor-related sequences can also possess or interact with LI transposable element (transposase_22) domains, some of which have been characterized to exhibit reverse transcriptase activity, and some of which are capable of retrotransposition.
  • Ribosomal_L10e ribosomal L10 domains
  • Receptor-related sequences can possess or interact with zinc finger C4 type domains, which are DNA binding domains of nuclear hormone receptors that share a conserved cysteine-rich region of approximately 65 amino acids and regulate such diverse biological processes as pattern formation, cellular differentiation, and homeostasis (http://www.sanger.ac.uk/cgi-bin/Pfam/getacc? PF00105).
  • Receptor-related sequences can also possess or interact with a ligand binding domain of nuclear hormone receptors (hormonejrec), which are helical domains involved in the regulation of eukaryotic gene expression, cellular proliferation, and differentiation in target tissues (http://www.sanger.ac.uk/cgi- bin/Pfam/getacc?PF00104).
  • Receptor-related sequences can also possess or interact with Mov34 domains, which are regulatory subunits of the proteasome found in some regulators of transcription factors (http://www.sanger.ac.uk/cgi-bin/Pfam/getacc? PF01398).
  • Receptor-related sequences can also possess or interact with immunoglobulin domains, which are described above.
  • Receptors, and fragments of receptors can be used as therapeutics.
  • a ligand-binding portion, an effector-binding portion, and a kinase or phosphatase domain or consensus sequence can comprise fragments that can function as agonists or antagonists enhance or reduce, e.g., ligand binding to the natural receptors, or effector function by the natural receptors.
  • a phosphatase is an enzyme that catalyses the hydrolysis of esters of phosphoric acid. Its substrates include, but are not limited to, nucleic acids, proteins, and lipids. Together with kinases, phosphatases are active in a broad range of cellular functions, including transcription, cell division, cell-cycle progression, intermediate cellular metabolism, glycogen metabolism, lipogenesis and lipolysis, maintenance of electrochemical gradients, neuronal function, immune responses, intracellular vesicular transport, cytoskeletal function, sperm motility, and skeletal, cardiac, and smooth muscle function (Oliver and Shenolikar, 1998). [059] Disruption in these functions may lead to disorders.
  • phosphatases regulate pathways of cell growth and programmed cell death; disruptions in these pathways can lead to abnormal cell growth, such as that which occurs in cancer.
  • the tumor suppressor "phosphatase and tensin-homology deleted on chromosome 10" (PTEN) gene encodes PIP 3 , a lipid phosphatase that dephosphorylates phosphatidlyinositol, thus countering the action of the oncogenes PI 3 -kinase and Akt, which promote cell survival.
  • PTEN has been identified as a tumor suppressor; it is deleted in multiple types of advanced human cancers.
  • phosphatases regulate pathways that control immune function.
  • the CD45 phosphotyrosine phosphatase is one of the most abundant glycoproteins expressed on immune cells, and regulates T-cell signaling and development (Alexander, 2000).
  • the serine/threonine phosphatase calcineurin plays a central role in lymphocyte activation, among other important and wide-ranging cellular functions (Baksh and Burakoff, 2000).
  • Certain compounds, specifically, cyclosporine and FK-506 (Tacrolimus) have been found to inhibit the phosphatase activity of calcineurin, thereby suppressing the production of IL-2 and other cytokines.
  • phosphatase inhibitors have proven to be valuable as immune suppressant drugs, and those in the field believe that modulators of phosphatase activity promise to be important immunoregulatory compounds (Allison, 2000).
  • DARPP-32 protein phosphatase inhibitor l/DARPP-32 domains
  • phosphatases can be used as targets for therapeutic intervention, in cell-free or cell-based assays, for example, in screening for drugs, including small molecule drugs.
  • Protease-Related Sequences
  • proteases also known as endopeptidases, are enzymes that cleave polypeptide chains by hydrolyzing peptide bonds at positions within the amino acid chain.
  • Different proteases recognize different polypeptide sequences. Endopeptidase substrate specificities vary from broad to narrow; for example, subtilisins are relatively non-specific, and can cleave polypeptide chains with a wide variety of amino acid sequences, whereas thrombin is more specific and can only cleave polypeptide chains with an arginine residue on the carboxyl side of the susceptible peptide bond and glycine on the amino side.
  • Additional examples of protease-related sequences include coUagenases, trypsin, and damage-induced neuronal endopeptidase (Kiryu-Seo et al., 2000).
  • Proteases mediate the continuous remodeling of living tissues.
  • the extracellular matrix a tissue skeleton that mediates communication among cells, and influences the structure and function of associated tissues and organs, is continuously remodeled.
  • a strictly controlled balance is maintained between breakdown of the extracellular matrix by proteases and reconstruction of the extracellular matrix.
  • This continued matrix remodeling is a dynamic process that shapes the structure and function of tissues and organs (Wojtowicz-Praga, 1999).
  • protease function Defects in protease function are responsible for a number of disorders, including cancer and other hyperproliferative disorders. Proteases are involved in the pathogenesis of such disorders both by virtue of their involvement in programmed cell death and tumor invasion and metastasis (Los et al., 2003; Stetler- Stevenson et al., 1993). Detection of the presence or characteristics of proteases can be used to screen for and diagnose prostate cancer (Karanazanashvili and Abrahamsson, 2003).
  • Proteases are also involved in the pathogenesis of inflammatory and arthritic diseases, such as pancreatitis, osteoarthritis, and rheumatoid arthritis (Pfutzer and Whitcomb, 2001; Martel-Pelleteir et al., 2001; Lerch and Gorelick, 2000).
  • Phosphodiesterases are enzymes that cleave phosphodiester bonds, i.e., bonds formed by two hydroxyl groups in an ester linkage to the same phosphate group, such as those between adjacent RNA or DNA nucleotides. Phosphodiesterases are found in both soluble and membrane-associated forms. Most phosphodiesterases act within a network of signal transduction molecules and other signaling effectors, and are modulated by components of these pathways. Phosphodiesterases regulate the metabolism and synthesis of cyclic nucleotides in signal-transduction pathways. They hydrolyze cAMP and cGMP, molecules that play an important and widespread role in signal transduction.
  • Phosphodiesterases also repair damage to nucleic acids. Some phosphodiesterases are regulated primarily by calcium and calmodulin, others are regulated primarily by cGMP. They differ in their sensitivity to individual inhibitors, but all share a homologous catalytic region (Siegel, et al., 1999).
  • phosphodiesterases examples include nucleotide pyrophosphatases (NPP) and plasma membrane glycoprotein PC-1, which are present in elevated levels in the fibroblasts of patients with Lowe's syndrome (Funakoshi et al., 1992).
  • NPP nucleotide pyrophosphatases
  • PC-1 plasma membrane glycoprotein PC-1
  • Another example of a phosphodiesterase is myomegalin-like protein, which is expressed at high levels in the nucleus and cytoplasm of heart and skeletal muscle (Soejima et al., 2001).
  • Phosphodiesterases have demonstrated promise in cancer chemotherapy, analgesia, the treatment of Parkinson's disease, and the treatment of learning and memory disorders (Weishaar, et al., 1985).
  • Phosphodiesterase-related sequences can possess or interact with type I phosphodiesterase/nucleotide pyrophosphatase (phosphodiest) domains, which catalyze the cleavage of phosphodiester and phosphosulfate bonds (http://www.sanger.ac.uk/cgi-bin/Pfam/getacc7PF01663). Phosphodiesterase-related sequences can also possess or interact with 3 '5 -cyclic nucleotide phosphodiesterase (PDEase) domains, which are involved in signal transduction (http://www.sanger.ac. uk/cgi-bin/Pfam getacc?PF00233).
  • PDEase 3 '5 -cyclic nucleotide phosphodiesterase
  • Phosphodiesterases are also useful as targets for therapeutic intervention, for example, for identification of agonists or antagonists, such as in the screening of small molecule inhibitors.
  • a well known PDE-5 inhibitor, sildenafil citrate (Viagra®) is used for treatment of erectile dysfunction (Brock, 2000).
  • the mechanism of action involves inhibition of PDE-5 enzyme and resulting increase in cyclic guanosine monophosphate (cGMP) and smooth muscle relaxation in the penis (Rosen and McKenna, 2002).
  • Such inhibitors may also find use for treatment of severe pulmonary arterial hypertension. (Ghofrani et al., 2003).
  • Cells transport proteins and organelles in an orderly and regulated manner along cytoskeletal filaments.
  • Molecular motor proteins such as kinesins
  • kinesins can carry such cargo along the cytoskeletal filaments to specific destinations, in a highly regulated manner.
  • Exemplary membrane-bound cargoes include mitochondria, lysosomes, endoplasmic reticulum, and axonal vesicles (Nale, 2003).
  • Kinesins also transport nonmembranous cargo, such as mR ⁇ As, tubulin monomers, and intermediate filaments (Nale, 2003).
  • Kinesins function in the cell division process (Miki et al., 2001).
  • kinesins are necessary to establish spindle bipolarity, position chromosomes on metaphase plates, and maintain forces in the spindle.
  • Several members of the kinesin family are associated with the chromosomes, and are likely to perform a role in mitotic chromosome movement (Miki et al., 2001).
  • the C-terminal kinesin KIFCl is involved in the processes of meiosis, mitosis, and karyogamy (Miki et al., 2001).
  • the kinesin GAKL ⁇ binds to the human analog of the Drosophila Discs Large tumor suppressor protein (hDlg), a membrane associated guanylate kinase (Hanada, 2000). GAKI ⁇ undergoes translocation in T- lymphocytes upon their cellular activation (Hanada, 2000). The GAKI ⁇ /hDlg complex is also hypothesized to play a role in cell division (Hanada, 2000). Thus, the kinesin GAKT ⁇ plays a role in cell proliferation and T-cell mediated immune function.
  • Kinesin-mediated intracellular transport is also implicated in as a mechanism of tumorigenesis.
  • kinesin transports the tumor suppressor adenomatous polyposis colon protein (APC) (Jimbo et al., 2002).
  • the APC gene is mutated in both sporadic and familial colorectal tumors.
  • the APC protein interacts with the microtubule plus-end-directed kinesin proteins KIF3A and KIF3B through an association with the kinesin superfamily-associated protein 3 (KAP3).
  • KAP3 kinesin superfamily-associated protein 3
  • Mutant APCs derived from cancer cells are unable to undergo kinesin-mediated transport, and do not accumulate with normal efficiency in clusters in the membrane protrusions, and thereby can not function efficiently as tumor suppressors.
  • KAP kinesin-associated protein
  • Kinesins like kinases, are useful as targets for therapeutic intervention, for example, in screening for small molecule inhibitors for the treatment of cancer.
  • Immunoglobulin-Related Sequences are useful as targets for therapeutic intervention, for example, in screening for small molecule inhibitors for the treatment of cancer.
  • An immunoglobulin is an antibody molecule, and is typically composed of heavy and light chains, each of which have constant regions that display similarity with other immunoglobulin molecules and variable regions that convey specificity to particular antigens. Most immunoglobulins can be assigned to classes, e.g., IgG, IgM, IgA, IgE, and IgD, based on antigenic determinants in the heavy chain constant region; each class plays a different role in the immune response.
  • Proteins with the ig domain comprise the immunoglobulin superfamily; members include antibodies, T- cell receptors, major histocomptability proteins, the CD4, CD8, and CD28 co- receptors, most of the invariant polypeptide chains associated with B and T cell receptors, leukocyte F c receptors, the giant muscle kinase titin, and receptor tyrosine kinases (Janeway et al, 2001; Alberts, et al., 1994).
  • Polypeptides with immunoglobulin-like domains can be markers for specific types of tissues and tumors. For example, a 43-kDa protein membrane antigen with two immunoglobulin-like domains in its extracellular region is expressed in normal human colonic and small bowel epithelium and > 95% of human colon cancers, but absent from most other human tissues and tumor types (Heath et al., 1997).
  • polypeptides with immunoglobulin-like domains are also involved in inflammation.
  • myelin oligodendrocyte glycoprotein a myelin-specific protein found in the central nervous system, specifically binds to and activates complement, an effector of the immune system, via its extracellular immunoglobulin- like domain.
  • myelin oligodendrocyte glycoprotein is a modulator of central nervous system inflammation and has been predicted by those in the field to be relevant to the pathogenesis of demyelinating diseases such as multiple sclerosis (Johns and Barnard, 1997).
  • WASp Homology domain 1 WHl
  • Glycosylphosphatidylinositol (GPI) anchor proteins are synthesized as single membrane proteins; the transmembrane segment is cleaved away in the endoplasmic reticulum, where a GPI membrane anchor is added. The resulting protein is bound to the non-cytoplasmic, i.e., either extracellular or luminal, side of the membrane by the GPI anchor.
  • GPI anchor proteins can be dissociated from the membrane by phosphatidylinositol-inositol-specific phospholipase C (Alberts et al., 1994).
  • GPI-anchor proteins examples include prefoldin, a chaperone that delivers unfolded proteins to cytosolic chaperonin (Nainberg et al., 1998), and carboxypeptidase M, which is associated with the differentiation of monocytes to macrophages (Rehli et al., 1995).
  • GPI anchor protein-related sequences can possess or interact with
  • KE2 domains which may contain a D ⁇ A binding leucine zipper motif(http://www. sanger.ac.uk /cgi-bin/Pfam/getacc?PF01920).
  • GPI anchor protein-related sequences can also possess or interact with zinc carboxypeptidase (Zn_carbOpept) domains, which include carboxypeptidase H regulatory domains and carboxypeptidase A digestive domains (http://www.sanger.ac.uk/cgi-bin Pfam/getacc7PF00246).
  • Zn_carbOpept zinc carboxypeptidase
  • An activator is a molecule or collection of molecules that positively modulates the activity of a regulatory protein, or that binds to D ⁇ A and regulates one or more genes by increasing the rate of transcription. Regulatory protein activators contribute to an increase in protein activity. Transcriptional activators provide a positive control over gene transcription; for example, they can sense the internal condition of the cell and bind to a sequence of D ⁇ A near a target promoter, resulting in the transcription of an appropriate gene. Examples of activator- related sequences include template-activating factors, bacterial catabolite activators, and the coenzyme thiamine pyrophosphatase. Activator-related sequences, e.g., factors that influence viral replication and transcription, can be encoded by oncogenes (Nagata et al., 1995).
  • NAP nucleosome assembly protein
  • Adaptors are proteins involved in the process of capturing specific cargo molecules into membrane-bound vesicles for transport through the cell. Different adaptors recognize different receptors for cargo molecules, and also recognize different vesicle coat proteins, accounting, in part, for the specificity of the content of intracellular vesicles bound to specific destinations within the cell (Kirsch et al., 1999). Examples of adaptor-related sequences include adaptins, clathrins, adaptor-related protein complex subunits, and Cas ligand with multiple Src homology 3 domains (CMS) adaptors.
  • CMS Src homology 3 domains
  • Adhesion molecules are molecules that mediate the adhesion of cells with other cells, and with the extracellular matrix.
  • adhesion molecules include members of the immunoglobulin superfamily, integrins, cadherins, selectins, and transmembrane proteoglycans.
  • the adhesion molecule carcinoembryonic antigen (CEA) is present nearly exclusively on cancer cells, and is expressed on the cell surface of approximately 80% of all solid cancerous tumors (Berinstein et al., 2002).
  • integrin_A integrin alpha cytoplasmic region
  • An antigen is a molecule that provokes an immune response; they include both foreign antigens and autoantigens.
  • Antigens can be expressed in a tissue-specific manner and their expression can be developmentally regulated.
  • the heat stable antigen HS A is expressed in both a tissue-specific manner, i.e., it is restricted to hematopoeitic cells, and a developmentally-regulated manner, i.e., it is more highly expressed in immature precursor cells than in terminally differentiated cells (Wenger et al., 1993).
  • Antigens can be expressed on the cell surface or inside the cell, e.g., in the nucleus or on intermediate filaments.
  • Antigen-related sequences include sequences related to tumor antigens, which are expressed exclusively in tumor cells, or in greater amounts in tumor cells than in normal cells.
  • Tumor antigens can be transmembrane proteins, with one or more transmembrane domains (Li et al., 1996; Linnenbach, et al., 1993).
  • Autoantigens which are components of the body that provoke an immune response, are involved in the pathogenesis of autoimmune disease. Autoantigens can be either selectively or ubiquitously expressed among cell and tissue types. They can be localized to any region of the cell, including the nucleus, nucleolus, nuclear envelope, and intermediate filaments (Racevskis et al., 1996). For example, pancreatic islet cell antigens are involved in the autoimmune pathogenesis of diabetes, and thyroid antigens are involved in autoimmune thyroid disease.
  • Antigen-related sequences can also possess or interact with the Ku70/Ku80 C-terminal arm (Ku_C) or Ku70/Ku80 N-terminal alpha/beta (Ku_N) domains, which belong to the Ku family of peptides (http://pfam.wustl.
  • bZIP bZIP transcription factor
  • YTH YT521-B-like domains
  • ATPases are enzymes that use the energy of ATP hydrolysis to move ions or small molecules across a membrane against a chemical concentration gradient or electrical potential.
  • ATPases can maintain low intracellular calcium and sodium ion concentrations, and generate a low pH inside lysosomes, plant-cell vacuoles, and the lumen of the stomach.
  • Nacuolar ATPases are ATP- dependent proton pumps that create pH gradients by transporting protons across membranes, while coupling the energy produced in the conversion of ATP to ADP with proton transport (Forgac, 1999).
  • ATPase-related sequences include proton transporters, glucose transporters, multidrug resistance factors, calcium ATPases, and porins.
  • V-ATPase vacuolar domains
  • Adenosine trisphosphate is a nucleotide comprising an adenine, a ribose, and a trisphosphate unit.
  • the trisphosphate unit contains two phosphoanhydride bonds that confer an energy-rich property to ATP.
  • the free energy liberated in the hydrolysis of one or both of these bonds can drive reactions that require an input of free energy.
  • a wide range of physiological and pathological processes are driven by the energy of ATP, including cellular movement, the synthesis of biomolecules from precursors, muscle contraction, ciliary and flagellar function, intermediary metabolism, glycolysis, fatty acid oxidation, oxidative phosphorylation, and membrane transport (Ku et al., 1990).
  • Examples of ATP-related sequences include ATPases, ATP synthases, ATP carrier proteins, and myosin.
  • ATP-related sequences can possess or interact with ATP- synthase subunit C protein domains (ATP-synt_C), which are protein domains that consist of two long terminal hydrophobic regions, and are implicated in the proton- conducting activity of ATPases (http://pfam.wustl.edu/cgi-bin/getdesc7name-----ATP- synt_C).
  • a binding protein is a protein that binds to another molecule with specificity. Binding proteins can be involved in building macromolecular structures, e.g., in cytoskeletal assembly or scaffolding (Machesky et al., 1997). Proteins often exist in the cell in complexes with other proteins, nucleic acids, lipids, and/or small molecules. For example, steroid receptors, e.g., the progestin, estrogen, androgen, and glucocorticoid receptors, bind to heat-shock proteins and FKBP52, a calcium- regulated immunosuppressant, to form functional complexes (Peattie et al., 1992; Sanchez et al., 1990).
  • DNA binding proteins and general transcription factors bind to the TATA box, a consensus sequence in a gene's promoter region that specifies the position of transcription initiation, forming a functional transcription complex (Chalut et al., 1995). Proteins can interact with multiple molecules simultaneously. For example, Nedd4, an ubiquitin-protein ligase, can interact with multiple proteins and lipids through its lipid binding domain and multiple protein binding domains (Jolliffe et al., 2000). [099] Proteins utilize a large number of motifs to bind other molecules.
  • Proteins induced by exposure to cold include DNA-binding proteins, and cold inducible RNA binding proteins, which have RNA binding domains at or near their N-termini (Nishiyama et al., 1997).
  • testis-specific DNA/RNA binding protein with a cold shock domain also has a large number of phosphorylation sites, each of which can mediate intermolecular interactions (Tekur et al, 1999). Contrin is involved in transcription of testis-specific genes; its inactivation could provide a reversible male contraceptive.
  • ARID-encoding genes are involved in a variety of biological processes, including regulation of cell growth, development, cell lineage gene regulation, cell cycle control, and tissue-specific gene expression.
  • Binding protein-related sequences can also possess or interact with nucleosomal binding domains to facilitate binding within the nucleosome, a nuclear structure comprised of chromosomal DNA and proteins.
  • RNA binding proteins possess the rrm domain, including heterogeneous nuclear ribonucleoproteins (hnRNP) proteins, which are implicated in the regulation of alternative splicing, and LA proteins, which are among the main autoantigens in systemic lupus erythematosus (SLE).
  • hnRNP heterogeneous nuclear ribonucleoproteins
  • LA proteins which are among the main autoantigens in systemic lupus erythematosus (SLE).
  • Binding protein-related sequences can also possess or interact with conserved motifs that mediate their binding to ions, e.g., calcium.
  • Ion-binding proteins include phosphoproteins that bind to other molecules in an manner dependent on their phosphorylation state, and can regulate many types of molecules and processes, including those that utilize complex signaling cascades (Pang et al., 2001; Pang et al., 2002; Lin et al., 1999).
  • a breakpoint is the location on a chromosome where a gene is disrupted, and one segment of the gene is severed from the other. Chromosomal breaks that disrupt coding or regulatory sequences can result in gene mutation. Chromosomal breaks can also serve as molecular landmarks, e.g., a break can be detected on Southern blots as the loss of an expected band and the appearance of two novel bands.
  • breakpoint-related sequences include the sequences that generate the Philadelphia chromosome translocation, the sequences that generate the chromosome translocation (t(l;7)(q42;pl 5)), which is implicated in Wilms' tumor, and the sequences that generate the chromosomal translocation t(18;21)(q22.1q21.3), which is implicated in Down syndrome.
  • Breakpoints commonly occur in discrete regions of the chromosome. Breakage at these regions can lead to a recognized disease phenotype.
  • One way of generating such a phenotype is by chromosomal translocation, i.e., chromosomes mutate by exchanging parts. When a segment from one chromosome is exchanged with a segment from another nonhomologous chromosome, two mutated chromosomes are simultaneously generated (Griffiths, et al., 1999).
  • the Philadelphia chromosome a mutation sometimes associated with chronic myelogenous leukemia (CML), is an example. It results from the translocation of a discrete segment of chromosome 22 into a discrete region of chromosome 9. Patients with the Philadelphia chromosome mutation generally have a better prognosis than CML patients with other characteristics.
  • Chromosome rearrangements affecting band 3q21 are associated with a particularly poor prognosis in myeloid leukemia or myelodysplasia. These breakpoints cluster in a breakpoint cluster region of approximately 30 kb, located centromeric and downstream of the ribophorin I (RPN-I) gene (Weiser, 2002). The apoptotic gene bcl-2, was isolated as a breakpoint rearrangement in human follicular lymphomas and was shown to act as an oncogene that promoted cell survival rather than cell proliferation.
  • RPN-I ribophorin I
  • Some proteins can act as leukemia or lymphoma-specific antigens for major histocompatibility complex-restricted T cell cytotoxicity. These include the breakpoint cluster region (bcr)-abl, and other fusion oncoproteins. Genetically engineered chimeric and humanized antibodies have demonstrated activity against overt lymphomas and leukemias. Radioimmunotherapy has produced significant therapeutic responses with minimal radiation exposure to normal tissues (Jurcic et al., 2000).
  • Breakpoint-related sequences can possess or interact with
  • Plectin/SlO S10__plectin domains
  • a membrane transport protein is an integral transmembrane protein that aids one or more molecules across a cell membrane. Most, if not all, types of molecules are transported across membranes, including proteins, ions, and fatty acids (Schaffer and Lodish, 1994). Even molecules such as water and urea, which can diffuse across pure phospholipid bilayers, are frequently accelerated by transport proteins. Transporters clear cells of toxins, and confer drug resistance on tumor lines (Ramalho-Santos et al., 2002). The rate of transport varies considerably among membrane transport proteins. Membrane transport proteins function in the plasma membrane and in intracellular organellar membranes, including the nuclear, mitochondrial, lysosomal, and vesicular membranes. For example, transportin, also known as karyopherin beta2, imports nuclear mRNA binding proteins from the cytoplasm across the nuclear membrane, into the nucleus (Bonifaci et al., 1997).
  • Membrane transport proteins can have either a broad or a narrow range of specificity for the transported substance.
  • nucleoside transport across membranes is mediated by broad specificity transporters.
  • Nucleoside transport plays a role in such diverse cellular functions as nucleotide synthesis, neurotransmission, and platelet aggregation.
  • Nucleoside transporters carry chemotherapeutic nucleosides, and are a target of interest in chemotherapeutic and cardiac drug design (Griffiths et al., 1997; Ku et al, 1990).
  • Carriers are another class of membrane transport proteins; they bind to a solute and transport it across the membrane by undergoing a series of conformational changes. In contrast to channel proteins, transporters bind only one, or a few, substrate molecules at a time; after binding substrate molecules, they undergo a conformational change such that the bound substrate molecules, and only those molecules, are transported across the membrane. Carriers transport a wide variety of molecules, including fatty acids across the plasma membrane (Schaffer and Lodish, 1994); purines, pyrimidines, and components of nucleosides across the nuclear membrane, and adenine nucleotides across the inner mitochondrial membrane (Battini et al., 1997).
  • nucleoside transporter nucleosidejran domains
  • AMP-binding AMP -binding enzyme
  • Membrane transport proteins such as those expressed in cancer cells, are useful as targets for therapeutic intervention, for example, in the screening for small molecule inhibitors. Inhibition of membrane transport, as indicated above, may make cancer cells more susceptible to chemotherapy, for example.
  • Channel proteins transport water or specific types of ions down their concentration or electrical potential gradients. They form a protein-lined passageway across the membrane through which multiple water molecules or ions move at a very rapid rate, e.g., up to IO 8 per second.
  • the plasma membrane for example, contains potassium-specific channel proteins that generate the cell's resting electric potential across the plasma membrane. Examples of channel-related sequences include the sodium hydrogen exchanger, sodium potassium ATPase, and the cystic fibrosis transmembrane regulator.
  • membrane transport proteins have wide-ranging functions in both normal physiology and in pathology.
  • the transport system that mediates the transmembrane exchange of sodium for hydrogen across the plasma membrane plays a physiological role in the regulation of intracellular pH, the control of cell growth and proliferation, stimulus-response coupling, metabolic responses to hormones, the regulation of cell volume, and the transepithelial absorption and secretion of several ions.
  • the sodium-hydrogen exchanger also plays a role in cancer and in tissue and organ hypertrophy (Mahensmith and Aronson, 1985).
  • the cell division cycle is the fundamental means by which living things are propagated. Fundamental to successful propagation is the faithful replication of DNA; a cell cycle control system exists to coordinate the cycle as a whole.
  • the control system is regulated by brakes that can stop the cycle at specific checkpoints.
  • the checkpoints arrest the cycle upon the occurrence of undesirable events, such as DNA damage, replication stress, or mitotic spindle disruption.
  • DNA lesions and disrupted replication forks are recognized by the DNA damage checkpoint and replication checkpoint, respectively.
  • Checkpoints can also, for example, initiate protein kinase-based signal transduction cascades to activate downstream effectors that elicit cell cycle arrest, DNA repair, or apoptosis. These actions prevent the conversion of aberrant DNA structures into inheritable mutations and minimize the survival of cells with unrepairable damage (Qin and Li, 2003).
  • Checkpoint function results in genetic modifications that contribute to tumorigenesis.
  • Checkpoint function can be abrogated by many different mechanisms (Bast, et al., 2000). For example, cyclin-dependent kinases that normally are activated at a checkpoint can be inactivated or activated in an abnormal manner. Alternatively, the normal activities of the cyclin-dependent kinase inhibitors, phosphatases, or other regulatory molecules of the cell cycle can be altered. Tumor suppressors are among the classes of molecules that can effect cell cycle dysregulation. The abrogation of checkpoint function can alter the sensitivity of tumor cells to chemotherapeutics (Stewart et al, 2003).
  • checkpoint related proteins e.g., kinases, phosphatases, etc.
  • kinases e.g., kinases, phosphatases, etc.
  • phosphatases e.g., phosphatases, etc.
  • Complexes are molecular entities comprised of two or more components. Molecular complexes within cells form functional units that carry out cellular operations. For example, complexes at the cell membrane perform structural and regulatory tasks, including regulating membrane traffic and maintaining organelle integrity. Complexes at the cytoskeleton perform static and dynamic roles with respect to cell shape, intracellular transport, and communication with the extracellular matrix. Complexes in the nucleus transcribe and regulate genes, and complexes at sites of protein synthesis translate and regulate proteins. Complexes can reside intracellularly and/or extracellularly, e.g., in the extracellular matrix. Examples of complex-related sequences include cytoskeletal and filamentous proteins, ADP- ribosylation factor (ARF) proteins, and protein synthesis initiation factors (Amor et al., 1994).
  • ADP- ribosylation factor (ARF) proteins ADP- ribosylation factor
  • Arf ADP- ribosylation factor family
  • IFN4E eukaryotic initiation factor 4E
  • a cytokine is an extracellular signaling protein or peptide that acts as a local mediator in communication among cells. Cytokines regulate proliferation and differentiation, for example, they mediate differentiation of cells in the hematopoeitic lineage. Examples of cytokines include interleukins, interferons, and colony stimulating factors of the hematopoeitic system. Some cytokines, e.g., interferons and interleukins, can be induced by viral activity, and possess antiviral activity (Sheppard et al., 2003). Cytokine-related sequences may enable the expression of a cytokine, for example, as a cytokine transcription factor (Kao et al., 1994).
  • cytokine effector pathway can also be part of a cytokine effector pathway, for example, as an intracellular effector of cytokine- related cytoskeletal changes in response to events in the extracellular matrix (Hirsh et al, 2001; Joberty et al., 1999).
  • CD225 interferon-induced transmembrane protein
  • Cytokine-related sequences can also possess or interact with SelR (SelR) domains, which bind both selenium and zinc, and/or methionine sulfoxide reductase enzymatic domains (http://pfam. wustl.
  • rvt reverse transcriptase domains
  • Cytokines thus, are useful as therapeutic proteins for the treatment of disorders such as cancer, immune disorders, and inflammation.
  • Dehydrogenase-Related Sequences
  • Dehydrogenases are enzymes that catalyze the removal of hydrogen atoms in the absence of oxygen. They contribute to a wide range of enzymatic reactions, including those involved in amino acid degradation, amino acid synthesis, the citric acid cycle, fatty acid oxidation, fatty acid synthesis, glycolysis, the pentose phosphate pathway, photosynthesis, pyruvate oxidation, and oxidative phosphorylation (Walker et al., 1992).
  • Examples of dehydrogenases include steroid dehydrogenases, NADH dehydrogenases, and gly ceraldehyde-3 -phosphate dehydrogenase.
  • GPDH NAD binding
  • Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) is a neurodegenerative disease that affects the motor neurons. The disease displays multiple clinical variants and can affect motor neurons throughout the nervous system, e.g., the spinal cord and brainstem.
  • HAPl Sf HAPl N-terminal conserved region
  • Gaucher's Disease is a genetic disease characterized by a deficiency of enzymes responsible for the breakdown and recycling of glycolipids, i.e., lipids with carbohydrate moieties, e.g., glucosylceramide; and sphingolipids, lipids with sphingosine moieties, e.g., sphingomyelin.
  • glycolipids i.e., lipids with carbohydrate moieties, e.g., glucosylceramide
  • sphingolipids lipids with sphingosine moieties, e.g., sphingomyelin.
  • the glycolipids and sphingolipids in the membranes of senescent cells are metabolized by a multi-step process that includes the activities of acid beta-glucosidases and saposins.
  • glucosylceramide and sphingolipids accumulate, and produce the Gaucher's disease phenotype.
  • the disease displays multiple clinical variants, and can manifest with central nervous system pathology, enlargement of organs, e.g., liver and spleen, and an increase in the level of the cytokine transforming growth factor beta (Zhao and Grabowski, 2002; Perez Calvo et al., 2000; Cormand et al, 1997).
  • the variability in clinical presentation is consistent with the large number of different mutations observed in the acid beta- glucosidase and saposin genes.
  • Acid beta-glucosidases are enzymes that metabolize glycolipids.
  • Huntington Disease is a progressive neurodegenerative genetic disorder characterized by dementia, psychiatric symptoms, and a choriform movement disorder. It is caused by an increased number of repeats of the codon CAG, which encodes the amino acid glutamine, in a gene located at the 4 ⁇ l6.3 region of chromosome 4, which codes for a protein called huntingtin.
  • the polyglutamine tracts expressed by the mutant form of the gene selectively ablate striatal and cortical neurons, (Ho et al., 2001).
  • the Huntington Disease gene is widely expressed, but exerts tissue- specific effects on neurons (Lin et al, 1993).
  • the gene expresses multiple distinct transcripts, and differential polyadenylation of the gene leads to the expression of transcripts of different sizes (Lin et al., 1993).
  • MS Multiple Sclerosis
  • MS Multiple sclerosis
  • demyelination i.e., the loss of the myelin coating, of nerve axons. Its clinical course varies among patients; these variations fall into two broad categories, a relapsing/remitting course, and a chronic progressive course.
  • MS has a complex etiology; it has an autoimmune component, is influenced by genetics, and sometimes involves infectious agents.
  • MS results from an abnormal immune response to one or more antigens present in the myelin sheaths that cover the nerve axons of genetically susceptible individuals, which may be preceded by exposure to a causal infectious agent (Oksenberg et al., 1999).
  • MS susceptibility genes most of which demonstrate only a small to moderate effect on susceptibility, e.g., the major histocompatibility complex at chromosome 6p21 (Oksenberg et al., 1999).
  • An etiological infectious agent has been isolated from the plasma and cerebrospinal fluid of patients with multiple sclerosis (Perron et al., 1997).
  • This agent is a retroviral oncovirus, known as multiple sclerosis-associated retrovirus (MSRN), also called LM7, and is found in association with virions produced by the cultured cells of MS patients (Perron et al., 1997).
  • MSRN proteins possess protein domains characteristic of retroviral proteins.
  • Tub Tub
  • an oncogene is any one of a large number of genes that can help make a cell cancerous.
  • an oncogene is a mutant form of a normal gene, and is often a gene involved in the control of cell growth, division, or differentiation.
  • Cells in higher organisms normally grow, divide, differentiate, and die under the regulation of other cells. Cancer cells proliferate, in part, because they are able to divide without input from other cells, as the result of accumulated mutations.
  • Oncogenes include, but are not limited to, genes encoding GTP binding proteins, e.g., ras; growth factors, e.g., platelet-derived growth factor; growth factor receptors, e.g., platelet-derived growth factor receptor; kinases, e.g., src; nuclear proteins, e.g., myc; and tumor suppressors, e.g., retinoblastoma proteins.
  • GTP binding proteins e.g., ras
  • growth factors e.g., platelet-derived growth factor
  • growth factor receptors e.g., platelet-derived growth factor receptor
  • kinases e.g., src
  • nuclear proteins e.g., myc
  • tumor suppressors e.g., retinoblastoma proteins.
  • the products of oncogenes are frequently proteins involved in cell signaling, e.g., kinases, GTP-binding proteins, and receptors.
  • kinases proteins involved in cell signaling
  • GTP-binding proteins proteins involved in cell signaling
  • receptors proteins involved in cell signaling
  • kinases proteins involved in cell signaling
  • ras gene e.g., kinases, GTP-binding proteins, and receptors.
  • Ras proteins function as switches, cycling between an active state in which GTP is bound, and an inactive state, in which GDP is bound.
  • a ras gene mutation can result in the translation of a protein that fails to hydrolyze its bound GTP, and persists abnormally in its active state, transmitting an intracellular signal for cell proliferation or differentiation even in the presence of regulatory non-proliferation and non- differentiation signals.
  • Gtrl_RagA G-protein conserved region
  • Oncogene-related sequences can also possess or interact with an ATPase domain associated with diverse cellular activities; proteins with the AAA ('ATPases 'Associated with diverse cellular ⁇ 'ctivities) domain can perform chaperone-like functions that assist in assembling, operating, or disassembling protein complexes.
  • C2 domains are typically located between Cl domains (which bind phorbol esters and diacylglycerol) and protein kinase catalytic domains. Regions with homology to the C2 domain are present in many proteins, e.g., synaptotagmin.
  • Parkinson's disease is a neurological disorder that affects movement control. Complex interactions among groups of nerve cells in the central nervous system coordinate to control movement. One such group of neurons is located in the substantia nigra of the midbrain; these neurons release the neurofransmitter dopamine, which allows an organism to fine-tune its movements. In Parkinson's disease, neurons of the substantia nigra progressively degenerate, leaving the patient with clinical symptoms that may include resting tremor, muscular rigidity, a slowness of spontaneous movement, and poor balance and motor coordination (Seigel et al., 1999). [0141] Parkinson's disease has multiple causes, including both genes and the environment.
  • PARK2 is a ubiquitin protein ligase that is a component in the pathway that attaches ubiquitin to specific proteins, designating them for degradation (Fishman, and Oyler, 2002).
  • Alpha-synuclein which possesses a synuclein domain, is mutated in several families with autosomal dominant Parkinson's disease.
  • Gamma-synuclein which also possesses a synuclein domain, is overexpressed in breast and ovarian cancers (Lavedan, 1998).
  • Retinitis pigmentosa is a group of inherited retinopathies characterized by early stage loss of night vision, followed by loss of peripheral vision. Defects in any structural or functional proteins associated with the rod photoreceptor neurons of the retina, which are the cells that transduce light into a neuronal action potential, can lead to the disease (Seigel et al., 1999).
  • GTPase regulators have been implicated in the pathology of retinitis pigmentosa.
  • GTPase regulators are proteins that determine whether a GTP binding protein exists in a GTP-bound or GDP-bound state (Zhao et al., 2003); they are described in more detail below.
  • GTPase regulators have a broad spectrum of intracellular functions, including intracellular vesicular transport. These proteins localize to a specific region of rod photoreceptor cells, in a narrow cilium that connects the cell body, where protein synthesis and basic metabolism takes place, with the rod outer segment, where light is transduced to an action potential of the optic nerve (Zhao et al., 2003).
  • Alzheimer's disease is a neurodegenerative dementing illness. It is a genetically complex disease with multiple forms, including familial and sporadic forms, and early onset and late-onset forms. Mutations in at least four genes are known to cause Alzheimer's disease, and there is evidence for additional Alzheimer's loci (McKusick, 2003).
  • Alzheimer's disease is caused by mutations in the amyloid precursor gene, another form is associated with the apolipoprotein E4 allele, a third form is caused by a mutant presenilin-1 gene that encodes a seven- transmembrane domain protein, and a fourth form is caused by a mutant gene encoding a similar seven -transmembrane domain protein, presenilin-2 (McKusick, 2003).
  • Alzheimer disease has a complex pathology.
  • One facet of the pathology of Alzheimer's disease is the formation of amyloid plaques from amyloid precursor protein (Clark and Karlawish, 2003).
  • Amyloid precursor protein can be processed in vitro by several different proteases such as secretases and caspases to yield peptide fragments, suggesting that these proteases may play a role in the formation of pathogenic amyloid plaques in vivo (Suh and Checler, 2002).
  • Presenilins have been identified as likely candidates for the proteases that cleave amyloid precursor protein to pathogenic peptide fragments in vivo (Selkoe, 2001).
  • Another facet of Alzheimer's disease pathology is an inflammatory component mediated by microglial cells, the brain's primary immunoeffector cells (Tan et al., 1999). Microglial cells are attracted to and activated by amyloid deposits; they release inflammatory mediators that promote the aggregation of the deposits into plaques, and also directly induce or promote neurodegeneration (Hoozemans et al., 2002). Therefore, current treatment strategies include anti-inflammatory and immunotherapeutic approaches, including vaccines (Weiner and Selkoe, 2002).
  • pt_a PT repeat
  • Williams-Beuren syndrome is a complex genetic developmental disorder with multisystemic manifestations, and variability in its presentation.
  • a gene deletion occurs at the 7ql 1.23 location on the long arm of chromosome 7; in the remaining cases, a variety of other chromosomal deletions and translocations have been observed (Wang et al., 1999).
  • the most severe cases are characterized by cardiac anomalies, including aortic stenosis, mental retardation, growth deficiency, a characteristic facial appearance, dental malformation, and infantile hypercalcemia (Lashkari et al., 1999).
  • the underlying molecular basis for the syndrome is the absence of the proteins encoded by the genes of the affected region of the chromosome. A missing elastin gene, with resulting extracellular matrix anomalies, is a consistent finding.
  • Other genes that are present in and near the commonly deleted region of chromosome 7, and thus are likely to contribute to pathogenesis are (1) a gene encoding a regulator of chromosome condensation-like G-exchanging factor, which is a factor that exchanges nucleotides for small GTP-binding proteins, (2) an N- acetylgalactosaminyltransferase, (3) a DNAJ-like chaperone, (4) NOLl/NOP2/sun domain-containing proteins, including a novel protein designated WBSCR20, which is expressed in skeletal muscle, and is similar to a 120 kilodalton proliferation- associated nucleolar antigen, (5) a methyltransferase designated WBSCR22, and (6) other proteins with no known homologies
  • GTF2I GTF2I-like repeat
  • Rheumatic diseases are inflammatory conditions that can have autoimmune, infective, or traumatic origins. They include arthritis, systemic lupus erythematosus, scleroderma, and Sjogren's syndrome. Arthritis refers to any inflammation of a joint. Systemic lupus erythematosus is an autoimmune disease in which patients produce antibodies to their own tissues, resulting in an inflammatory process that can damage organs. Scleroderma can present as systemic scleroderma, a chronic, progressive disease that is characterized by hardening and stiffening of the skin and damage to internal organs, e.g., heart, lungs, kidneys and esophagus. Sjogren's syndrome is a progressive immunological disorder characterized by inflammation and the subsequent destruction of exocrine glands, e.g., salivary glands, sweat glands, and lacrimal (tear) glands.
  • exocrine glands e.g., salivary glands, sweat gland
  • the serum of patients with scleroderma and Sjogren's syndrome have antibodies directed against a protein that is a normal component of the Golgi apparatus (Seelig et al., 1994), an intracellular organelle composed of a stack of flattened cisternae with associated transport vesicles.
  • the Golgi apparatus sorts proteins and sends them to their correct intracellular destination.
  • This antigenic protein is a "golgin,” one of a class of molecules characterized by an integral membrane domain and a large cytoplasmic region. Golgins organize the Golgi 's structure, and influence protein sorting (Gillingham et al., 2002).
  • Golgins function in a variety of ways, including cross-bridging Golgi cisternae to one another (Linstedt and Hauri, 1993) and tethering Golgi transport vesicles to the cisternal membranes (Shorter et al, 2002).
  • Disintegrins are proteins that interfere with the function of integrins. Disintegrins are generally proteins of about 70 amino acid residues that contain multiple disulfide bonds, bind with high affinity to a subset of integrins, and interfere with integrin binding to physiological ligands.
  • disintegrin- related sequences include snake venoms and related proteins, cysteine-rich metalloproteinases and related non-enzymatic sequences, e.g., those expressed in the male reproductive tract, and membrane-anchored metalloproteinases with diverse functions, e.g., the shedding of cell-surface proteins such as cytokines and cytokine receptors, and the conferring of asthma susceptibility (Nan Eerdewegh et al., 2002; Perry et al., 1995).
  • a factor is any molecule that contributes to a bodily process. Factors can function in specific biochemical reactions and cellular functions. There are many categories of factors, and factors are involved in many, if not all, physiological and pathological processes. Some exemplary factors are described in the following paragraphs; they are not exhaustive of the category.
  • Transcription factors are factors that initiate or regulate transcription in eukaryotes. They include gene regulatory proteins, which turn specific sets of genes on or off, and general transcription factors, which assemble at the promoter region to enable and regulate transcription of many genes. They also include transcription elongation factors, which are proteins required for the addition of amino acids to growing polypeptide chains on ribosomes (Alberts et al., 1994). Transcription factors interact with a wide variety of molecules, including D ⁇ A binding proteins, polymerases, regulatory molecules such as kinases, and specific regions of D ⁇ A, e.g., promoters, and enhancers (Alberts et al., 1994; Nallejo et al., 1993).
  • Translation factors including translation initiation factors and release factors, are involved in initiating and regulating the rate of protein synthesis. They also interact with many molecules, including ribosomal proteins, mR ⁇ A, and molecules that regulate the incorporation of amino acids into protein, such as kinases and GTP (Price et al., 1993; Alberts, 1994).
  • Export factors are involved in the export of molecules, e.g., RNA, from the nucleus (Stutz et al., 2000). Folding factors are involved in the process of folding proteins into their functional three dimensional shapes, and are also involved in receptor function (Gao et al., 1994). Factors such as activators and coactivators interact with nuclear receptors to modulate cellular processes, e.g., transcription (Mahajan et al., 2002).
  • ADP-ribosylation factors are involved in the addition of an ADP- ribose group donated from nicotinamide adenine dinucleotide (NAD) to specific amino acid residues in heterotrimeric G-proteins. They are involved in, for example, normal cellular processes, such as vesicular transport, and also in the pathologic states induced by cholera, pertussis, and botulinum toxins (Alberts et al., 1994; Amor et al., 1994). Guanine nucleotide exchange factors bind to small G-proteins, such as Ras, and displace GDP in favor of GTP. They act as effectors or modulators of small G- proteins (Ehrhardt et al., 2001; Janeway et al., 2001; Shao and Andres, 2000).
  • IFN4E eukaryotic initiation factor 4E
  • Germ cells also called gametes, are cells that contribute to a new generation of organisms by giving rise to either an egg or a sperm. They are haploid cells specialized for sexual fusion. Proteins that are specific to germ cells can be found at one or more developmental stages of gametes.
  • Germ cell-related sequences include germ cell genes and their gene products, their regulators and effectors, genes and gene products affected in disorders associated with germ cells, and antibodies that specifically recognize or modulate germ cell-related sequences.
  • Examples of germ cell-related sequences include the germ cell-specific Y-box binding protein and contrin.
  • Germ cell specific protein-related sequences possess or interact with the cold-shock DNA-binding (CSD) domain, which is described above.
  • a growth factor is an extracellular polypeptide signaling molecule that stimulates a cell to grow or proliferate.
  • Many types of growth factors exist including protein hormones and steroid hormones. Some growth factors have a broad specificity, and some have a narrow specificity. Examples of growth factors with broad specificity include platelet-derived growth factor, epidermal growth factor, insulin like growth factor I, transforming growth factor ⁇ , and fibroblast growth factor, which act on many classes of cells.
  • growth factors with narrow specificity include erythropoeitin, which induces proliferation of precursors of red blood cells, interleukin-2, which stimulates proliferation of activated T-lymphocytes, interleukin-3, which stimulates proliferation and survival of various types of blood cell precursors, and nerve growth factor, which promotes the survival and the outgrowth of nerve processes from specific classes of neurons.
  • growth factors have other actions in addition to inducing cell growth or proliferation, e.g., they may influence survival, differentiation, migration, or other cellular functions. Growth factors can have complex effects on their targets, e.g., they may act on some cells to stimulate cell division, and on others to inhibit it. They may stimulate growth at one concentration, and inhibit it an another. Growth factors are also involved in tumorogenesis.
  • Growth factor related sequences include sequences associated with the process of stimulating cell growth or proliferation by a growth factor. For example, they include intracellular effectors of growth, such as components of intracellular pathways that respond to growth factors (Kothapalli et al., 1997; Wax et al., 1994), sequences that bind directly or indirectly to growth factors (Nan den Berghe et al., 2000), and sequences affected as a result of growth factor action.
  • FGF fibroblast growth factor
  • GTPases are enzymes that catalyze. GTP hydrolysis, and comprise a large family of proteins with a similar globular GTP binding domain. When GTP is bound to a GTPase, it is hydrolyzed to GDP, and the domain undergoes a conformational change that inactivates the protein. GTPases are regulated by GTPase regulators, proteins that determine whether a GTP binding protein exists in a GTP-bound or GDP-bound state (Zhao et al., 2003).
  • GTPase regulators include GTPase activating proteins, which bind the GTPase and induce it to hydrolyze its bound GTP to GDP; the GTPase remains in an inactive, GDP-bound state until it encounters a guanine nucleotide releasing protein, which binds to the GTPase and causes the release of the nucleotide.
  • GTPases have a broad spectrum of intracellular functions, including intracellular vesicular transport. Examples of GTPase-related sequences include ras, GTPase-activating proteins, and guanine nucleotide releasing proteins.
  • PH pleckstrin homology
  • Heat-shock proteins also referred to as stress-response proteins, are proteins that are synthesized in response to an elevated temperature or other cell sfressor, and help the cell withstand environmental insults.
  • a cell sfressor can induce a battery of genes that encode gene products that protect the cell from the result of the insult, e.g., proteins that stabilize and repair partially denatured cell proteins.
  • Some heat-shock proteins, e.g., chaperones are present at high levels in unstressed cells, and further induced by stress. Chaperones assist other proteins in attaining their proper secondary and tertiary structures.
  • Heat and other stressors further induce the synthesis of a family of 90-kDa heat-shock proteins that are already abundant in unstressed cells (Pepin et al., 2001;Lees-Miller et al., 1989; Rebbe et al, 1987).
  • Members of this family possess a hsp 90 protein (HSP90) domain that interacts with tubulin, actin, tyrosine kinase oncogene products of refroviruses, eIF2alpha kinase, and steroid hormone receptors (Lees-Miller and Anderson, 1989).
  • Hsp70 proteins Another family of heat-shock proteins, the hsp70 proteins, have an average molecular weight of 70 kDa; some members of this family are only expressed under conditions of stress, while some are present in cells under normal conditions. Hsp70 proteins reside in different cellular compartments, e.g., the nucleus, cytosol, mitochondria, and endoplasmic reticulum. Hsp70 proteins, e.g., Hsc73, can be differentially expressed at different stages of development (Soulier et al., 1996).
  • Hsp70 proteins e.g., the chaperone hsp70-like dnaK protein
  • Proteins with DnaJ domains can be postranslationally modified by farnesylation (Andres et al., 1997).
  • Helicases are enzymes that use energy from the hydrolysis of
  • Proteins with DNA helicase activity play roles in DNA replication, repair, and recombination.
  • Disorders associated with helicases include Xeroderma pigmentosum, Cockayne syndrome, diffuse collagen disease, alpha-thalassemia, Bloom syndrome, Werner syndrome, and Rothmund-Thomson syndrome (Miyajima, 2002).
  • Examples of helicases include RNA helicases, RECQL4, and minichromosome maintenance helicase.
  • HA helicase associated
  • Hydrolases are enzymes that catalyze the hydrolysis of a variety of bonds, such as esters, glycosides, and peptides. Hydrolases split a molecule into fragments by adding water; the water's hydrogen atom is incorporated into one fragment, and the hydroxyl group is incorporated into another. Hydrolases are involved in a wide range of physiological and pathological processes, including proteolysis, phosphatase activity, and sugar metabolism. Examples of hydrolases include protein hydrolases, lipid hydrolases, nucleic acid hydrolases, and small molecule, e.g., coenzyme A, hydrolases (Hawes et al., 1996).
  • dUTPase domains which are proteins domains that hydrolyze dUTP to dUMP and pyrophosphate.
  • An immune cell is a cell involved in, or associated with, the immune system.
  • Immune cells include cells in the myeloid and lymphocytic arms of the immune response, as well as their precursors. Immune cells also include cells at all stages in the differentiation pathways that produce cells associated with the immune system. These cells can reside, either permanently or temporarily, in the spleen, lymph nodes or mucosal-associated lymphoid tissues (MALT).
  • MALT mucosal-associated lymphoid tissues
  • Immune cell-related sequences are involved in all functions of the immune response, e.g., antibody production and ceU-mediated immunity, and can function at any point in time, ranging from the embryonic formation of the immune system, through the time of an immune challenge, to many decades later, e.g., when a B-cell memory response is invoked (Janeway, 2001).
  • Immune-cell related sequences of differentiating immune cells include pre-B cells that do not produce immunoglobulin light chain, but express a transcript homologous to immunoglobulin lambda light-chain genes, the expression of which is limited to pre-B cells and select other cells that have no surface immunoglobulin (Hollis et al., 1989).
  • Immune-cell related sequences of activated immune cells include a B-cell-restricted transcription factor expressed by activated B cells; its expression pattern suggests it has a role in regulating B-cell differentiation (Massari et al, 1998).
  • Immune cell-related sequences can also possess or interact with sushi domains, also known as complement control protein (CCP) modules, or short consensus repeats (SCR).
  • CCP complement control protein
  • SCR short consensus repeats
  • Immune cell-related sequences can also possess or interact with SH2 domains and rvt domains; both are described above.
  • Integrases are enzymes that form proviruses by inserting a linear double-stranded DNA copy of a retroviral genome into host cell DNA. Examples of integrases include HIV integrase, PhiC31 integrase, and Sip.
  • integrase integrase DNA binding domain
  • Integrins are transmembrane proteins that mediate cell to cell as well as cell to matrix adhesion, and provide a means of communication between the interior of a cell and the extracellular matrix.
  • the exfracellular portion of integrins binds to components of the exfracellular matrix, e.g., collagen, fibronectin and laminin.
  • the intracellular portion of integrins interacts with the cell cytoskeleton, e.g., actin filaments near the cell surface. Integrins transmit information about the exfracellular environment across the plasma membrane to the cytoskeleton, where it is available to intracellular signaling mechanisms (Alberts et al., 1994).
  • integrins consist of heterodimers of an alpha and a beta subunit. Each subunit has a large N-terminal exfracellular domain followed by a transmembrane domain and a short C-terminal cytoplasmic region.
  • the pairing of certain alpha subunits with certain beta-subunits determines ligand specificity, localization and function.
  • the extracellular binding domains of integrins often bind their ligands with low affinity; simultaneous, weak, binding with multiple matrix molecules provides the cell with a means to sense its complex, changing, extracellular environment without becoming glued to it.
  • Examples of integrin-related sequences include integrin alpha and beta subunits, collagens, and integrin-linked kinase (Zhang et al., 2002).
  • Integrin-related sequences can possess or interact with von
  • FG-GAP FG-GAP repeat
  • An "interacting protein” is a protein that interacts with another molecule. Interacting proteins are involved in every aspect of cellular function. Interacting proteins have been characterized in all known locations in the cell, and include all, or most types of, proteins. Interacting proteins in the nucleus regulate such diverse functions as apoptosis, transcription, homologous recombination, and DNA repair. Nuclear fibroblast growth factor-2 interacting factor interacts with fibroblast growth factor 2 to prevent apoptosis (Van den Berghe et al., 2000).
  • Grap2 cyclin-D interacting protein a nuclear cell-cycle protein, inhibits select transcriptional events, and reduces the leve 1 of phosphorylation of nuclear retinoblastoma protein (Chang et al., 2000).
  • Pir 51 a human homologue of Rec A, a bacterial enzyme that mediates genetic recombination, interacts with the enzyme rad51 to regulate homologous recombination and DNA repair in mammalian cells (Kovalenko et al., 1997).
  • Hepatitis B virus X-associated protein HBXAP
  • HBXAP Hepatitis B virus X-associated protein
  • Interacting protein-related proteins can utilize many protein domain motifs for interaction. They can possess or interact with domains that mediate interaction with DNA, RNA, ions, or other proteins. For example, PDZ domains, which are also known as DHR or GLGF domains, target signaling molecules to membranes and mediate the assembly of functional membrane domains (Fanning and Anderson, 1999). Interacting protein-related proteins can also possess or interact with rrm domains, which are described above.
  • Isomerases are enzymes that convert molecules into their positional isomers, i.e., into molecules with the same chemical formula but a different stereochemical arrangement of atoms. Isomerases act on a wide variety of molecules, including sugars, amino acids, and nucleic acids. They are involved in a wide range of physiological and pathological functions, including those involving metabolic and synthetic pathways.
  • Isomerase-related sequences include isomerase genes and gene products, their substrates, products, activators, inhibitors, effectors, and cofactors, regulatory molecules that modulate their function, genes and gene products affected in disorders associated with isomerases and antibodies that specifically recognize or modulate isomerase-related sequences.
  • isomerase-related sequences include triosephosphate isomerases, peptidyl-prolyl isomerases, glucose phosphate isomerases, disulfide isomerases, ketosteroid isomerases, and ribosyltransferase- isomerases (Brown et al., 1985).
  • TIM triosephosphate isomerase
  • pro_isomerase cyclophilin type peptidyl-prolyl cis-trans isomerase domains
  • mucin refers to both an albumin-like substance that is present in mucus, and to transmembrane proteins that can typically be produced in both soluble and transmembrane forms.
  • Soluble mucins comprise mucus gels that protect epithelial cells in the airways, digestive tract, and other organs, and are found in body fluids, such as milk, tears, and saliva. In their transmembrane forms, mucins provide a steric barrier to protect the apical surface of epithelial cells.
  • Transmembrane mucins are also involved in pathogenesis; for example, they mediate viral entry into cells, promulgate the inflammatory response, and are involved in the regulation of abnormal cell proliferation (Jeffery and Zhu, 2002; Tsuda et al., 1993).
  • mucins include MUC2 mucin, mucin carcinoembryonic antigen, and Muc3 membrane bound intestinal mucin.
  • sequences of the invention include nucleotide and amino acid sequences, some with known function, and some with unknown function, that fall into a broad array of categories. These sequences are listed below in SEQ ID NOS.: 210 - 418, as “Other Polypeptides with Known Function,” and “Other Polypeptides,” respectively.
  • SNF7 domains protein domains involved in protein sorting and transport from the endosome to the lysosome or vacuole of eucaryotic cells
  • CKS cyclin-dependent kinase regulatory subunit
  • NUDIX nucleoside diphosphate linked to some other moiety X domains
  • F_actin_cap_B beta subunit domains
  • G-alpha G-protein alpha subunit
  • thioredoxin thiored domains
  • TUDOR domains protein domains involved in the formation of primordial germ cells, and for normal abdominal segmentation
  • ank protein domains of approximately 33 amino acids
  • Polypeptide-related sequences of the invention can also possess or interact with nicotinamide N-methylfransferase/phenylethanolamine N- methyltransferase/ thioether S-methyltransferase (NNMT_PNMT_TEMT) domains, which are protein domains that are found in proteins that use S-adenosyl-L- methionine as the methyl donor (http://pfam.wustl.edu/cgi-bin/getdesc7name*---- : NNMT_PNMT_TEMT).
  • NNMT_PNMT_TEMT nicotinamide N-methylfransferase/phenylethanolamine N- methyltransferase/ thioether S-methyltransferase domains, which are protein domains that are found in proteins that use S-adenosyl-L- methionine as the methyl donor (http://pfam.wustl.edu/cgi-bin
  • HABP4_PAI-RBP1 hyaluronan/mRNA binding family
  • Oxygenases are enzymes that catalyze the incorporation of molecular oxygen into organic substances. Dioxygenases, also known as oxygen transferases, catalyze the introduction of both atoms of molecular oxygen, and typically contain iron. Monooxygenases, also known as mixed function oxygenases, introduce one oxygen atom; the other is reduced to water. Examples of oxygenase- related sequences include cytochrome oxygenases, heme oxygenases, cyclooxygenases, lipoxygenases, and peptide-aspartate beta-dioxygenase.
  • FAD flavin adenine dinucleotide
  • Peroxidases are enzymes that catalyze the reduction of hydrogen peroxide. Peroxidases are generally located within peroxisomes, which are infracellular organelles that metabolize fatty acids and toxic compounds. Disorders associated with peroxidase-related sequences include X-linked adrenoleukodysfrophy. Examples of peroxidase-related sequences include glutathione peroxidases, thiol peroxidases, catalases, horseradish peroxidases, anionic peroxidases, and thyroid peroxidases.
  • AhpC-TSA alkyl hydroperoxide reductase/thiol specific antioxidant
  • Phospholipases are enzymes that act on phospholipids. They characteristically generate products that are active in signal transduction pathways. For example, phospholipase C hydrolyzes phosphatidylinositol bisphosphate (PIP 2 ) to generate the two intracellular mediators, inositol trisphosphate (IP 3 ) and diacylglycerol. IP 3 releases Ca 2+ from stores in the endoplasmic reticulum, increasing the cytosolic Ca 2+ concentration. Diacylglycerol remains in the plasma membrane and activates protein kinase C.
  • PIP 2 phosphatidylinositol bisphosphate
  • IP 3 inositol trisphosphate
  • IP 3 diacylglycerol
  • Phospholipase activity is involved in the synthesis of eicosanoids, inflammatory mediators that include prostaglandins, prostacyclins, thromboxanes, and leukotrienes.
  • Corticosteroid hormones such as cortisone, for example, inhibit phospholipase activity in the first step of the eicosanoid synthesis pathway.
  • Corticosteroid hormones are widely used clinically to treat noninfectious inflammatory diseases, such as some forms of arthritis (Ribardo et al., 2002).
  • Phospholipids play a pivotal role in the modulation of intestinal inflammation.
  • the mucosal surface of the digestive tract functions as a regulatory barrier between the gastrointestinal lumen and the underlying mucosal immune system.
  • Phospholipids help preserve the mucosa following various forms of injury or physiological damage to the lumen, thus preventing invasion of harmful luminal factors into the host, which subsequently may lead to inflammation, or a pathological immune response, both promoting and inhibiting gastrointestinal inflammation and immunity (Sturm and Dignass, 2002).
  • Lipase_GDSL GDSL-like lipase/acylhydrolase
  • Saposins are small lysosomal proteins that activate lysosomal lipid-degrading enzymes, including enzymes that metabolize sphingosine. They typically isolate lipids from their membrane surroundings, and increase their accessibility to degradative enzymes. Mammalian saposins are synthesized as a single precursor molecule, prosaposin, which becomes an active saposin following proteolytic activation. Examples of prosaposin-related sequences include saposin A, saposin B, and saposin C. Disorders associated with prosaposin-related sequences include neurodegenerative diseases similar to similar to Tay-Sachs and Sandhoff diseases, e.g., Gaucher's disease, which is described above.
  • Prosaposin-related sequences can possess or interact with saposin-A (SAP A) domains, saposin Bl (SapB_l) domains, and saposin B2 (SapB_2) domains, which are described above.
  • Proteasomes are intracellular complexes that degrade proteins.
  • proteasomes recognize proteins that have been marked for destruction by the addition of an ubiquitin molecule, unfold these ubiquitinated proteins, cleave them into small peptides of 6-12 amino acids, and release them into the cytosol (Mitch and Goldberg, 1996).
  • proteasome-related sequences include 26S proteasome subunits, 26S proteasome regulatory chains, and ubiquitin.
  • PC_rep proteasome/cyclosome repeat
  • Reductases are enzymes that catalyze reduction reactions, i.e., reactions in which hydrogen is combined with a molecule, or reactions in which oxygen is removed from a molecule.
  • reductases include dehydrogenase reductases, oxidoreductases, quinone reductases, CoA reductases, dihydrofolate reductases, tetrahydrofolate reductases, carbonyl reductases, nitrate reductases, epoxide reductases, NADP(+) reductases, ribonucleotide reductases, and thioredoxin reductases (Loeffen et al., 1998).
  • Reverse transcriptases are enzymes that make double stranded
  • a reverse transcriptase is a DNA polymerase that can copy both RNA and DNA templates, and has an integral RNase H activity (Lim et al., 2002).
  • the two enzymatic domains of reverse transcriptase reflect these two activities; the first is a DNA polymerase domain that can use either RNA or DNA as a template to synthesize either the minus-strand or the plus strand of DNA, and the second is an RNase H domain that degrades the RNA in RNA-DNA hybrids (Coffin, 1997; Wu and Gallo, 1975).
  • Reverse transcriptase plays a role in the replication of some viruses, e.g., refroviruses. It copies the retroviral RNA genome to produce a single minus strand of DNA, then catalyzes the synthesis of a complementary plus strand. Accordingly, reverse franscriptase is a therapeutic target for conditions that involve refroviruses, e.g., Aquired Immune Deficiency Syndrome (AIDS). A number of anti- retroviral drags inhibit reverse transcriptase (Frank, 2002).
  • viruses e.g., refroviruses. It copies the retroviral RNA genome to produce a single minus strand of DNA, then catalyzes the synthesis of a complementary plus strand. Accordingly, reverse franscriptase is a therapeutic target for conditions that involve refroviruses, e.g., Aquired Immune Deficiency Syndrome (AIDS). A number of anti- retroviral drags inhibit reverse transcriptase (Frank,
  • Reverse transcriptase is also a standard scientific research tool in the field of molecular biology.
  • the reverse transcriptase polymerase chain reaction (RTPCR) amplifies specific DNA sequences rapidly, and in vitro.
  • RTPCR can detect trace amounts of RNA and DNA, and is used in a wide range of applications, including forensics, the diagnosis of genetic diseases, determination of the prognosis of diagnosed diseases, and the detection of viral infection (Alberts, et al., 1994).
  • RTPCR reverse transcriptase is used to diagnose cancer (Rowland, 2002), and to provide prognostic information about the predicted survival of patients with prostate cancer (Kantoff et al., 2001).
  • telomerase a general tumor marker with a reverse transcriptase catalytic subunit
  • Most human somatic cells do not express the telomerase reverse transcriptase gene; conversely, most cancer cells express this gene (Ducrest et al., 2002; Kyo et al., 2000 ).
  • the human telomerase reverse transcriptase promoter has been placed in gene therapy vectors that specifically target telomerase-positive tumor cells, and spare nearby telomerase-negative cells (Pan and Koeneman, 1999).
  • Human telomerase reverse transcriptase is also recognized as a tumor antigen that can be a target for immunotherapeutic approaches to cancer (Gordan and Vonderheide, 2002).
  • Reverse franscriptase-related sequences can possess or interact with rvt, transposase_22, WD40, and Exo_endo_phos domains, all of which are described above.
  • a ribosome is a particle comprised of ribosomal proteins and ribosomal RNA that catalyzes protein synthesis from messenger RNA. Ribosomes are composed of two subunits, the large (L) subunit and the small (S) subunit.
  • the typical mammalian ribosome comprises four RNA molecules and approximately eighty different proteins, which are highly conserved among prokaryotes and eukaryotes, and perform a variety of tasks related to protein synthesis . e.g., coordinating protein synthesis in a manner that maintains cell homeostasis (Yoshihama et al., 2002; Kenmochi et al., 1998).
  • Ribosomal proteins can perform functions independent of their involvement in protein synthesis. For example, they are involved in cell-cycle progression, e.g., as cell cycle checkpoints, and mediators of homologous recombination, embryogenesis, and skeletal development (Yoshihama et al., 2002; Chen and loannou, 1999). They also contribute to the regulation of cell growth, transformation, and death, and can induce apoptosis (Chen and loannou, 1999; Naora et al., 1999). Mutations in ribosomal proteins are associated with human diseases, including Down syndrome, Diamond-Blackfan anemia, Turner syndrome, and Noonan syndrome (Yoshihama et al., 2002).
  • Ribosomal proteins have been grouped into protein families on the basis of sequence similarities in functional domains.
  • One family of ribosomal proteins, the ribosomal protein LI 1, RNA binding (Ribosomal_Ll 1) domain is comprised of members that possess the LI 1 RNA binding domain; this family includes the ribosomal proteins LI 1 and LI 2, which are components of the large subunit.
  • Ribosomal_S6e ribosomal protein S6e domain
  • RNases are enzymes that cleave RNA. RNases generally recognize their targets by tertiary structure, rather than by sequence; they include exonucleases, which remove the terminal base in an RNA sequence, and endonucleases, which can cleave non-terminal bases.
  • RNases examples include RNase E, which is involved in the formation of 5S ribosomal RNA from pre- ribosomal RNA; RNase F, which cleaves both viral and host RNA in response to interferons, inhibiting protein synthesis; RNase H, which is specific for the RNA strand of an RNA-DNA hybrid; RNase P, which generates transfer RNA from precursor transcripts; and RNase T, which removes the terminal AMP from nonaminoacylated tRNA (Coffin, et al., 1997).
  • RNase-related sequences can possess or interact with rvt, rve,
  • RNase H is a nuclease specific for the RNA strand of an RNA-
  • RNase H DNA hybrid that cleaves phosphodiester bonds to produce molecules with 3 -OH and 5'-PO 4 ends.
  • Multiple forms of RNase H are present in both prokaryotes and eukaryotes. RNase H may be part of larger polypeptides and its activity can be influenced by other regions of these polypeptides (Coffin, et al., 1997; Crouch 1990).
  • RNase H activity forms oligonucleotides that prime DNA synthesis. Therefore, the RNase H activity of reverse transcriptase is a target for therapeutic intervention.
  • small molecule inhibitors of retroviral RNase H function have shown promise in managing HIV infection (Klarman, et al, 2002).
  • RNase H Another therapeutic indication for RNase H is the regulation of cancer genes by targeting mRNA translation.
  • Antisense deoxyoligonucleotides down- regulate mRNA expression by annealing to specific regions of an mRNA. Formation of the DNA:RNA heteroduplex then triggers mRNA cleavage by RNase H. Cleavage is rapidly followed by further degradation, irreversibly preventing translation of the target mRNA.
  • Antisense deoxyoligonucleotides that trigger RNase H activity can thus be used as cancer therapeutic agents (Crooke, 1996; Curcio et al., 1997).
  • RNase H-related sequences can possess or interact with rnaseH
  • Gag_p30, rvt, and rve domains all of which are described above.
  • Src homology region 3 is a polypeptide domain commonly found in intracellular signaling proteins; it binds with moderate affinity and selectivity to proline-rich ligands. SH3 domains are heterogeneous; different SH3 domains bind to different proline-rich sequences (Gmeiner and Horita, 2001). SH3 domains are involved in a wide variety of biological processes, including mediating the assembly of large multiprotein complexes, regulating enzyme activity, and modulating the local concentration or subcellular localization of signaling pathway components (Mayer, 2001).
  • SH3-related sequences include phosphotyrosine receptors, membrane associated guanylate kinases, mitogen-activated protein kinases, myosin 1, the Crk adaptor protein, phospholipase C- ⁇ , Grb2, Sos, src-SH3, Abl-SH3, the Nek adaptor, and alpha-s ⁇ ectrin-SH3.
  • Stem cells are pluripotent or multipotent cells that generate maturing cells in multiple differentiation lineages. Pluripotent cells have the capacity to differentiate into each and every cell present in the organism. Embryonic stem cells are pluripotent; they can differentiate into any of the cells present in the adult. Multipotent cells have the ability to differentiate into more than one cell type. Organ- specific stem cells are multipotent; they can differentiate into any of the cells of the organ they inhabit.
  • both pluripotent and multipotent stem cells can maintain their pluripotency or multipotency while giving rise to differentiated progeny.
  • stem cells can produce replicas of themselves which are pluri- or multipotent, and are also able to differentiate into lineage-restricted committed progenitor cells.
  • hematopoeitic stem cells which are multipotent cells specifically able to form blood cells, can divide to produce replicate hematopoeitic stem cells. They can also divide to produce more highly differentiated cells, which are precursors of blood cells. The precursors differentiate, sometimes through several generations of cells, into blood cells.
  • a hematopoetic stem cell can also divide into a cell with the capacity to form, for example, a relatively undifferentiated cell that is committed to differentiate into, i.e., granulocytes, or erythrocytes, or another type of blood cell.
  • Stem cells can also reproduce and differentiate in vitro.
  • Embryonic stem cells have been directed to differentiate into cardiac muscle cells in vitro and, alternatively, into early progenitors of neural stem cells, and then into mature neurons and glial cells in vitro (Trounson, 2002).
  • Stem cell therapy is effective in treating cancer in humans (Slavin et al., 2001), and offers several advantages over traditional cancer therapies (Weissman, 2000).
  • One advantage of stem cell therapy exists when used in conjunction with radiation therapy.
  • radiation therapy for cancer the dose of radiation necessary to kill the cancer cells in an organ can also be sufficient to destroy the healthy cells of the organ.
  • stem cells are infused to repopulate the organ. In the ensuing weeks, as the cancer cells and healthy cells die, the stem cells replace the healthy cells.
  • Another advantage of this approach compared to heterologous organ transplants, is that there is no risk of rejection, since stem cells do not provoke an immune response.
  • a further advantage is that stem cells are inherently programmed to regulate their numbers and differentiation status, i.e., once provided to the patient, the necessary number will differentiate, and the rest will remain undifferentiated (Weissman, 2000).
  • Stem cell therapy is also effective in treating autoimmune disease in humans.
  • immunosuppression in conjunction with stem-cell transplantation has induced remission in patients with refractory, severe rheumatic autoimmune disease (Van Laar and Tyndall, 2003).
  • Patients with rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and juvenile idiopathic arthritis have benefited from stem cell transplants (Van Laar and Tyndall, 2003).
  • Preclinical studies also suggest the potential of stem cell transplantation for the treatment of neural and muscular injuries and disorders, including those of the central nervous system, peripheral nervous system, and skeletal, cardiac and smooth muscle (Deasy and Huard, 2002).
  • Stem cells transplanted into the bone marrow of mice migrate to the site of injured muscle and differentiate into new muscle cells.
  • patients with myasthenia gravis, muscular dystrophies, amyotrophic lateral sclerosis, congestive heart failure, Parkinson's disease, and Alzheimer's disease may benefit from stem cell therapy (Henningson, 2003).
  • stem cells derived from a patient with a genetic disease can provide a tool for studying that disease.
  • a somatic cell i.e., a cell that is not in the oocyte or spermatocyte lineage
  • This nuclear transplant procedure produces, at the blastocyst stage of development, embryonic stem cells with the same set of genes as the patient with the genetic disease. Studying these cells, and their progeny in vitro, permits analysis of a specific model of the disease. For example, placing stem cells derived from a patient with a genetic disorder under the control of various stem cell regulatory factors can elicit abnormal responses from the affected stem cells compared to stem cells derived from a healthy individual's somatic nucleus.
  • SCF stem cell factor
  • Certain stem cell related sequences can possess the ability to maintain the stem cell in undifferentiated state while allowing cell proliferation. Such compositions can be useful in ex vivo cell therapy to expand populations of cells for cell replacement therapy.
  • Certain stem cell related sequences can possess the ability to cause cell differentiation to a relatively mature cell type and are useful to in vivo or ex vivo therapy to compensate for deficiency of such relatively mature cell type.
  • a synthetase is an enzyme that catalyzes the synthesis of a molecule.
  • Synthetases comprise a broad class of enzymes; they catalyze the synthesis of nucleic acids, peptides, and lipids (Agou et al., 1996).
  • Examples of synthetases include lysyl-tRNA synthetase, asparaginyl t-RNA synthetase, holocarboxylase synthetase, carbamyl phosphate synthetase I, and argininosuccinate synthetase.
  • the 20 aminoacyl- tRNA synthetases are divided into class I and class II, each of which contain multiple synthetases with different specificities. For example, there is a protein domain involved in the asparagines, aspartic acid, and lysine synthesis (http://pfam.wustl.
  • LpxB lipid- A-disaccharide synthetase
  • a TATA box is a consensus sequence in the promoter region of many eucaryotic genes that binds a general transcription factor and plays a role in specifying the position for transcription initiation. TATA boxes are generally found approximately 25 nucleotides before the site of transcription initiation (Chalut et al., 1995). Examples of TATA box-related sequences include TATA box binding protein, 13 TATA/TBP, and small nuclear RNA-activating protein 190 Myb DNA.
  • Tat is a human immunodeficiency virus (HIV) protein involved in viral production of new RNA genomes and new complete viral particles. Tat is also involved in AIDS pathogenesis; it plays a role in reactivating latent viruses, e.g., the JC retrovirus; it is involved in the development of AIDS-related Kaposi's Sarcoma; and it depresses the function of, and induces apoptosis in, helper CD4 cells (Yu et al., 1995).
  • Examples of Tat-related sequences include Tat-associated proteins, e.g., Tap, HIV-1 Rev, and tat-associated kinase (also known as positive transcriptional elongation factor b).
  • Tat transactivating regulatory protein
  • MAM33 mitochondrial glycoprotein
  • Transferases are enzymes that transfer a designated group of atoms from a donor molecule to an acceptor molecule.
  • acyl fransferases transfer acyl groups
  • methyl fransferases transfer methyl groups
  • nucleotidyl fransferases transfer nucleotides
  • prenylfransferases transfer prenyl groups
  • glycosyl transferases transfer glycosyl groups (Lin et al., 1996).
  • transferases examples include acetylfransferases, hydroxymethylfransferases, sialylfransferases, arginine N-methylfransferase, glucoronosyltransferase, NTP-transferase, and GDP- mannose pyrophosphorylase B.
  • Transposases are site-specific recombination enzymes that catalyze the transposition of a segment of DNA from one part of the genome to another.
  • the movable segments are called transposable elements; each transposable element is occasionally moved by a transposase, which functions as an integrase, by inserting DNA sequences into other DNA sequences.
  • Transposases are often encoded by the DNA of the transposable element itself.
  • Transposases bind specifically to terminal inverted repeats of 10-500 bp that are characteristically part of transposable elements (Smit and Riggs, 1996). They catalyze both cutting and pasting of a transposable element from one segment of the genome to another.
  • Sequences related to transposases can have other functions, e.g., as transcription factors, or in the assembly of centromere proteins (Smit and Riggs, 1996).
  • Examples of transposase- related sequences include mariner, pogo, hobo, tigger, MER37, Galileo, Ocean, Impala, Tn MERI1, MsqTc3, and the sleeping beauty transposon system (Robertson and Zumpano, 1997; Robertson, 1996; Smit and Riggs, 1996).
  • Transposase-related sequences can also possess or interact with LI transposable element (Transposase_22) domains, which have been described above.
  • DDE DDE endonuclease
  • Transposase-related sequences can also possess or interact with a reverse transcriptase (rvt) domain, and/or a low-density lipoprotein receptor (ldljrece) domain, both of which are described above.
  • Ubiquitin is a protein found in all eucaryotic cells examined to date. When it is linked to the lysine side chain of a protein by the formation of an amide bond with its C-terminal glycine, ubiquitin renders the ubiquitin-bound protein subject to rapid proteolysis in the proteasome. In addition to its role in the selective degradation of cellular proteins, ubiquitin also plays a role in maintaining chromosome structure, regulating gene expression, responding to stresses on the organism, the regulation of gene expression, and ribosome biogenesis.
  • ubiquitin-related sequences include elongins, ubiquitin-specif ⁇ c proteases, ubiquitin- calmodulin ligase, ubiquitin carrier protein kinase, ubiquitin N-alpha-protein hydrolase, and the small ubiquitin-related modifier (Sumo-1) (Kamitani et al., 1997).
  • UCH ubiquitin carboxyl-terminal hydrolase
  • the human chromosome has integrated endogenous genes that are related to viral genes.
  • Some endogenous viral genes e.g., the retroviral HERV-W family, are widely and heterogeneously dispersed among human chromosomes (Voisset et al, 2000; Everett et al., 1997; Werner et al., 1990).
  • Endogenous proviruses are usually franscriptionally silent, but are expressed under certain conditions (Coffin et al., 1997).
  • Endogenous viral expression can be specific to host factors, such as cell type or stage of differentiation, as well as other factors including the position on the chromosome, the influence of cw-acting sequences, or the presence of host-mediated DNA methylation (Coffin).
  • Endogenous viral expression can have a number of consequences, both beneficial and detrimental.
  • beneficial consequences is the ability of endogenous refroviruses to confer resistance to infection by exogenous viruses.
  • mice with endogenous mouse mammary tumor virus (MMTV) can be immune to exogenous infection (Golovkina, et al., 1992).
  • detrimental effects is a causative role in disease.
  • Evidence indicates an association between endogenous viruses with cancers and autoimmune diseases (Coffin et al., 1997). For example, spontaneous tumors of specific origin, murine mammary adenocarcinomas, and murine T-cell lymphomas have been associated with the presence of specific endogenous refroviruses.
  • a transformed phenotype is associated with the increased transcription of certain classes of endogenous viral elements (Coffin et al., 1997).
  • endogenous virus that influences the immunoregulatory process has been associated with spontaneous autoimmune thyroiditis in a chicken model of human Hashimoto disease (Wick et al., 1987).
  • viral-related proteins include hepatitis B virus x- interacting protein, herpesvirus associated ubiquitin-specific protease, and Coxsackievirus and adenovirus receptor precursor.
  • Viral-related sequences can possess or interact with rvt, rve, and gag_p30 sequences, all of which are described above.
  • a zinc finger domain is a small, self-folding, structural motif of 25 to 30 amino-acid residues present in many nucleic acid-binding proteins. It is comprised of a polypeptide loop held in a hairpin bend and bound to a zinc atom, and includes two conserved cysteine and two conserved histidine residues. Many classes of zinc fingers have been characterized according to the number and positions of the conserved histidine and cysteine residues.
  • the amino acid configuration that holds the zinc atom in a tetrahedral array has a finger-like projection that interacts with nucleotides in the major groove of the bound nucleic acid.
  • Zinc fmger motifs have conserved regions near the zinc molecule, and variable regions at the nucleic acid binding site that provide specificity for the nucleic acid sequences they bind.
  • Zinc fmger proteins have a variety of functions, including as transcription regulators and intracellular receptors.
  • Zinc finger domains are also involved in protein-protein interactions, e.g., those involving protein kinase C.
  • zinc finger nucleases have been used to target genes for gene replacement by homologous recombination (Bibikova et al., 2003). Examples of zinc finger proteins include XC3H-3b, the transcription factor Slug, and transcription factor IIIA.
  • Zinc knuckles are also found in retroviral gag and nucleocapsid proteins, where they function in genome packaging, and early in the infection process.
  • KRAB domains can function as transcription factors, e.g., as a transcriptional repressor, and can assume roles in cell differentiation and development (Aubry et al., 1992; Lovering and Trowsdale, 1991).
  • Zinc finger-related sequences can possess or interact with a transposase_22 domain, which is described above.
  • the invention provides sequences related to secreted sequences, single-transmembrane sequences, multiple-transmembrane sequences, kinase-related sequences, ligase-related sequences, nuclear hormone receptor-related sequences, phosphatase-related sequences, protease-related sequences, phosphodiesterase-related sequences, kinesin-related sequences, immunoglobulin-related sequences, T-cell receptor-related sequences, glycosylphosphatidylinositol anchor-related sequences, and sequences related to other nucleic acid and amino acid sequences of the invention, including activators, adaptors, adhesion molecules, ATPases, ATP, breakpoints, channels, checkpoints, complexes, dehydrogenases, disintegrins, endopeptidases, germ-cells, GTPases, helicases, hydrolases, integrases, integrins, isomerases, membranes, mucins, oxygena
  • the present invention also provides for vectors, host cells, and methods for producing the polynucleotides and polypeptides of the invention in these vectors and host cells.
  • the present invention further provides for antisense molecules that are capable of regulating the expression of the polynucleotides or polypeptides herein.
  • modulators including antibodies that bind specifically to the polypeptides or modulate the activity of the polypeptides, are also provided.
  • the present polynucleotides, polypeptides, and modulators find use in therapeutic agent screening/discovery applications, such as screening for receptors or competitive ligands, for use, for example, as small molecule therapeutic drugs. Also provided are methods of modulating a biological activity of a polypeptide and methods of treating associated disease conditions, particularly by administering modulators of the present polypeptides, such as small molecule modulators, antisense molecules, and specific antibodies.
  • the present polypeptides, polynucleotides, and modulators find use in a number of diagnostic, prophylactic, and therapeutic applications.
  • the polynucleotides and polypeptides of the invention can be detected by methods provided herein; these methods are useful in diagnosis, and can be accomplished by the use of diagnostic kits.
  • the polynucleotides and polypeptides of the invention are useful for treating a variety of disorders, including cancer, proliferative disorders, inflammatory disorders, immune disorders, bacterial or viral disorders, and other metabolic disorders.
  • subjects who suffer from a deficiency, or a lack of a particular protein, or are otherwise in need of such protein to repair or enhance a desirable function benefit from the administration of a protein or an active fragment thereof by any conventional routes of administration.
  • therapeutic vaccines in the form of nucleic acid or polypeptide vaccines, such as cancer vaccines, where the vaccines can be administered alone, such as naked DNA, or can be facilitated, such as via viral vectors, microsomes, or liposomes.
  • Therapeutic antibodies include those that are administered alone or in combination with cytotoxic agents, such as radioactive or chemotherapeutic agents.
  • the polypeptides, polynucleotides, and modulators of the present invention can be used to treat cancers, including, but not limited to, cancers of the prostate, breast, bone, soft tissue, liver, kidney, ovary, cervix, skin, pancreas, and brain, as well as leukemias, lymphomas, lung cancers such as adenocarcinomas and squamous cell carcinoma, and cancers of gastrointestinal organs such as stomach, colon, and rectum.
  • cancers including, but not limited to, cancers of the prostate, breast, bone, soft tissue, liver, kidney, ovary, cervix, skin, pancreas, and brain, as well as leukemias, lymphomas, lung cancers such as adenocarcinomas and squamous cell carcinoma, and cancers of gastrointestinal organs such as stomach, colon, and rectum.
  • polypeptides, polynucleotides, and modulators of the present invention can be used to treat inflammatory, immune, bacterial, viral, and metabolic diseases, disorders, syndromes, or conditions, including, but not limited to, intestinal inflammation and immunity, autoimmune thyroiditis, and retroviral infections, as well as tissue and/or organ hypertrophy.
  • the present invention features an isolated polynucleotide that encodes a polypeptide.
  • the polypeptide has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity with an amino acid sequence derived from a polynucleotide sequence chosen from at least one nucleotide sequence according to SEQ ID NOS.: 1 - 209 and 419 - 627.
  • the polypeptide has an amino acid sequence chosen from at least one amino acid sequence according to SEQ ID. NOS. 210 - 418.
  • the polypeptide has at least one activity associated with the naturally occurring encoded polypeptide.
  • the polypeptide includes a signal peptide.
  • the polypeptide comprises a mature form of a protein, from which the signal peptide has been cleaved.
  • the polypeptide is a signal peptide.
  • the invention provides fragments of a polypeptide chosen from at least one amino acid sequence according to SEQ ID NOS.: 210 - 418, where each fragment is an extracellular fragment of the polypeptide, or an extracellular fragment of the polypeptide minus the signal peptide.
  • the invention provides an N-terminal fragment containing a Pfam domain and a C-terminal fragment containing a Pfam domain and either or both may be biologically active.
  • the polypeptides function as secreted proteins. In yet further embodiments, the polypeptides function as single- transmembrane proteins. In yet further embodiments, the polypeptides function as multiple-transmembrane proteins. In yet further embodiments, the polypeptides function as kinases. In yet further embodiments, the polypeptides function as protein kinases. In yet further embodiments, the polypeptides function as ligases. In yet further embodiments, the polypeptides function as nuclear hormone receptors. In yet further embodiments, the polypeptides function as phosphatases. In yet further embodiments, the polypeptides function as proteases.
  • the polypeptides function as phosphodiesterases. In yet further embodiments, the polypeptides function as kinesins. In yet further embodiments, the polypeptides function as immunoglobulins. In yet further embodiments, the polypeptides function as T-cell receptors. In yet further embodiments, the polypeptides function as glycosylphosphatidylinositol anchors.
  • the polypeptides function as cytokines. In still further embodiments, the polypeptides function as immune cells. In further embodiments, the polypeptides function as antigens. In yet further embodiments, the polypeptides function as receptors. In other embodiments, the polypeptides function as binding proteins. In other embodiments, the polypeptides function as factors. In further embodiments, the polypeptides function as growth factors. In further embodiments, the polypeptides function as heat-shock proteins. In some embodiments, the polypeptides function as membrane transport proteins. In yet further embodiments, the polypeptides function as ribosomal proteins. In some embodiments, the polypeptides function as zinc fingers. In some embodiments, the polypeptides function as embryonic stem cell-related peptides. In still further embodiments, the polypeptides function in pathological states. In other embodiments, the polypeptides function as one or more of these.
  • the polypeptides function as activators. In yet further embodiments, the polypeptides function as adaptors. In yet further embodiments, the polypeptides function as adhesion molecules. In yet further embodiments, the polypeptides function as ATPases. In yet further embodiments, the polypeptides function as ATP-related polypeptides. In further embodiments, the polypeptides function as channel-related polypeptides. In yet further embodiments, the polypeptides function as checkpoint-related polypeptides. In yet further embodiments, the polypeptides function as complexes. In yet further embodiments, the polypeptides function as dehydrogenases. In yet further embodiments, the polypeptides function as disintegrins.
  • the polypeptides function as endopeptidases. In yet further embodiments, the polypeptides function as germ-cells. In yet further embodiments, the polypeptides function as GTPases. In yet further embodiments, the polypeptides function as helicases. In yet further embodiments, the polypeptides function as hydrolases. In yet further embodiments, the polypeptides function as integrases. In yet further embodiments, the polypeptides function as integrins. In yet further embodiments, the polypeptides function as isomerases. In yet further embodiments, the polypeptides function as membranes. In yet further embodiments, the polypeptides function as mucins.
  • the polypeptides function as oxygenases. In yet further embodiments, the polypeptides function as peroxidases. In some embodiments, the polypeptides function as phospholipases. In yet further embodiments, the polypeptides function as prosaposins. In yet further embodiments, the polypeptides function as proteasomes. In yet further embodiments, the polypeptides function as reductases. In other embodiments, the polypeptides function as reverse transcriptase-related polypeptides. In yet further embodiments, the polypeptides function as RNases. In further embodiments, the polypeptides function as RNase H-related polypeptides. In yet further embodiments, the polypeptides function as SH3-related polypeptides.
  • the polypeptides function as synthetases. In yet further embodiments, the polypeptides function as TATA box-related polypeptides. In yet further embodiments, the polypeptides function as TAT-related polypeptides. In yet further embodiments, the polypeptides function as transferases. In yet further embodiments, the polypeptides function as transposases. In yet further embodiments, the polypeptides function as ubiquitin-related polypeptides. In yet further embodiments, the polypeptides function as virus-related polypeptides. In other embodiments, the polypeptides function as one or more of these.
  • the present invention features an isolated polynucleotide that hybridizes under stringent hybridization conditions to a coding region of at least one nucleotide sequence shown in SEQ ID NOS.: 1 - 209, 419 - 627, or a complement thereof.
  • the present invention features an isolated polynucleotide that shares at least about 70%, at least about 75%, at least about 80%, at least about 85%), at least about 90%, at least about 95%, at least about 97%, at least about 98%, at least about 99%) nucleotide sequence identity with a nucleotide sequence of the coding region of at least one sequence shown in SEQ ID NOS.: 1 - 209, 419 - 627, or a complement thereof.
  • a subject polynucleotide has the nucleotide sequence shown in at least one of SEQ ID NOS.: 1 - 209, 419 - 627, or a coding region thereof.
  • the present invention also features a vector, e.g., a recombinant vector, that includes a subject polynucleotide, and a promoter the drives its expression.
  • This vector can transform a host cell, and the present invention further features such host cells, e.g., isolated in vitro host cells, and in vivo host cells, that comprise a polynucleotide of the invention, or a recombinant vector of the invention.
  • the present invention further features a library of polynucleotides, wherein at least one of the polynucleotides comprises the sequence information of a polynucleotide of the invention.
  • the library is provided on a nucleic acid array.
  • the library is provided in computer- readable format.
  • the present invention features a pair of isolated nucleic acid molecules, each from about 10 to about 200 nucleotides in length.
  • the first nucleic acid molecule of the pair comprises a sequence of at least 10 contiguous nucleotides having 100% sequence identity to at least one nucleic acid sequence shown in SEQ ID NOS.: 1 - 209 and 419 - 627.
  • the second nucleic acid molecule of the pair comprises a sequence of at least 10 contiguous nucleotides having 100% sequence identity to the reverse complement of at least one nucleic acid sequence shown in SEQ ID NOS.: 1 - 209 and 419 - 627.
  • the sequence of said second nucleic acid molecule is located 3 ' of the nucleic acid sequence of the first nucleic acid molecule shown in SEQ ID NOS.: 1 - 209 and 419 - 627.
  • the pair of isolated nucleic acid molecules are useful in a polymerase chain reaction or in any other method known in the art to amplify a nucleic acid that has sequence identity to the sequences shown in SEQ ID NOS.: 1 - 209 and 419 - 627, particularly when cDNA is used as a template.
  • the invention features a method of determining the presence of a polynucleotide substantially identical to a polynucleotide sequence shown in the Sequence Listing, or a complement of such a nucleotide by providing its complement, allowing the polynucleotides to interact, and determining whether such interaction has occurred.
  • the invention further features methods of regulating the expression of the subject polynucleotides and encoded polypeptides.
  • the invention provides a method of inhibiting transcription or translation of a first polynucleotide encoding a first polypeptide of the invention by providing a second polynucleotide that hybridizes to the first polynucleotide, and allowing the first polynucleotide to contact and bind to the second polynucleotide.
  • the second polynucleotide can be chosen from an antisense molecule, a ribozyme, and an interfering RNA (RNAi) molecule.
  • the present invention further features an isolated polypeptide, e.g., an isolated polypeptide encoded by a polynucleotide, and biologically active fragments of such polypeptide.
  • the polypeptide is a fusion protein.
  • the polypeptide has one or more amino acid substitutions, and/or insertions and or deletions, compared with at least one sequence shown in SEQ ID NOS.: 210 - 418.
  • the polypeptide has an amino acid sequence derived from at least one nucleotide sequence shown in SEQ ID NOS.: 1 - 209 and 419 - 627.
  • the polypeptide has an amino acid sequence substantially identical to at least one sequence shown in SEQ ID NOS.: 210 - 418.
  • the invention also provides a method of making a polypeptide of the invention by providing a nucleic acid molecule that comprises a polynucleotide sequence encoding a polypeptide of the invention, introducing the nucleic acid molecule into an expression system, and allowing the polypeptide to be produced.
  • the method involves in vitro cell-free transcription and/or translation.
  • the expression system can comprise a cell-free expression system, such as an E. coli system, a wheat germ extract system, a . rabbit reticulocyte system, or a frog oocyte system.
  • the expression system can comprise a prokaryotic or eukaryotic cell, for example, a bacterial cell expression system, a fungal cell expression system, such as yeast or Aspergillus, a plant cell expression system, e.g., a cereal plant, a tobacco plant, a tomato plant, or other edible plant, an insect cell expression system, such as SF9 of High Five cells, an amphibian cell expression system, a reptile cell expression system, a crustacean cell expression system, an avian cell expression system, a fish cell expression system, or a mammalian cell expression system, such as one using Chinese Hamster Ovary (CHO) cells.
  • a prokaryotic or eukaryotic cell for example, a bacterial cell expression system, a fungal cell expression system, such as yeast or Aspergillus, a plant cell expression system, e.g., a cereal plant, a tobacco plant, a tomato plant, or other edible plant, an insect cell expression system, such as SF9 of High Five
  • the method involves culturing a subject host cell under conditions such that the subject polypeptide is produced by the host cells; and recovering the subject polypeptide from the culture, e.g., from within the host cells, or from the culture medium.
  • the polypeptide can be produced , in vivo in a multicellular animal or plant, comprising a polynucleotide encoding the subject polypeptide.
  • the present invention further features a non-human animal injected with at least one polynucleotide comprising at least one nucleotide sequence chosen from SEQ ID NOS.: 1 - 209 and 419 - 627, and/or at least one polypeptide comprising at least one amino acid sequence chosen form SEQ ID NOS.: 210 - 418.
  • the present invention further features an antibody that specifically recognizes, binds to, interferes with, or modulates the biological activity of a subject polypeptide or a fragment thereof.
  • the polypeptide can be a single-transmembrane protein, multiple-transmembrane protein, kinase, protein kinase, ligase, nuclear hormone receptor, phosphatase, protease, phosphodiesterase, kinesin, immunoglobulin, T-cell receptor, glycosylphosphatidylinositol anchor, or other nucleic acid and amino acid sequences, including, activators, adaptors, adhesion molecules, ATPases, ATP, breakpoints, channels, checkpoints, complexes, dehydrogenases, disintegrins, endopeptidases, germ-cells, GTPases, helicases, hydrolases, integrases, integrins, isomerases, membranes, mucins, oxygenases, peroxidases
  • the present invention further features an antibody that specifically inhibits binding of a polypeptide to its ligand or substrate. It also features an antibody that specifically inhibits binding of a polypeptide as a substrate to another molecule.
  • Another aspect of the present invention features a library of antibodies or fragments thereof, wherein at least one antibody or fragment thereof specifically binds to at least a portion of a polypeptide comprising an amino acid sequence according to SEQ ID NOS.: 210 - 418 , and/or wherein at least one antibody or fragment thereof interferes with at least one activity of such polypeptide or fragment thereof.
  • the antibody library comprises at least one antibody or fragment thereof that specifically inhibits binding of a subject polypeptide to its ligand or substrate, or that specifically inhibits binding of a subject polypeptide as a substrate to another molecule.
  • the present invention also features corresponding polynucleotide libraries comprising at least one polynucleotide sequence that encodes an antibody or antibody fragment of the invention.
  • the library is provided on a nucleic acid array or in computer-readable format.
  • An antibody of the present invention may comprise a monoclonal antibody, polyclonal antibody, single chain antibody, intrabody, and active fragments of any of these.
  • the active fragments include variable regions from either heavy chains or light chains.
  • the antibody can comprise the backbone of a molecule with an immunoglobulin domain, e.g., a fibronectin backbone, a T-cell receptor backbone, or a CTLA4 backbone.
  • the present invention further features a targeting antibody, a neutralizing antibody, a stabilizing antibody, an enhancing antibody, an antibody agonist, an antibody antagonist, an antibody that promotes cellular endocytosis of a target antigen, a cytotoxic antibody, and an antibody that mediates antibody dependent cellular cytotoxicity (ADCC).
  • the antibody that mediates ADCC can have a cytotoxic component, e.g., a radioisotope, a radioactive molecule, a microbial toxin, a plant toxin, a chemotherapeutic agent, or a chemical substance, such as doxorubicin or cisplatin.
  • the invention also features an inhibitory antibody, functioning to specifically inhibit the binding of a cognate polypeptide to its ligand or its substrate, or to specifically inhibit the binding of a cognate peptide as the substrate of another molecule.
  • the antibodies of the present invention also encompass a human antibody, a non-human primate antibody, a monkey antibody, a non-primate animal antibody, e.g., a rodent antibody, rat antibody, a mouse antibody, a hamster antibody, a guinea pig antibody, a chicken antibody, a cattle antibody, a sheep antibody, a goat antibody, a horse antibody, porcine antibody, a cow antibody, a rabbit antibody, a cat antibody, or a dog antibody. It also features a humanized antibody, a primatized antibody, and a chimeric antibody.
  • the antibodies of the invention can be produced in vitro or in vivo.
  • the present invention features an antibody produced in a cell-free expression system, a prokaryote expression system or a eukaryote expression system, as described herein.
  • the invention further provides a host cell that can produce an antibody of the invention or a fragment thereof.
  • the antibody may also be secreted by the cell.
  • the host cell can be a hybridoma, or a prokaryotic or eukaryotic cell.
  • the invention also provides a bacteriophage or other virus particle comprising an antibody of the invention, or a fragment thereof.
  • the bacteriophage or other virus particle may display the antibody or fragment thereof on its surface, and the bacteriophage itself may exist within a bacterial cell.
  • the antibody may also comprise a fusion protein with a viral or bacteriophage protein.
  • the invention further provides transgenic multicellular organisms, e.g., plants or non-human animals, as well as tissues or organs, comprising a polynucleotide sequence encoding a subject antibody or fragment thereof.
  • the organism, tissues, or organs will generally comprise cells producing an antibody of the invention, or a fragment thereof.
  • the present invention features a method of making an antibody by immunizing a host animal.
  • a polypeptide or a fragment thereof, a polynucleotide encoding a polypeptide, or a polynucleotide encoding a fragment thereof is introduced into an animal in a sufficient amount to elicit the generation of antibodies specific to the polypeptide or fragment thereof, and the resulting antibodies are recovered from the animal.
  • the polypeptide can be encoded by a nucleic acid molecule comprising a nucleotide sequence chosen from at least one polynucleotide sequence according to SEQ ID NOS.: 1 - 209 and 419 - 627.
  • the polypeptide may comprise at least one amino acid sequence chosen from SEQ ID NOS.: 210 - 418 .
  • the invention thus also provides a non-human animal comprising an antibody of the invention.
  • the animal can be a non-human primate, (e.g., a monkey) a rodent (e.g., a rat, a mouse, a hamster, a guinea pig), a chicken, cattle (e.g., a sheep, a goat, a horse, a pig, a cow), a rabbit, a cat, or a dog.
  • a non-human primate e.g., a monkey
  • rodent e.g., a rat, a mouse, a hamster, a guinea pig
  • a chicken e.g., cattle (e.g., a sheep, a goat, a horse, a pig, a cow), a rabbit, a cat, or a dog.
  • cattle e.g., a sheep, a goat, a horse, a pig, a cow
  • the present invention also features a method of making an antibody by isolating a spleen from an animal injected with a polypeptide or a fragment thereof, a polynucleotide encoding a polypeptide, or a polynucleotide encoding a fragment thereof, and recovering antibodies from the spleen cells.
  • Hybridomas can be made from the spleen cells, and hybridomas secreting specific antibodies can be selected.
  • the present invention further features a method of making a polynucleotide library from spleen cells, and selecting a cDNA clone that produces specific antibodies, or fragments thereof.
  • the cDNA clone or a fragment thereof can be expressed in an expression system that allows production of the antibody or a fragment thereof, as provided herein.
  • the invention also provides a method for determining the presence or measuring the level of a polypeptide that specifically binds to an antibody of the invention. This method involves allowing the antibody to interact with a sample, and determining whether interaction between the antibody and any polypeptide in the sample has occurred. Antibodies that specifically bind to at least one subject polypeptide are useful in diagnostic assays, e.g., to detect the presence of a subject polypeptide. Similarly, the invention features a method of determining the presence of an antibody to a polypeptide of the invention, by providing the polypeptide, allowing the antibody and the polypeptide to interact, and determining whether interaction has occurred.
  • the present invention further features a method of identifying an agent that modulates the level of a subject polypeptide (or an mRNA encoding a subject polypeptide) in a cell.
  • the method generally involves contacting a cell (e.g., a eukaryotic cell) that produces the subject polypeptide with a test agent; and determining the effect, if any, of the test agent on the level of the polypeptide in the cell.
  • a cell e.g., a eukaryotic cell
  • the present invention further features a method of identifying an agent that modulates biological activity of a subject polypeptide.
  • the methods generally involve contacting a subject polypeptide with a test agent; and determining the effect, if any, of the test agent on the activity of the polypeptide.
  • the polypeptide is expressed on a cell surface.
  • the agent or modulator is an antibody, for example, where an antibody binds to the polypeptide or affects its biological activity.
  • the present invention further features biologically active agents (or modulators) identified using a method of the invention.
  • the present invention also features a method of modulating biological activity using an agent selectable by the above methods. Briefly, the method of modulating biological activity comprises contacting the agent with a first human or a non-human host cell, thereby modulating the activity of the first host cell or a second host cell. In one example, contacting the agent with the first human or non-human host cell results in the recruitment of a second host cell.
  • the agent may be an antibody or antibody fragment of the invention.
  • the modulation can comprise directly enhancing cell activity, indirectly enhancing cell activity, directly inhibiting cell activity, or indirectly inhibiting cell activity.
  • the cell activity that is modulated can include transcription, translation, cell cycle control, signal transduction, intracellular trafficking, cell adhesion, cell mobility, proteolysis, ion transport, water transport, DNA repair, hydrolysis, lipase activity, polymerization using an RNA temple or a DNA template, and nuclease activity.
  • the modulation can result in cell death or apoptosis, or inhibition of cell death or apoptosis, as well as cell growth, cell proliferation, or cell survival, or inhibition of cell growth, cell proliferation, or cell survival; as well as mucosal preservation, inhibition of eicosanoid synthesis, or resistance to infection by viruses.
  • Either the first or the second host cell can be a human or a non- human host cell.
  • Either the first or the second host cell can be an immune cell, e.g., a T cell, B cell, NK cell, dendritic cell, macrophage, muscle cell, stem cell, skin cell, fat cell, blood cell, brain cell, bone marrow cell, endothelial cell, retinal cell, bone cell, kidney cell, pancreatic cell, liver cell, spleen cell, prostate cell, cervical cell, ovarian cell, breast cell, lung cell, liver cell, soft tissue cell, colorectal cell, other cell of the gastrointestinal tract, or a cancer cell.
  • an immune cell e.g., a T cell, B cell, NK cell, dendritic cell, macrophage, muscle cell, stem cell, skin cell, fat cell, blood cell, brain cell, bone marrow cell, endothelial cell, retinal cell, bone cell, kidney cell, pancreatic cell, liver cell, spleen cell
  • the invention also provides a method of diagnosing cancer, proliferative, inflammatory, immune, bacterial, viral, or metabolic disorder in a patient, by allowing an antibody specific for a polypeptide of the invention to contact a patient sample, and detecting specific binding between the antibody and any antigen in the sample to determine whether the subject has cancer, proliferative, inflammatory, immune, bacterial, viral, or metabolic disorder.
  • the invention further provides a method of diagnosing cancer, proliferative, inflammatory, immune, bacterial, viral, or metabolic disorder in a patient, by allowing a polypeptide of the invention to contact a patient sample, and detecting specific binding between the polypeptide and any interacting molecule in the sample to determine whether the subject has cancer, proliferative, inflammatory, immune, bacterial, viral, or metabolic disorder.
  • the invention also features a method of providing a polynucleotide, a polypeptide, or an agent of the invention, such as an antibody, to a subject by oral, buccal, nasal, rectal, intraperitoneal, intradermal, transdermal, infratracheal, intrathecal, or parenteral administration, or otherwise by implantation or inhalation.
  • the polynucleotide, polypeptide or agent can be administered intranasally, intravenously, intra-arterially, intracardiacally, subcutaneously, intraperitoneally, transdermally, infraventricularly, or intracranially.
  • the invention also provides a method for formulating a polynucleotide, polypeptide, or modulator composition, such as an antibody composition, for delivery by any of the routes of administration provided above, for example, for treatment of disorders.
  • a polynucleotide, polypeptide, or modulator composition such as an antibody composition
  • the parenteral delivery can be via inhalation or implantation.
  • the parenteral delivery can also be oral, intranasal, infraventricular, or intracranial.
  • the present invention also features a pharmaceutical composition
  • a pharmaceutical composition comprising a polynucleotide, polypeptide, or modulator of the invention and a carrier.
  • the carrier can be a pharmaceutically acceptable carrier.
  • the modulator can be obtainable by any methods of the invention, for example, the modulator can be an antibody or a fragment thereof.
  • oral formulations, preparations for injection, aerosol formulations, and suppositories can be prepared, each comprising the polynucleotide, polypeptide, or modulator composition.
  • nucleic acid compositions comprising polynucleotide sequences encoding the subject antibodies, or fragments thereof, can be prepared for administration to a subject.
  • the invention also features a non-human animal injected with the polynucleotide, polypeptide, or modulator composition, for example the antibody composition.
  • the animal can be a non-human primate, (e.g., a monkey) a rodent (e.g., a rat, a mouse, a hamster, a guinea pig), a chicken, cattle (e.g., a sheep, a goat, a horse, a pig, a cow), a rabbit, a cat, or a dog.
  • the invention provides a method of treating a disorder in a subject needing or desiring such treatment, comprising administering a polynucleotide, polypeptide, or modulator of the invention to the subject.
  • the subject can be a human or a non-human animal.
  • the disorder can be cancer, proliferative, inflammatory, immune, metabolic, ulcerative, bacterial, or viral disorders.
  • the method of treatment may comprise administering an antibody composition with a first antibody that specifically binds to a first epitope of a first polypeptide or a fragment thereof, or that interferes with at least one activity of the first polypeptide or a fragment thereof, wherein the first polypeptide is encoded by a nucleic acid molecule comprising a nucleotide sequence chosen from SEQ ID NOS.: 1 - 209 and 419 - 627, or any nucleic acid of the present invention.
  • the first polypeptide may comprise an amino acid sequence chosen from SEQ ID NOS.: 210 - 418.
  • this method further comprises using a second antibody that binds specifically to or interferes with the activity of a second epitope of the first polypeptide or to a first epitope of a second polypeptide.
  • the second polypeptide can be encoded by a nucleic acid molecule comprising a nucleotide sequence chosen from SEQ ID NOS.: 1 - 209 and 419 - 627, or any nucleic acid of the present invention.
  • the second polypeptide may comprise an amino acid sequence chosen from SEQ ID NOS.: 210 - 418.
  • the antibody binds, or interferes with the activity of, at least one polypeptide fragment, wherein the fragment is an extracellular fragment of the polypeptide, or an extracellular fragment of the polypeptide minus the signal peptide, for the treatment, for example, of proliferative disorders, such as cancer.
  • the modulator may bind to a cell surface molecule that is over-expressed in the disorder. Further the modulator may be linked to an antibody of the invention.
  • the antibody can be capable of initiating antibody dependent cell cytotoxicity, e.g., where the antibody is in turn coupled to cytotoxic agents. This method is applicable when the disorder is cancer, another proliferative disorder, inflammatory, immune, bacterial, viral, or metabolic disorder, and the cell surface molecule is over-expressed in a cancer cell, diseased cell or virus-infected cell.
  • the cell surface molecule can be a single-transmembrane-related protein, a multiple-transmembrane-related protein, a kinase-related protein, a protein kinase- related protein, a ligase-related protein, a nuclear hormone receptor-related protein, a phosphatase-related protein, a protease-related protein, a phosphodiesterase-related protein, a kinesin-related protein, an immunoglobulin-related protein, a T-cell receptor-related protein, a glycosylphosphatidylinositol anchor-related protein, or other amino acid sequence, including, an activator-related protein, an adaptor-related protein, an adhesion molecule-related protein, an ATPase-related protein, an ATP- related protein, a breakpoint-related protein, a channel-related protein, a checkpoint- related protein, a complex-related protein, a dehydrogenase-related protein, a disintegrin-
  • the invention also provides a method for prophylactic or therapeutic treatment of a subject needing or desiring such treatment by providing a vaccine, that can be administered to the subject.
  • the vaccine may comprise one or more of a polynucleotide, polypeptide, or modulator of the invention, for example an antibody vaccine composition, a polypeptide vaccine composition, or a polynucleotide vaccine composition, useful for treating cancer, proliferative, inflammatory, immune, metabolic, bacterial, or viral disorders.
  • the vaccine can be a cancer vaccine, and the polypeptide can concomitantly be a cancer antigen.
  • the vaccine may be an anti- inflammatory vaccine, and the polypeptide can concomitantly be an inflammation- related antigen.
  • the vaccine may be a viral vaccine, and the polypeptide can concomitantly be a viral antigen.
  • the vaccine comprises a polypeptide fragment, comprising at least one extracellular fragment of a polypeptide of the invention, and/or at least one exfracellular fragment of a polypeptide of the invention minus the signal peptide, for the treatment, for example, of proliferative disorders, such as cancer.
  • the vaccine comprises a polynucleotide encoding one or more such fragments, administered for the treatment, for example, of proliferative disorders, such as cancer. Further, the vaccine can be administered with or without an adjuvant.
  • the invention provides a method for gene therapy by providing a polynucleotide comprising a nucleic acid molecule encoding a polypeptide, such as an antibody of the invention, and administering the polynucleotide to a subject needing or desiring such treatment.
  • kits comprising one or more of a polynucleotide, polypeptide, or modulator composition, such as an antibody composition, which may include instructions for its use.
  • a polynucleotide, polypeptide, or modulator composition such as an antibody composition
  • kits are useful in diagnostic applications, for example, to detect the presence and/or level of a polypeptide in a biological sample by specific antibody interaction.
  • Each sequence shown in Tables 1 -3 is identified by a Five Prime Therapeutics, Inc. (FP) identification number (FP ID).
  • FP ID Five Prime Therapeutics, Inc.
  • Table 1 specifies the predicted number of amino acid residues in each FP protein of the invention (Length, Predicted Protein).
  • Table 1 also specifies the percent of the FP sequence that is covered by the public National Center for Information Biotechnology (NCBI) database (Prediction Covered by Public).
  • NCBI National Center for Information Biotechnology
  • Table 1 also describes the characteristics of the protein in the NCBI database displaying the greatest degree of similarity to each claimed sequence. This protein is described by its NCBI accession number (Top Hit Accession No.), and by the NCBI's annotation of that sequence (Top Hit Annotation).
  • Table 2 describes the characteristics of the human protein in the NCBI database with the greatest degree of similarity to each claimed sequence. The predicted number of amino acids of this human protein is specified (Length, Human Top Hit). Table 2 also specifies any existing protein family (Pfam) classification for these human sequences. Table 2 specifies the result of the algorithm described above that predicts whether the claimed FP sequence is secreted (Tree Vote, Secreted). Table 2 sets forth the the position of the amino acid residues comprising the signal peptide sequences (SP Positions) of the claimed FP sequences. Table 2 also specifies the position(s), if any, of the amino acid residues comprising the transmembrane domains in each claimed FP sequence (TM domains), and the number of transmembrane domains of each claimed FP sequence (TM Total).
  • Table 3 describes the characteristics of the Fantom mouse protein with the greatest degree of similarity to the claimed sequences.
  • the Fantom database was compiled by the Fantom Consortium and is accessible, for example, at http://fantom.gsc.riken.go.jp/db/ (Bono et al., 2002). It provides curated functional annotation to full-length mouse sequences (Okzaki et al., 2002).
  • the similarities of the claimed sequences of the invention with the annotated sequences in Tables 1-3 suggest that they may share structural and functional properties, and exhibit similar expression profiles and localizations. Definitions
  • Related sequences include nucleotide and amino acid sequences that are involved in the function of their referent.
  • receptor-related sequences include all sequences that are involved in receptor function. This includes, but is not limited to, sequences that are involved in receptor synthesis, receptor regulation, receptor effector function, and receptor degradation.
  • Related sequences also encompass complementary nucleic acid sequences, and biologically active fragments of nucleic acid and amino acid sequences.
  • polynucleotide refers to polymeric forms of nucleotides of any length.
  • the polynucleotides can contain deoxyribonucleotides, ribonucleotides, and/or their analogs or derivatives.
  • nucleic acids can be naturally occurring DNA or RNA, or can be synthetic analogs, as known in the art.
  • the terms also encompass genomic DNA, genes, gene fragments, exons, introns, regulatory sequences or regulatory elements (such as promoters, enhancers, initiation and termination regions, other control regions, expression regulatory factors, and expression controls), DNA comprising one or more single-nucleotide polymorphisms (SNPs), allelic variants, isolated DNA of any sequence, and cDNA.
  • SNPs single-nucleotide polymorphisms
  • allelic variants isolated DNA of any sequence
  • cDNA cDNA.
  • the terms also encompass mRNA, tRNA, rRNA, ribozymes, splice variants, antisense RNA, antisense conjugates, RNAi, and isolated RNA of any sequence.
  • the terms also encompass recombinant polynucleotides, heterologous polynucleotides, branched polynucleotides, labeled polynucleotides, hybrid DNA/RNA, polynucleotide constructs, vectors comprising the subject nucleic acids, nucleic acid probes, primers, and primer pairs.
  • the polynucleotides can comprise modified nucleic acid molecules, with alterations in the backbone, sugars, or heterocyclic bases, such as methylated nucleic acid molecules, peptide nucleic acids, and nucleic acid molecule analogs, which may be suitable as, for example, probes if they demonstrate superior stability and/or binding affinity under assay conditions.
  • Analogs of purines and pyrimidines, including radiolabeled and fluorescent analogs, are known in the art.
  • the polynucleotides can have any three-dimensional structure, and can perform any function, known or as yet unknown.
  • the terms also encompass single-stranded, double-stranded and triple helical molecules that are either DNA, RNA, or hybrid DNA/RNA and that may encode a full-length gene or a biologically active fragment thereof.
  • Biologically active fragments of polynucleotides can encode the polypeptides herein, as well as anti-sense and RNAi molecules.
  • the full length polynucleotides herein may be treated with enzymes, such as Dicer, to generate a library of short RNAi fragments which are within the scope of the present invention.
  • novel polynucleotides herein include those shown in the Tables, SEQ ID NOS.: 1 - 209 and 419 - 627, as well as those that encode the polypeptides of SEQ ID NOS.: 210 - 418, and biologically active fragments thereof.
  • the polynucleotides also include modified, labeled, and degenerate variants of the nucleic acid sequences, as well as nucleic acid sequences that are substantially similar or homologous to nucleic acids encoding the subject proteins.
  • a “biologically active” entity, or an entity having “biological activity,” is one having structural, regulatory, or biochemical functions of a naturally occurring molecule or any function related to or associated with a metabolic or physiological process.
  • Biologically active polynucleotide fragments are those exhibiting activity similar, but not necessarily identical, to an activity of a polynucleotide of the present invention.
  • the biological activity can include an improved desired activity, or a decreased undesirable activity.
  • an entity demonstrates biological activity when it participates in a molecular interaction with another molecule, or when it has therapeutic value in alleviating a disease condition, or when it has prophylactic value in inducing an immune response to the molecule, or when it has diagnostic value in determining the presence of the molecule, such as a biologically active fragment of a polynucleotide that can be detected as unique for the polynucleotide molecule, or that can be used as a primer in PCR.
  • nucleic acid sequence refers to all nucleic acid sequences that can be directly translated, according to the standard genetic code, to provide an amino acid sequence identical to that franslated from a reference nucleic acid sequence.
  • gene or “genomic sequence” as used herein is an open reading frame encoding specific proteins and polypeptides, for example, an mRNA, cDNA, or genomic DNA, and also may or may not include intervening introns, or adjacent 5' and 3 'non-coding nucleotide sequences involved in the regulation of expression up to about 20 kb beyond the coding region, and possibly further in either direction.
  • a gene can be introduced into an appropriate vector for exfrachromosomal maintenance or for integration into a host genome.
  • transgene as used herein is a nucleic acid sequence that is incorporated into a transgenic organism.
  • a “transgene” can contain one or more transcriptional regulatory sequences, and. other sequences, such as infrons, that may be useful for expressing or secreting the nucleic acid or fusion protein it encodes.
  • cDNA as used herein is intended to include all nucleic acids that share the sequence elements of mature mRNA species, where sequence elements are exons and 3 ' and 5 ' non-coding regions. Generally, mRNA species have contiguous exons, the intervening introns having been removed by nuclear RNA splicing to create a continuous open reading frame encoding a protein.
  • splice variant refers to all types of RNAs transcribed from a given gene that when processed collectively encode plural protein isoforms.
  • alternative splicing and related terms refer to all types of RNA processing that lead to expression of plural protein isoforms from a single gene. Some genes are first transcribed as long mRNA precursors that are then shortened by a series of processing steps to produce the mature mRNA molecule. One of these steps is RNA splicing, in which the intron sequences are removed from the mRNA precursor. A cell can splice the primary transcript in different ways, making different "splice variants," and thereby making different polypeptide chains from the same gene, or from the same mRNA molecule. Splice variants can include, for example, exon insertions, exon extensions, exon truncations, exon deletions, alternatives in the 5 'untranslated region and alternatives in the 3 ' untranslated region.
  • Oligonucleotide may generally refer to polynucleotides of between about 5 and about 100 nucleotides of single-or double-stranded nucleic acids. For the purposes of this disclosure, there is no upper limit to the length of an oligonucleotide. Oligonucleotides are also known as oligomers or oligos and can be isolated from genes, or chemically synthesized by methods known in the art.
  • Nucleic acid composition is a composition comprising a nucleic acid sequence, including one having an open reading frame that encodes a polypeptide and is capable, under appropriate conditions, of being expressed as a polypeptide.
  • the term includes, for example, vectors, including plasmids, cosmids, viral vectors (e.g., retrovirus vectors such as lentivirus, adenovirus, and the like), human, yeast, bacterial, PI -derived artificial chromosomes (HACs, YAC's, BAC's, PAC's, etc), and mini-chromosomes, in vitro host cells, in vivo host cells, tissues, organs, allogenic or congenic grafts or transplants, multicellular organisms, and chimeric, genetically modified, or transgenic animals comprising a subject nucleic acid sequence.
  • vectors including plasmids, cosmids, viral vectors (e.g., retrovirus vectors such as lentivirus, aden
  • an "isolated,” “purified,” or “substantially isolated” polynucleotide, or a polynucleotide in “substantially pure form,” in “substantially purified form,” in “substantial purity,” or as an “isolate,” is one that is substantially free of the sequences with which it is associated in nature, or other nucleic acid sequences that do not include a sequence or fragment of the subject polynucleotides.
  • substantially free is meant that less than about 90%, less than about 80%, less than about 70%, less than about 60%), or less than about 50% of the composition is made up of materials other than the isolated polynucleotide.
  • the isolated polynucleotide is at least about 50%), at least about 60%, at least about 70%, at least about 80%>, at least about 90%, at least about 95%, at least about 97%, or at least about 99% free of the materials with which it is associated in nature.
  • an isolated polynucleotide may be present in a composition wherein at least about 50%, at least about 60%), at least about 70%>, at least about 80%>, at least about 90%>, at least about 95%o, at least about 97%, at least about 99% of the total macromolecules (for example, polypeptides, fragments thereof, polynucleotides, fragments thereof, lipids, polysaccharides, and oligosaccharides) in the composition is the isolated polynucleotide. Where at least about 99%) of the total macromolecules is the isolated polynucleotide, the polynucleotide is at least about 99% pure, and the composition comprises less than about 1% contaminant.
  • the total macromolecules for example, polypeptides, fragments thereof, polynucleotides, fragments thereof, lipids, polysaccharides, and oligosaccharides
  • an "isolated,” “purified” or “substantially isolated” polynucleotide, or a polynucleotide in “substantially pure form,” in “substantially purified form,” in “substantial purity,” or as an “isolate,” also refers to recombinant polynucleotides, modified, degenerate and homologous polynucleotides, and chemically synthesized polynucleotides, which, by virtue of origin or manipulation, are not associated with all or a portion of a polynucleotide with which it is associated in nature, are linked to a polynucleotide other than that to which it is linked in nature, or do not occur in nature.
  • the subject polynucleotides are generally provided as other than on an intact chromosome, and recombinant embodiments are typically flanked by one or more nucleotides not normally associated with the subject polynucleotide on a naturally-occurring chromosome.
  • polypeptide refers to a polymeric form of amino acids of any length, which can include naturally-occurring amino acids, coded and non-coded amino acids, chemically or biochemically modified, derivatized, or designer amino acids, amino acid analogs, peptidomimetics, and depsipeptides, and polypeptides having modified, cyclic, bicyclic, depsicyclic, or depsibicyclic peptide backbones.
  • the term includes single chain protein as well as multimers.
  • the term also includes conjugated proteins, fusion proteins, including, but not limited to, GST fusion proteins, fusion proteins with a heterologous amino acid sequence, fusion proteins with heterologous and homologous leader sequences, fusion proteins with or without N-terminal methionine residues, pegolyated proteins, and immunologically tagged proteins. Also included in this term are variations of naturally occurring proteins, where such variations are homologous or substantially similar to the naturally occurring protein, as well as corresponding homologs from different species. Variants of polypeptide sequences include insertions, additions, deletions, or substitutions compared with the subject polypeptides. The term also includes peptide aptamers.
  • bicyclic refers to a peptide with two ring closures formed by covalent linkages between amino acids.
  • a covalent linkage between two nonadjacent amino acids constitutes a ring closure, as does a second covalent linkage between a pair of adjacent amino acids which are already linked by a covalent peptide linkage.
  • the covalent linkages forming the ring closures can be amide linkages, i.e., the linkage formed between a free amino on one amino acid and a free carboxyl of a second amino acid, or linkages formed between the side chains or "R" groups of amino acids in the peptides.
  • bicyclic peptides can be "true” bicyclic peptides, i.e., peptides cyclized by the formation of a peptide bond between the N-terminus and the C-terminus of the peptide, or they can be "depsi-bicyclic" peptides, i.e., peptides in which the terminal amino acids are covalently linked through their side chain moieties.
  • novel polypeptides herein include amino acid sequences encoded by an open reading frame (ORF) as shown in SEQ ID NOS.: 210 - 418, described in greater detail below, including the full length protein and fragments thereof, particularly biologically active fragments and/or fragments corresponding to functional domains, e.g., a signal peptide or leader sequence, an enzyme active site, including a cleavage site and an enzyme catalytic site, a domain for interaction with other protein(s), a domain for binding DNA, a regulatory domain, a consensus domain that is shared with other members of the same protein family, such as a kinase family or an immunoglobulin family; an extracellular domain that may act as a target for antibody production or that may be cleaved to become a soluble receptor or a ligand for a receptor; an intracellular fragment of a transmembrane protein that participates in signal transduction; a transmembrane domain of a transmembrane protein that may facilitate
  • a “biologically active” entity is one having structural, regulatory, or biochemical functions of a naturally occurring molecule or any function related to or associated with a metabolic or physiological process.
  • Biologically active polypeptide fragments are those exhibiting activity similar, but not necessarily identical, to an activity of a polypeptide of the present invention.
  • the biological activity can include an improved desired activity, or a decreased undesirable activity.
  • an entity demonstrates biological activity when it participates in a molecular interaction with another molecule, or when it has therapeutic value in alleviating a disease condition, or when it has prophylactic value in inducing an immune response to the molecule, or when it has diagnostic value in determining the presence of the molecule.
  • a biologically active polypeptide or fragment thereof includes one that can participate in a biological reaction, for example, as a transcription factor that combines with other transcription factors for initiation of transcription, or that can serve as an epitope or immunogen to stimulate an immune response, such as production of antibodies, or that can transport molecules into or out of cells, or that can perform a catalytic activity, for example polymerization or nuclease activity, or that can participate in signal transduction by binding to receptors, proteins, or nucleic acids, activating enzymes or substrates.
  • a transcription factor that combines with other transcription factors for initiation of transcription, or that can serve as an epitope or immunogen to stimulate an immune response, such as production of antibodies, or that can transport molecules into or out of cells, or that can perform a catalytic activity, for example polymerization or nuclease activity, or that can participate in signal transduction by binding to receptors, proteins, or nucleic acids, activating enzymes or substrates.
  • a "signal peptide,” or a “leader sequence,” comprises a sequence of amino acid residues, typically, at the N terminus of a polypeptide, which directs the intracellular trafficking of the polypeptide.
  • Polypeptides that contain a signal peptide or leader sequence typically also contain a signal peptide or leader sequence cleavage site. Such polypeptides, after cleavage at the cleavage sites, generate mature polypeptides, for example, after extracellular secretion or after being directed to the appropriate intracellular compartment.
  • Depsipeptides are compounds containing a sequence of at least two alpha-amino acids and at least one alpha-hydroxy carboxylic acid, which are bound through at least one normal peptide link and ester links, derived from the hydroxy carboxylic acids.
  • Linear depsipeptides can comprise rings formed through S-S bridges, or through an hydroxy or a mercapto group of an hydroxy-, or mercapto- amino acid and the carboxyl group of another amino- or hydroxy-acid but do not comprise rings formed only through peptide or ester links derived from hydroxy carboxylic acids.
  • Cyclic depsipeptides are peptides containing at least one ring formed only through peptide or ester links, derived from hydroxy carboxylic acids.
  • an "isolated,” “purified,” or “substantially isolated” polypeptide, or a polypeptide in “substantially pure form,” in “substantially purified form,” in “substantial purity,” or as an “isolate,” is one that is substantially free of the materials with which it is associated in nature or other polypeptide sequences that do not include a sequence or fragment of the subject polypeptides.
  • substantially free is meant that less than about 90%, less than about 80%>, less than about 70%, less than about 60%), or less than about 50% of the composition is made up of materials other than the isolated polypeptide.
  • the isolated polypeptide is at least about 50%), at least about 60%>, at least about 70%>, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% free of the materials with which it is associated in nature.
  • an isolated polypeptide may be present in a composition wherein at least about 50%, at least about 60%, at least about 70%, at least about 80%>, at least about 90%, at least about 95%, at least about 97%, or at least about 99% of the total macromolecules (for example, polypeptides, fragments thereof, polynucleotides, fragments thereof, lipids, polysaccharides, and oligosaccharides) in the composition is the isolated polypeptide.
  • the total macromolecules for example, polypeptides, fragments thereof, polynucleotides, fragments thereof, lipids, polysaccharides, and oligosaccharides
  • the polypeptide is at least about 99%o pure, and the composition comprises less than about 1% contaminant.
  • an "isolated,” “purified,” or “substantially isolated” polypeptide, or a polypeptide in “substantially pure form,” in “substantially purified form,” in “substantial purity,” or as an “isolate,” also refers to recombinant polypeptides, modified, tagged and fusion polypeptides, and chemically synthesized polypeptides, which by virtue or origin or manipulation, are not associated with all or a portion of the materials with which they are associated in nature, are linked to molecules other than that to which they are linked in nature, or do not occur in nature.
  • Detection methods of the invention can be qualitative or quantitative.
  • the terms “detection,” “identification,” “determination,” and the like refer to both qualitative and quantitative determinations, and include “measuring.”
  • detection methods include methods for detecting the presence and/or level of polynucleotide or polypeptide in a biological sample, and methods for detecting the presence and/or level of biological activity of polynucleotide or polypeptide in a sample.
  • array or “microarray” may be used interchangeably and refers to a collection of plural biological molecules such as nucleic acids, polypeptides, or antibodies, having locatable addresses that may be separately detectable.
  • microarray encompasses use of sub microgram quantities of biological molecules.
  • the biological molecules may be affixed to a substrate or may be in solution or suspension.
  • the substrate can be porous or solid, planar or non-planar, unitary or distributed, such as a glass slide, a 96 well plate, with or without the use of microbeads or nanobeads.
  • microarray includes all of the devices referred to as microarrays in Schena, 1999; Bassett et al., 1999; Bowtell, 1999; Brown and Botstein, 1999; Chakravarti, 1999; Cheung et al., 1999; Cole et al., 1999; Collins, 1999; Debouck and Goodfellow, 1999; Duggan et al, 1999; Hacia, 1999; Lander, 1999; Lipshutz et al., 1999; Southern, et al., 1999; Schena, 2000; Brenner et al, 2000; Lander, 2001; Steinhaur et al., 2002; and Espejo et al, 2002.
  • Nucleic acid microarrays include both oligonucleotide arrays (DNA chips) containing expressed sequence tags ("ESTs") and arrays of larger DNA sequences representing a plurality of genes bound to the substrate, either one of which can be used for hybridization studies.
  • Protein and antibody microarrays include arrays of polypeptides or proteins, including but not limited to, polypeptides or proteins obtained by purification, fusion proteins, and antibodies, and can be used for specific binding studies (Zhu and Snyder, 2003; Houseman et al., 2002; Schaeferling et al., 2002; Weng et al., 2002; Winssinger et al., 2002; Zhu et al., 2001; Zhu et al. 2001; and MacBeath and Schreiber, 2000).
  • a "nucleic acid hybridization reaction” is one in which single strands of DNA or RNA randomly collide with one another, and bind to each other only when their nucleotide sequences have some degree of complementarity.
  • the solvent and temperature conditions can be varied in the reactions to modulate the extent to which the molecules can bind to one another.
  • Hybridization reactions can be performed under different conditions of "stringency.”
  • the "stringency” of a hybridization reaction as used herein refers to the conditions (e.g., solvent and temperature conditions) under which two nucleic acid strands will either pair or fail to pair to form a "hybrid" helix.
  • T m is the temperature in degrees Celsius at which 50% of a polynucleotide duplex made of complementary strands of nucleic acids that are hydrogen bonded in an anti-parallel direction by Watson-Crick base pairing dissociate into single strands under conditions of the hybridization reaction.
  • a "buffer” is a system that tends to resist change in pH when a given increment of hydrogen ion or hydroxide ion is added. Buffered solutions contain conjugate acid-base pairs. Any conventional buffer can be used with the inventions herein including but not limited to, for example, Tris, phosphate, imidazole, and bicarbonate.
  • a "library" of polynucleotides comprises a collection of sequence information of a plurality of polynucleotide sequences, which information is provided in either biochemical form (e.g., as a collection of polynucleotide molecules), or in electronic form (e.g., as a collection of polynucleotide sequences stored in a computer-readable form, as in a computer-based system, a computer data file, and/or as part of a computer program).
  • a "library" of polypeptides comprises a collection of sequence information of a plurality of polypeptide sequences, which information is provided in, e.g., a collection of polypeptide sequences stored in a computer-readable form, as in a computer-based system, a computer data file, and or as part of a computer program.
  • Media refers to a manufacture, other than an isolated nucleic acid molecule, that contains the sequence information of the present invention. Such a manufacture provides the genome sequence or a subset thereof in a form that can be examined by means not directly applicable to the sequence as it exists in a nucleic acid, e.g., with computer-readable media comprising data storage structures.
  • Such media include, but are not limited to: magnetic storage media, such as a floppy disc, a hard disc storage medium, and a magnetic tape; optical storage media such as CD- ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media.
  • Recorded refers to a process for storing information on computer readable media, using any such methods as known in the art.
  • a computer-based system refers to the hardware means, software means, and data storage means used to analyze the nucleotide sequence information of the present invention.
  • the minimum hardware of the computer-based systems of the present invention comprises a central processing unit (CPU), input means, output means, and data storage means.
  • CPU central processing unit
  • the data storage means can comprise any manufacture comprising a recording of the present sequence information as described above, or a memory access means that can access such a manufacture.
  • Search means refers to one or more programs implemented on the computer-based system, to compare a target sequence or target structural motif, or expression levels of a polynucleotide in a sample, with the stored sequence information.
  • a variety of known algorithms are publicly known and commercially available, e.g., MacPattern (EMBL), BLAST, BLASTN and BLASTX (NCBI), gapped BLAST, BLAZE, the Wise package, FASTX, Clustalw, FASTA, FASTA3, AlignO, TCoffee, BestFit, FastDB, and TeraBLAST (TimeLogic, Crystal Bay, Nevada).
  • Search means can be used to identify fragments or regions of the genome that match a particular target sequence or target motif, for example, based on sequence similarity, for example, to identify open reading frames (ORFs) within the genome that contain homology to ORFs from other organisms.
  • ORFs open reading frames
  • sequence similarity means the exact match-up of two or more nucleotide sequences or two or more amino acid sequences, where the nucleotide or amino acids being compared are the same.
  • similarity means the exact match-up of two or more nucleotide sequences or two or more amino acid sequences, where the nucleotide or amino acids being compared are either the same or possess similar chemical and/or physical properties.
  • sequences can be aligned in a number of different ways and sequence similarity can be determined in a number of different ways.
  • the bases or amino acid residues of one sequence can be aligned to a gap in the other sequence, or they can be aligned only to another base or amino acid residue in the other sequence.
  • a gap can range anywhere from one nucleotide, base, or amino acid residue to multiple exons in length, up to any number of nucleotides or amino acid residues.
  • sequences can be aligned such that nucleotides (or bases) align with nucleotides, nucleotides align with amino acid residues, or amino acid residues align with amino acid residues.
  • a "target sequence” can be any polynucleotide or amino acid sequence of six or more contiguous nucleotides or two or more amino acids, for example, from about 5 or from about 10 to about 100 amino acids, or from about 15 or from about 30 to about 300 nucleotides.
  • a variety of comparing means can be used to accomplish comparison of sequence information from a sample (e.g., to analyze target sequences, target motifs, or relative expression levels) with the data storage means.
  • any one of the publicly available homology search programs can be used as the search means for the computer based systems of the present invention to accomplish comparison of target sequences and motifs.
  • Computer programs to analyze expression levels in a sample and in controls are also known in the art.
  • a "target sequence” includes an "antibody target sequence,” which refers to an amino acid sequence that can be used as an immunogen for injection into animals for production of antibodies or for screening against a phage display or antibody library for identification of binding partners.
  • a "target structural motif,” or “target motif,” refers to any rationally selected sequence or combination of sequences in which the sequence(s) are chosen based on a three-dimensional configuration that is formed upon the folding of the target motif, or on consensus sequences of regulatory or active sites.
  • target motifs include, but are not limited to, enzyme active sites and signal sequences.
  • Nucleic acid target motifs include, but are not limited to, hairpin structures, promoter sequences, and other expression elements such as binding sites for transcription factors.
  • a "matrix” is a geometric network of antibody molecules and their antigens, as found in immunoprecipitation and flocculation reactions.
  • An antibody matrix can exist in solution or on a solid phase support.
  • Antibody binding to such epitope on a polypeptide can be stronger than binding of the same antibody to any other epitopes, particularly other epitopes that can be present in molecules in association with, or in the same sample as the polypeptide of interest.
  • adjusting the binding conditions can result in antibody binding almost exclusively to the specific epitope and not to any other epitopes on the same polypeptide, and not to any other polypeptide, which does not comprise the epitope.
  • Antibodies that bind specifically to a subject polypeptide may be capable of binding other polypeptides at a weak, yet detectable, level (e.g., 10% or less of the binding shown to the polypeptide of interest). Such weak binding, or background binding, is readily discernible from the specific antibody binding to a subject polypeptide, e.g., by use of appropriate controls.
  • antibodies of the invention bind to a specific polypeptide with a binding affinity of IO "7 M or greater (e.g., IO "8 M, 10 "9 M, 10 "10 , 10 "11 , etc.).
  • host cell includes an individual cell, cell line, cell culture, or in vivo cell, which can be or has been a recipient of any polynucleotides or polypeptides of the invention, for example, a recombinant vector, an isolated polynucleotide, antibody or fusion protein.
  • Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology, physiology, or in total DNA, RNA, or polypeptide complement) to the original parent cell due to natural, accidental, or deliberate mutation and/or change.
  • Host cells can be prokaryotic or eukaryotic, including mammalian, insect, amphibian, reptile, crustacean, avian, fish, plant and fungal cells.
  • a host cell includes cells transformed, transfected, transduced, or infected in vivo or in vitro with a polynucleotide of the invention, for example, a recombinant vector.
  • a host cell which comprises a recombinant vector of the invention may be called a "recombinant host cell.”
  • Bio sample encompasses a variety of sample types obtained from an individual, including biological fluids such as blood, serum, plasma, urine, cerebrospinal fluid, tears, saliva, lymph, dialysis fluid, lavage fluid, semen, and other liquid samples or tissues of biological origin. It includes tissue samples and tissue cultures or cells derived therefrom and the progeny thereof, including cells in culture, cell supernatants, and cell lysates. It includes organ or tissue culture derived fluids, tissue biopsy samples, tumor biopsy samples, stool samples, and fluids extracted from physiological tissues. Cells dissociated from solid tissues, tissue sections, and cell lysates are included.
  • the definition also includes samples that have been manipulated in any way after their procurement, such as by treatment with reagents, solubilization, or enrichment for certain components, such as polynucleotides or polypeptides. Also included in the term are derivatives and fractions of biological samples.
  • a biological sample can be used in a diagnostic, monitoring, or screening assay.
  • the terms "individual,” “host,” “patient,” and “subject,” used interchangeably herein, refer to a mammal, including, but not limited to, murines, simians, humans, felines, canines, equines, bovines, porcines, ovines, caprines, mammalian farm animals, mammalian sport animals, and mammalian pets.
  • mammals or “mammalian,” are used broadly to describe organisms which are within the class mammalia, including the orders carnivore (e.g., dogs and cats), rodentia (e.g., mice, guinea pigs, and rats), and other mammals, including cattle, goats, sheep, cows, horses, rabbits, and pigs, and primates (e.g., humans, chimpanzees, and monkeys).
  • carnivore e.g., dogs and cats
  • rodentia e.g., mice, guinea pigs, and rats
  • other mammals including cattle, goats, sheep, cows, horses, rabbits, and pigs, and primates (e.g., humans, chimpanzees, and monkeys).
  • agent refers to a substance that binds to or modulates a level or activity of a subject polypeptide or a level of mRNA encoding a subject protein or nucleic acid, or that modulates the activity of a cell containing the subject protein or nucleic acid .
  • agent modulates a level of mRNA encoding a subject protein
  • agents include ribozymes, antisense, and RNAi molecules.
  • agents include antibodies specific for the subject polypeptide, peptide aptamers, small molecules, agents that bind a ligand-binding site in a subject polypeptide, and the like.
  • Antibody agents include antibodies that specifically bind a subject polypeptide and activate the polypeptide, such as receptor-ligand binding that initiates signal transduction; antibodies that specifically bind a subject polypeptide and inhibit binding of another molecule to the polypeptide, thus preventing activation of a signal transduction pathway; antibodies that bind a subject polypeptide to modulate transcription; antibodies that bind a subject polypeptide to modulate translation; as well as antibodies that bind a subject polypeptide on the surface of a cell to initiate antibody-dependent cytotoxicity ("ADCC”) or to initiate cell killing or cell growth.
  • Small molecule agents include those that bind the polypeptide to modulate activity of the polypeptide or cell containing the polypeptide in a similar fashion.
  • agent also refers to substances that modulate a condition or disorder associated with a subject polynucleotide or polypeptide. Such agents include subject polynucleotides themselves, subject polypeptides themselves, and the like. Agents may be chosen from amongst candidate agents, as defined below.
  • Candidate agents can be small organic compounds having a molecular weight of more than about 50 and less than about 2,500 daltons.
  • Candidate agents can comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and can include at least an amine, carbonyl, hydroxyl or carboxyl group, and can contain at least two of the functional chemical groups.
  • the candidate agents can comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups.
  • Candidate agents are also found among biomolecules, including oligonucleotides, polynucleotides, and fragments thereof, depsipeptides, polypeptides and fragments thereof, oligosaccharides, polysaccharides and fragments thereof, lipids, fatty acids, steroids, purines, pyrimidines, derivatives thereof, structural analogs, modified nucleic acids, modified, derivatized or designer amino acids, or combinations thereof.
  • an "agent which modulates a biological activity of a subject polypeptide” describes any substance, synthetic, semi-synthetic, or natural, organic or inorganic, small molecule or macromolecular, pharmaceutical or protein, with the capability of altering a biological activity of a subject polypeptide or of a fragment thereof, as described herein.
  • a plurality of assay mixtures is run in parallel with different agent concentrations to obtain a differential response to the various concentrations.
  • one of these concentrations serves as a negative control, i.e., at zero concentration or below the level of detection.
  • the biological activity can be measured using any assay known in the art.
  • An agent which modulates a biological activity of a subject polypeptide increases or decreases the activity at least about 10%>, at least about 15%, at least about 20%>, at least about 25%, at least about 50%, at least about 100%>, or at least about 2-fold, at least about 5-fold, or at least about 10-fold or more when compared to a suitable control.
  • agonist refers to a substance that mimics the function of an active molecule.
  • Agonists include, but are not limited to, drags, hormones, antibodies, and neurotransmitters, as well as analogues and fragments thereof.
  • Antagonist refers to a molecule that competes for the binding sites of an agonist, but does not induce an active response. Antagonists include, but are not limited to, drags, hormones, antibodies, and neurotransmitters, as well as analogues and fragments thereof.
  • receptor refers to a polypeptide that binds to a specific extracellular molecule and may initiate a cellular response.
  • ligand refers to any molecule that binds to a specific site on another molecule.
  • modulate encompasses an increase or a decrease, a stimulation, inhibition, or blockage in the measured activity when compared to a suitable control.
  • Modulation of expression levels includes increasing the level and decreasing the level of an mRNA or polypeptide encoded by a polynucleotide of the invention when compared to a control lacking the agent being tested.
  • agents of particular interest are those which inhibit a biological activity of a subject polypeptide, and/or which reduce a level of a subject polypeptide in a cell, and/or which reduce a level of a subject mRNA in a cell and/or which reduce the release of a subject polypeptide from a eukaryotic cell.
  • agents of interest are those that increase a biological activity of a subject polypeptide, and/or which increase a level of a subject polypeptide in a cell, and/or which increase a level of a subject mRNA in a cell and/or which increase the release of a subject polypeptide from a eukaryotic cell.
  • An agent that "modulates the level of expression of a nucleic acid" in a cell is one that brings about an increase or decrease of at least about 1.25-fold, at least about 1.5 -fold, at least about 2-fold, at least about 5 -fold, at least about 10-fold, or more in the level (i.e., an amount) of mRNA and/or polypeptide following cell contact with a candidate agent compared to a control lacking the agent.
  • Modulating a level of active subject polypeptide includes increasing or decreasing activity of a subject polypeptide; increasing or decreasing a level of active polypeptide protein; increasing or decreasing a level of mRNA encoding active subject polypeptide, and increasing or decreasing the release of subject polypeptide for a eukaryotic cell.
  • an agent is a subject polypeptide, where the subject polypeptide itself is administered to an individual.
  • an agent is an antibody specific for a subject polypeptide.
  • an agent is a chemical compound such as a small molecule that may be useful as an orally available drag.
  • Such modulation includes the recruitment of other molecules that directly effect the modulation.
  • an antibody that modulates the activity of a subject polypeptide that is a receptor on a cell surface may bind to the receptor and fix complement, activating the complement cascade and resulting in lysis of the cell.
  • over-expressed refers to a state wherein there exists any measurable increase over normal or baseline levels.
  • a molecule that is over-expressed in a disorder is one that is manifest in a measurably higher level compared to levels in the absence of the disorder.
  • Treatment refers to obtaining a desired pharmacologic and/or physiologic effect, covering any treatment of a pathological condition or disorder in a mammal, including a human.
  • the effect may be prophylactic in terms of completely or partially preventing a disorder or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disorder and/or adverse affect attributable to the disorder.
  • treatment includes (1) preventing the disorder from occurring or recurring in a subject who may be predisposed to the disorder but has not yet been diagnosed as having it, (2) inhibiting the disorder, such as arresting its development, (3) stopping or terminating the disorder or at least symptoms associated therewith, so that the host no longer suffers from the disorder or its symptoms, such as causing regression of the disorder or its symptoms, for example, by restoring or repairing a lost, missing or defective function, or stimulating an inefficient process, or (4) relieving, alleviating, or ameliorating the disorder, or symptoms associated therewith, where ameliorating is used in a broad sense to refer to at least a reduction in the magnitude of a parameter, such as inflammation, pain, and/or tumor size.
  • a parameter such as inflammation, pain, and/or tumor size.
  • a "pharmaceutically acceptable carrier,” “pharmaceutically acceptable diluent,” or “pharmaceutically acceptable excipient,” or “pharmaceutically acceptable vehicle,” used interchangeably herein, refer to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any conventional type.
  • a pharmaceutically acceptable carrier is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
  • the carrier for a formulation containing polypeptides would not normally include oxidizing agents and other compounds that are known to be deleterious to polypeptides.
  • Suitable carriers include, but are not limited to, water, dextrose, glycerol, saline, ethanol, and combinations thereof.
  • the carrier can contain additional agents such as wetting or emulsifying agents, pH buffering agents, or adjuvants which enhance the effectiveness of the formulation.
  • Adjuvants of the invention include, but are not limited to Freunds's, Montanide ISA Adjuvants [Seppic, Paris, France], Ribi's Adjuvants (Ribi ImmunoChem Research, Inc., Hamilton, MT), Hunter's TiterMax (CytRx Corp., Norcross, GA), Aluminum Salt Adjuvants (Alhydrogel - Superfos of Denmark/ Accurate Chemical and Scientific Co., Westbury, NY), Nitrocellulose- Adsorbed Protein, Encapsulated Antigens, and Gerbu Adjuvant (Gerbu Biotechnik GmbH, Gaiberg, Germany/C-C Biotech, Poway, CA).
  • Topical carriers include liquid petroleum, isopropyl palmitate, polyethylene glycol, ethanol (95%), polyoxyethylene monolaurate (5%) in water, or sodium lauryl sulfate (5%) in water. Other materials such as anti-oxidants, humectants, viscosity stabilizers, and similar agents can be added as necessary. Percutaneous penetration enhancers such as Azone can also be included.
  • “Pharmaceutically acceptable salts” include the acid addition salts (formed with the free amino groups of the polypeptide) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, mandelic, oxalic, and tartaric.
  • Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, and histidine.
  • inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, and histidine.
  • compositions for oral administration can form solutions, suspensions, tablets, pills, capsules, sustained release formulations, oral rinses, or powders.
  • unit dosage form refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of compounds of the present invention calculated in an "effective amount,” that is, a dosage sufficient to produce the desired result or effect in association with a pharmaceutically acceptable carrier.
  • effective amount that is, a dosage sufficient to produce the desired result or effect in association with a pharmaceutically acceptable carrier.
  • the specifications for the novel unit dosage forms of the present invention depend on the particular compound employed, the host, and the effect to be achieved, as well as the pharmacodynamics associated with each compound in the host.
  • the present invention provides novel isolated polynucleotides encoding polypeptides and fragments thereof.
  • the present invention also provides novel isolated polypeptides, fragments thereof, and compositions comprising same.
  • the present invention further provides polynucleotide compositions that can be used to identify the polypeptides.
  • the present invention provides recombinant vectors and host cells for use in gene expression, primer pairs for use in hybridizations, computer-based embodiments for use in bioinformatics, and transgenic animals and embryonic stem cell lines for use in mutating and regulating gene expression.
  • This invention provides genes encoding proteins, the encoded proteins, and fragments and homologs thereof. It provides human polynucleotide sequences and the corresponding mouse polynucleotide sequences.
  • the nucleic acids of the subject invention can encode all or a part of the subject proteins. Double or single stranded fragments can be obtained from the • DNA sequence by chemically synthesizing oligonucleotides in accordance with conventional methods, for example by restriction enzyme digestion or polymerase chain reaction (PCR) amplification. The use of the polymerase chain reaction has been described (Saiki et al, 1985) and current techniques have been reviewed (Sambrook et al, 1989; McPherson et al.
  • DNA fragments will be of at least about 5 nucleotides, at least about 8 nucleotides, at least about 10 nucleotides, at least about 15 nucleotides, at least about 18 nucleotides, at least about 20 nucleotides, at least about 25 nucleotides, at least about 30 nucleotides, or at least about 50 nucleotides, at least about 75 nucleotides, or at least about 100 nucleotides.
  • Nucleic acid compositions that encode at least six contiguous amino acids i.e., fragments of 18 nucleotides or more
  • nucleic acid compositions encoding at least 8 contiguous amino acids are useful in directing the expression or the synthesis of peptides that can be used as immunogens (Lerner, 1982; Shinnick et al., 1983; Sutcliffe et al., 1983).
  • a polynucleotide of the invention comprises a nucleotide sequence of at least about 5, at least about 8, at least about 10, at least about 15, at least about 18, at least about 20, at least about 25, at least about 30, at least about 50, at least about 75, at least about 100, at least about 150, at least about 200, at least about 250, at least about 300, at least about 350, at least about 400, at least about 450, at least about 500, at least about 550, at least about 600, at least about 650, at least about 700, at least about 750, at least about 800, at least about 850, at least about 900, at least about 950, at least about 1000, at least about 1100, at least about 1200, at least about 1300, at least about 1400, at least about 1500, at least about 1600, at least about 1700, at least about 1800, at least about 1900, at least about 2000, at least about 2100, at least about 2200, at least about 2300, at least about 2400, at least about
  • a polynucleotide of the invention has at least about 60%, 70%), at least about 75%>, at least about 80%, at least about 85%, at least about 90%, at least about 95%>, at least about 97%>, at least about 98%, or at least about 99% nucleotide sequence identity with a nucleotide sequence, or a fragment thereof, of the coding region of any one of the sequences shown in SEQ ID NOS.: 1 - 209 and 419 - 627, or a complement thereof.
  • sequence variants include naturally-occurring variants (e.g., SNPs, allelic variants, and homologs from other species), degenerate variants, variants associated with disease or pathological states, and variants resulting from random or directed mutagenesis, as well as from chemical or other modification.
  • naturally-occurring variants e.g., SNPs, allelic variants, and homologs from other species
  • degenerate variants e.g., SNPs, allelic variants, and homologs from other species
  • variants associated with disease or pathological states e.g., allelic variants, and homologs from other species
  • variants resulting from random or directed mutagenesis e.g., random or directed mutagenesis
  • a polynucleotide of the invention comprises a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence of at least about 5, at least about 8, at least about 10, at least about 15, at least about 18, at least about 20, at least about 25, at least about 30, at least about 50, at least about 75, at least about 100, at least about 150, at least about 200, at least about 250, at least about 300, at least about 350, at least about 400, at least about 450, at least about 500, at least about 550, at least about 600, at least about 650, at least about 700, at least about 750, at least about 800, at least about 850, at least about 900, at least about 950, or at least about 1000 contiguous amino acids of at least one of the sequences shown in SEQ ID NOS.: 210 - 418 (e.g., a polypeptide encoded by at least one of the nucleotide sequences shown in SEQ ID NOS.: 1 -
  • the present invention includes the present polynucleotide selected from SEQ ID NOS.: 1 - 209 and 419 - 627, which contain 300 bp of 5 ' terminus of a protein encoding polynucleotide sequence.
  • Such a polynucleotide is useful for the purposes of clustering gene sequences to determine gene family.
  • a polynucleotide of the invention hybridizes under stringent hybridization conditions to a polynucleotide having the coding region of any one of the sequences shown in SEQ ID NOS.: 1 - 209 and 419 - 627, or a complement thereof.
  • polynucleotides of the invention include those that encode variants of the polypeptide sequences encoded by the polynucleotides of the Sequence Listing.
  • these polynucleotides encode variant polypeptides that include insertions, additions, deletions, or substitutions compared with the polypeptides encoded by the nucleotide sequences shown in SEQ ID NOS.: 1 - 209 and 419 - 627, and in Table 1.
  • Conservative amino acid substitutions include serine/threonine, valine/leucine/isoleucine, asparagine/histidine/glutamine, glutamic acid/aspartic acid, etc. (Gonnet et al., 1992).
  • nucleic acids of the invention include degenerate variants that can be translated, according to the standard genetic code, to provide an amino acid sequence identical to that translated from the nucleic acid sequences herein.
  • synonymous codons include GGG, GGA, GGC, and GGU, each encoding Glycine.
  • the nucleic acids of the invention include single nucleotide polymorphisms (SNPs), which occur frequently in eukaryotic genomes (Lander, et al. 2001).
  • SNPs single nucleotide polymorphisms
  • the nucleotide sequence determined from one individual of a species can differ from other allelic forms present within the population.
  • the nucleic acids of the invention include homologs of the polynucleotides.
  • the source of homologous genes can be any species, e.g., primate species, particularly human; rodents, such as rats, hamsters, guinea pigs, and mice; rabbits, canines, felines; catties, such as bovines, goats, pigs, sheep, equines, crustaceans, birds, chickens, reptiles, amphibians, fish, insects, plants, fungi, yeast, nematodes, etc.
  • homologs Among mammalian species, e.g., human and mouse, homologs have substantial sequence similarity, e.g., at least about 60% sequence identity, at least about 75% sequence identity, or at least about 80% sequence identity among nucleotide sequences. In many embodiments of interest, homology will be at least about 75%), at least about 80% ,at least about 85%, at least about 90%), at least about 95%, at least about 97%, or at least about 98%, where in certain embodiments of interest homology will be as high as about 99%.
  • nucleic acids Modifications in the native structure of nucleic acids, including alterations in the backbone, sugars or heterocyclic bases, have been shown to increase infracellular stability and binding affinity.
  • backbone chemistry phosphorothioates; phosphorodithioates, where both of the non-bridging oxygens are substituted with sulfur; phosphoroamidites; alkyl phosphotriesters and boranophosphates.
  • Achiral phosphate derivatives include 3 -O -5 - S -phosphorothioate, 3 -S-5 -O- phosphorothioate, 3'-CH -5'-O-phosphonate and 3'-NH-5'-O-phosphoroamidate.
  • Peptide nucleic acids replace the entire ribose phosphodiester backbone with a peptide linkage.
  • Sugar modifications are also used to enhance stability and affinity.
  • the ⁇ -anomer of deoxyribose can be used, where the base is inverted with respect to the natural ⁇ -anomer.
  • the 2 -OH of the ribose sugar can be altered to form 2 -O- methyl or 2 -O-allyl sugars, which provides resistance to degradation without comprising affinity.
  • Modification of the heterocyclic bases must maintain proper base pairing.
  • Some useful substitutions include deoxyuridine for deoxythymidine; 5-methyl-2 - deoxycytidine and 5 -bromo-2'-deoxy cytidine for deoxycytidine.
  • 5- propynyl-2 - deoxyuridine and 5 -propynyl-2 -deoxycytidine have been shown to increase affinity and biological activity when substituted for deoxythymidine and deoxycytidine, respectively.
  • a genomic sequence of interest comprises the nucleic acid present between the initiation codon and the stop codon, as defined in the listed sequences, including all of the introns that are normally present in a native chromosome. It can further include the 3 ' and 5 ' untranslated regions found in the mature mRNA. It can i further include specific transcriptional and translational regulatory sequences, such as promoters, enhancers, etc., including about 1 kb, about 2 kb, and possibly more, of flanking genomic DNA at either the 5' or 3' end of the transcribed region.
  • the genomic DNA can be isolated as a fragment of 100 kbp or smaller; and substantially free of flanking chromosomal sequence.
  • the genomic DNA flanking the coding region, either 3 'or 5', or internal regulatory sequences as sometimes found in introns contains sequences required for proper tissue and stage specific expression.
  • Nucleic acid molecules of the invention can comprise heterologous nucleic acid molecules, i.e., nucleic acid molecules other than the subject nucleic acid molecules, of any length.
  • the subject nucleic acid molecules can be flanked on the 5 ' and/or 3 ' ends by heterologous nucleic acid molecules of from about 1 nucleotide to about 10 nucleotides, from about 10 nucleotides to about 20 nucleotides, from about 20 nucleotides to about 50 nucleotides, from about 50 nucleotides to about 100 nucleotides, from about 100 nucleotides to about 250 nucleotides, from about 250 nucleotides to about 500 nucleotides, or from about 500 nucleotides to about 1000 nucleotides, or more in length.
  • the subject polynucleotides include those that encode fusion proteins comprising the subject polypeptides fused to "fusion partners."
  • the present soluble receptor or ligand can be fused to an immunoglobulin fragment, such as an Fc fragment for stability in circulation or to fix complement.
  • an immunoglobulin fragment such as an Fc fragment for stability in circulation or to fix complement.
  • Other polypeptide fragments that have equivalent capabilities as the Fc fragments can also be used herein.
  • the isolated nucleic acids of the invention can be used as probes to detect and characterize gross alteration in a genomic locus, such as deletions, insertions, translocations, and duplications, e.g., applying fluorescence in situ hybridization (FISH) techniques to examine chromosome spreads (Andreeff et al., 1999).
  • FISH fluorescence in situ hybridization
  • the nucleic acids are also useful for detecting smaller genomic alterations, such as deletions, insertions, additions, translocations, and substitutions (e.g., SNPs).
  • nucleic acid molecules When used as probes to detect nucleic acid molecules capable of hybridizing with nucleic acids described in the Sequence Listing, the nucleic acid molecules can be flanked by heterologous sequences of any length.
  • a subject nucleic acid can include nucleotide analogs that incorporate labels that are directly detectable, such as radiolabels or fluorophores, or nucleotide analogs that incorporate labels that can be visualized in a subsequent reaction, such as biotin or various haptens. Haptens that are commonly conjugated to nucleotides for subsequent labeling include biotin, digoxigenin, and dinitrophenyl.
  • Suitable fluorescent labels include fluorochrom.es e.g., fluorescein and its derivatives, e.g., fluorescein isothiocyanate (FITC6-carboxyfluorescein (6- FAM), 2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein (JOE), ), 6-carboxy- 2',4',7',4,7-hexachlorofluorescein (HEX), 5 -carboxy fluorescein (5-FAM); coumarin and its derivatives, e.g., 7-amino-4-methylcoumarin, aminocoumarin; bodipy dyes, such as Bodipy FL; cascade blue; Oregon green; rhodamine dyes, e.g., rhodamine, 6- carboxy-X-rhodamine (ROX), Texas red, phycoerythrin, and tetramethylrhodamine; e
  • Fluorescent labels also include a green fluorescent protein (GFP), i.e., a "humanized” version of a GFP, e.g., wherein codons of the naturally-occurring nucleotide sequence are changed to more closely match human codon bias; a GFP derived from Aequoria victoria or a derivative thereof, e.g., a "humanized” derivative such as Enhanced GFP, which are available commercially, e.g., from Clontech, Inc.; other fluorescent mutants of a GFP from Aequoria victoria, e.g., as described in U.S. Patent No.
  • GFP green fluorescent protein
  • Probes can also contain fluorescent analogs, including commercially available fluorescent nucleotide analogs that can readily be incorporated into a subject nucleic acid. These include deoxyribonucleotides and/or ribonucleotide analogs labeled with Cy3, Cy5, Texas Red, Alexa Fluor dyes, rhodamine, cascade blue, or BODIPY, and the like.
  • Suitable radioactive labels include, e.g., 32 P, 35 S, or 3 H
  • probes can contain radiolabeled analogs, including those commonly labeled with 32 P or 35 S, such as ⁇ - 32 P-dATP, -dTTP, -dCTP, and dGTP; ⁇ - 35 S-GTP and ⁇ - 35 S- dATP, and the like.
  • Nucleic acids of the invention can also be bound to a substrate.
  • Subject nucleic acids can be attached covalently, attached to a surface of the support or applied to a derivatized surface in a chaotropic agent that facilitates denaturation and adherence, e.g., by noncovalent interactions, or some combination thereof.
  • the nucleic acids can be bound to a substrate to which a plurality of other nucleic acids are concurrently bound, hybridization to each of the plurality of the bound nucleic acids being separately detectable.
  • the substrate can be porous or solid, planar or non-planar, unitary or distributed; and the bond between the nucleic acid and the substrate can be covalent or non-covalent.
  • the substrate can be in the form of microbeads or nanobeads.
  • Substrates include, but are not limited to, a membrane, such as nitrocellulose, nylon, positively-charged derivatized nylon; a solid substrate such as glass, amorphous silicon, crystalline silicon, plastics (including e.g., polymethylacrylic, polyethylene, polypropylene, polyacrylate, polymethylmethacrylate, polyvinylchloride, polytefrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, cellulose acetate, or mixtures thereof).
  • a membrane such as nitrocellulose, nylon, positively-charged derivatized nylon
  • a solid substrate such as glass, amorphous silicon, crystalline silicon
  • plastics including e.g., polymethylacrylic, polyethylene, polypropylene, polyacrylate, polymethylmethacrylate, polyvinylchloride, polytefrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, cellulose
  • the subject nucleic acids include antisense RNA, ribozymes, and RNAi. Further, The nucleic acids of the invention can be used for antisense or RNAi inhibition of transcription or translation using methods known in the art (Phillips, 1999a; Phillips, 1999b; Hartmann et al., 1999; Stein et al., 1998; Agrawal et al, 1998).
  • the instant invention further provides host cells, e.g., recombinant host cells, that comprise a subject nucleic acid, host cells that comprise a recombinant vector, and host cells that secrete antibodies of the invention.
  • Subject host cells can be cultured in vitro, or can be part of a multicellular organism. Host cells are described in more detail below.
  • the instant invention further provides transgenic plants and non-human animals, as described in more detail below.
  • the subject nucleic acids find use in the preparation of all or a portion of the polypeptides of the subject invention, as described above, using an expression system.
  • an expression vector can be employed.
  • the expression vector will provide a transcriptional and translational initiation region, which may be inducible, conditionally-active, or constitutive, or tissue-specific, where the coding region is operably linked under the transcriptional control of the transcriptional initiation region, and a transcriptional and translational termination region.
  • These control regions can be native to a gene encoding the subject peptides, or can be derived from heterologous or exogenous sources.
  • the subject nucleic acids can also be provided as part of a vector (e.g., a polynucleotide construct comprising an expression cassette), a wide variety of which are known in the art.
  • Vectors include, but are not limited to, plasmids; cosmids; viral vectors; human, yeast, bacterial, PI -derived artificial chromosomes (HACs, YAC's, BAC's, PACs, etc.), mini-chromosomes, and the like.
  • Vectors are amply described in numerous publications well known to those in the art (Ausubel, et al.; Jones et al., 1998a; Jones et al., 1998b).
  • Vectors can provide for nucleic acid expression, for nucleic acid propagation, or both.
  • a recombinant vector or constract that includes a nucleic acid of the invention is useful for propagating a nucleic acid in a host cell; such vectors are known as "cloning vectors.”
  • Vectors can transfer nucleic acid between host cells derived from disparate organisms; these are known in the art as “shuttle vectors.”
  • Vectors can also insert a subject nucleic acid into a host cell's chromosome; these are known in the art as “insertion vectors.”
  • Vectors can express either sense or antisense RNA transcripts of the invention in vitro (e.g., in a cell-free system or within an in vitro cultured host cell) or in vivo (e.g., in a multicellular plant or animal); these are known in the art as "expression vectors," which can be part of an expression system.
  • Vectors can also produce a subject antibody.
  • Vectors typically include at least one origin of replication, at least one site for insertion of heterologous nucleic acid (e.g., in the form of a polylinker with multiple, tightly clustered, single cutting restriction endonuclease recognition sites), and at least one selectable marker, although some integrative vectors will lack an origin that is functional in the host to be chromosomally modified, and some vectors will lack selectable markers.
  • Vectors are transiently or stably be maintained in the cells, usually for a period of at least about one day, at least about several days to at least about several weeks.
  • the DNA of interest Prior to vector insertion, the DNA of interest will be obtained substantially free of other nucleic acid sequences.
  • the DNA can be "recombinant,” and flanked by one or more nucleotides with which it is not normally associated on a naturally occurring chromosome.
  • Expression vectors generally have convenient restriction sites located near the promoter sequence to provide for the insertion of nucleic acid sequences encoding heterologous protein or RNA molecules.
  • a selectable marker operative in the expression system or host can be present.
  • Expression vectors can be used for the production of fusion proteins, where the fusion peptide provides additional functionality, i.e., increased protein synthesis, a leader sequence for secretion, stability, reactivity with defined antisera, or an enzyme marker, e.g., ⁇ -galactosidase.
  • Promoters of the invention can be naturally contiguous or not naturally contiguous to the expressed nucleic acid molecule.
  • the promoters can be inducible, conditionally active (such as the cre-lox promoter), constitutive, and/or tissue specific.
  • Expression vectors can be prepared comprising a transcription cassette comprising a franscription initiation region, the gene or fragment thereof, and a transcriptional termination region.
  • DNA sequences that allow for the expression of functional epitopes or domains, at least about 5, at least about 8, at least about 10, at least about 15, at least about 18, at least about 20, at least about 25, at least about 30, at least about 50, at least about 75, at least about 100, at least about 150, at least about 200, at least about 250, at least about 300, at least about 350, at least about 400, at least about 450, at least about 500, at least about 550, at least about 600, at least about 650, at least about 700, at least about 750, at least about 800, at least about 850, at least about 900, at least about 950, or at least about 1000 amino acids in length, or any of the above-described fragments, up to and including the complete open reading frame of the gene.
  • the cells containing the vector construct can be prepared comprising a transcription cassette comprising a fran
  • Host cells can comprise prokaryotes or eukaryotes that express proteins and polypeptides in accordance with conventional methods, the method depending on the purpose for expression.
  • a unicellular organism such as E. coli, B. subtilis, S. cerevisiae, insect cells in combination with baculovirus vectors, or cells of a higher organism such as vertebrates, particularly mammals, e.g., COS 7 cells, can be used as the expression host cells.
  • Specific expression systems of interest include plants, bacteria, yeast, insect cells, and mammalian cell-derived expression systems. Representative systems from each of these categories are provided below.
  • Expression systems in plants include those described in U.S. Patent No. 6,096,546 and U.S. Patent No. 6,127,145.
  • Expression systems in bacteria include those described by Chang et al, 1978; Goeddel et al., 1979; Goeddel et al., 1980; EP 0 036,776; U.S. Patent No. 4,551,433; DeBoer et al., 1983); and Siebenlist et al., 1980.
  • Expression systems in yeast include those described by Hinnen et al., 1978; Ito et al, 1983; Kurtz et al., 1986; Kunze et al, 1985; Gleeson et al., 1986; Roggenkamp et al., 1986; Das et al., 1984; De Louvencourt et al., 1983; Van den Berg et al., 1990; Kunze et al., 1985; Cregg et al., 1985; U.S. Patent Nos.
  • Expression systems for heterologous genes in insects include those described in U.S. Patent No. 4,745,051; Friesen et al., 1986; EP 0 127,839; EP 0 155,476; Vlak et al, 1988; Miller et al., 1988; Carbonell et al., 1988; Maeda et al., 1985; Lebacq-Verheyden et al., 1988; Smith et al, 1985); Miyajima et al., 1987; and Martin et al., 1988.
  • insect cell expression system is useful not only for production of heterologous proteins intracellularly, but can be used for expression of transmembrane proteins on the insect cell surfaces.
  • Such insect cells can be used as immunogen for production of antibodies, for example, by injection of the insect cells into mice or rabbits or other suitable animals, for production of antibodies.
  • Mammalian expression systems include those described in Dijkema et al., 1985; Gorman et al., 1982; Boshart et al., 1985; and U.S. Patent No. 4,399,216. Additional features of mammalian expression are facilitated as described in Ham and Wallace, 1979; Barnes and Sato, 1980 U.S. Patent Nos. 4,767,704, 4,657,866, 4,927,762, 4,560,655, WO 90/103430, WO 87/00195, and U.S. RE 30,985. Mammalian cell expression systems can also be used for production of antibodies.
  • the present polynucleotides can also be used in cell-free expression systems such as bacterial system, e.g., E. coli lysate, rabbit reticulocyte lysate system, wheat germ extract system, frog oocyte lysate system, and the like which is conventional in the art. See, for example, WO 00/68412, WO 01/27260, WO 02/24939, WO 02/38790, WO 91/02076, and WO 91/02075.
  • bacterial system e.g., E. coli lysate, rabbit reticulocyte lysate system, wheat germ extract system, frog oocyte lysate system, and the like which is conventional in the art.
  • bacterial system e.g., E. coli lysate, rabbit reticulocyte lysate system, wheat germ extract system, frog oocyte lysate system, and the like which is conventional in the art.
  • the resulting replicated nucleic acid, RNA, expressed protein or polypeptide is within the scope of the invention as a product of the host cell or organism.
  • the gene corresponding to a selected polynucleotide is identified, its expression can be regulated in the gene's native cell types.
  • an endogenous gene of a cell can be regulated by an exogenous regulatory sequence inserted into the genome of the cell at a location that will enhance or reduce expression of the gene corresponding to the subject polypeptide.
  • the regulatory sequence can be designed to integrate into the genome via homologous recombination, as disclosed in U.S. Patent Nos. 5,641,670 and 5,733,761, the disclosures of which are herein incorporated by reference.
  • the invention provides isolated nucleic acids that, when used as primers in a polymerase chain reaction, amplify a subject polynucleotide, or a polynucleotide containing a subject polynucleotide.
  • the amplified polynucleotide is from about 20 to about 50, from about 50 to about 75, from about 75 to about 100, from about 100 to about 125, from about 125 to about 150, from about 150 to about 175, from about 175 to about 200, from about 200 to about 250, from about 250 to about 300, from about 300 to about 350, from about 350 to about 400, from about 400 to about 500, from about 500 to about 600, from about 600 to about 700, from about 700 to about 800, from about 800 to about 900, from about 900 to about 1000, from about 1000 to about 2000, from about 2000 to about 3000, from about 3000 to about 4000, from about 4000 to about 5000, or from about 5000 to about 6000 nucleotides or more in length.
  • the isolated nucleic acids themselves are from about 10 to about 20, from about 20 to about 30, from about 30 to about 40, from about 40 to about 50, from about 50 to about 100, or from about 100 to about 200 nucleotides in length.
  • the nucleic acids are used in pairs in a polymerase chain reaction, where they are referred to as "forward" and "reverse” primers.
  • the invention provides a pair of isolated nucleic acid molecules, each from about 10 to about 200 nucleotides in length, the first nucleic acid molecule of the pair comprising a sequence of at least 10 contiguous nucleotides having 100%> sequence identity to a nucleic acid sequence as shown in SEQ ID NOS.: 1 - 209 and 419 - 627 and the second nucleic acid molecule of the pair comprising a sequence of at least 10 contiguous nucleotides having 100%) sequence identity to the reverse complement of the nucleic acid sequence shown in SEQ ID NOS.: 1 - 209 and 419 - 627 , wherein the sequence of the second nucleic acid molecule is located 3 'of the nucleic acid sequence of the first nucleic acid molecule shown in SEQ ID NOS.: 1 - 209 and 419 - 627.
  • the primer nucleic acids are prepared using any known method, e.g., automated synthesis, and can be chosen to
  • the first and/or the second nucleic acid molecules comprise a detectable label.
  • the label can be a radioactive molecule, fluorescent molecule or another molecule, e.g., hapten, as described in detail above.
  • the label can be a two stage system, where the amplified DNA is conjugated to another molecule, i.e., biotin, digoxin, or a hapten, that has a high affinity binding partner, i.e., avidin, antidigoxin, or a specific antibody, respectively, and the binding partner conjugated to a detectable label.
  • the label can be conjugated to one or both of the primers.
  • the pool of nucleotides used in the amplification is labeled, so as to incorporate the label into the amplification product.
  • Conditions that increase stringency of both DNA/DNA and DNA/RNA hybridization reactions are widely known and published in the art. See, for example, Sambrook, 1989, and examples provided above. Examples of relevant conditions include (in order of increasing stringency): incubation temperatures of 25°C, 37°C, 50°C, and 68°C; buffer concentrations of 10 x SSC, 6 x SSC, 1 x SSC, 0.1 x SSC (where 1 x SSC is 0.15 M NaCl and 15 mM citrate buffer); and their equivalents using other buffer systems; formamide concenfrations of 0%, 25%, 50%, and 75%; incubation times from 5 minutes to 24 hours; 1, 2, or more washing steps; wash incubation times of 1, 2, or 15 minutes; and wash solutions of 6 x SSC, 1 x SSC, 0.1 x SSC, or deionized water.
  • high stringency conditions include hybridization in 50% formamide, 5X SSC, 0.2 ⁇ g/ ⁇ l poly(dA), 0.2 ⁇ g/ ⁇ l human cotl DNA, and 0.5% SDS, in a humid oven at 42°C overnight, followed by successive washes in IX SSC, 0.2% SDS at 55°C for 5 minutes, followed by washing at 0.1X SSC, 0.2% SDS at 55°C for 20 minutes.
  • high stringency conditions include hybridization at 50°C and O.lxSSC (15 mM sodium chloride/1.5 mM sodium citrate); overnight incubation at 42°C in a solution containing 50% formamide, 1 x SSC (150 mM NaCl, 15 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 ⁇ g/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1 x SSC at about 65°.
  • High stringency conditions also include aqueous hybridization (e.g., free of formamide) in 6X SSC (where 20X SSC contains 3.0 M NaCl and 0.3 M sodium citrate), 1% sodium dodecyl sulfate (SDS) at 65°C for about 8 hours (or more), followed by one or more washes in 0.2 X SSC, 0.1 % SDS at 65°C.
  • Highly stringent hybridization conditions are hybridization conditions that are at least as stringent as any one of the above representative conditions.
  • Other stringent hybridization conditions are known in the art and can also be employed to identify nucleic acids of this particular embodiment of the invention.
  • Conditions of "reduced stringency,” suitable for hybridization to molecules encoding structurally and functionally related proteins, or otherwise serving related or associated functions, are the same as those for high stringency conditions but with a reduction in temperature for hybridization and washing to lower temperatures (e.g., room temperature or about 22°C to 25°C).
  • moderate stringency conditions include aqueous hybridization (e.g., free of formamide) in 6X SSC, 1% SDS at 65°C for about 8 hours (or more), followed by one or more washes in 2X SSC, 0.1%) SDS at room temperature.
  • Low stringency conditions include, for example, aqueous hybridization at 50°C and 6xSSC (0.9 M sodium chloride/0.09 M sodium citrate) and washing at 25°C in lxSSC (0.15 M sodium chloride/0.015 M sodium citrate).
  • the specificity of a hybridization reaction allows any single-stranded sequence of nucleotides to be labeled with a radioisotope or chemical and used as a probe to find a complementary strand, even in a cell or cell extract that contains millions of different DNA and RNA sequences. Probes of this type are widely used to detect the nucleic acids corresponding to specific genes, both to facilitate the purification and characterization of the genes after cell lysis and to localize them in cells, tissues, and organisms.
  • the polynucleotide libraries of the invention generally comprise a collection of sequence information of a plurality of polynucleotide sequences, where at least one of the polynucleotides has a sequence shown in SEQ ID NOS.: 1 -209 and 419 - 627.
  • plurality is meant at least 2, at least 3, or at least all of the sequences in the Sequence Listing.
  • the information may be provided in either biochemical form (e.g., as a collection of polynucleotide molecules), or in electronic form (e.g., as a collection of polynucleotide sequences stored in a computer-readable form, as in a computer-based system, a computer data file, and/or as a part of a computer program).
  • biochemical form e.g., as a collection of polynucleotide molecules
  • electronic form e.g., as a collection of polynucleotide sequences stored in a computer-readable form, as in a computer-based system, a computer data file, and/or as a part of a computer program.
  • the length and number of polynucleotides in the library will vary with the nature of the library, e.g., if the library is an oligonucleotide array, a cDNA array, or a computer database of the sequence information.
  • sequence information contained in either a biochemical or an electronic library of polynucleotides can be used in a variety of ways, e.g., as a resource for gene discovery, as a representation of sequences expressed in a selected cell type (e.g., cell type markers), or as markers of a given disorder or disease state.
  • a disease marker is a representation of a gene product that is present in all cells affected by disease either at an increased or decreased level relative to a normal cell (e.g., a cell of the same or similar type that is not substantially affected by disease).
  • a polynucleotide sequence in a library can be a polynucleotide ' that represents an mRNA, polypeptide, or other gene product encoded by the polynucleotide, that is either over-expressed or under-expressed in one cell compared to another (e.g., a first cell type compared to a second cell type; a normal cell compared to a diseased cell; a cell not exposed to a signal or stimulus compared to a cell exposed to that signal or stimulus; and the like).
  • the nucleotide sequence information of the library can be embodied in any suitable form, e.g., electronic or biochemical forms.
  • a library of sequence information embodied in electronic form comprises an accessible computer data file that may contain the representative nucleotide sequences of genes that are differentially expressed (e.g., over-expressed or under-expressed) as between, e.g., a first cell type compared to a second cell type (e.g., expression in a brain cell compared to expression in a kidney cell); a normal cell compared to a diseased cell (e.g., a non- cancerous cell compared to a cancerous cell); a cell not exposed to an internal or external signal or stimulus compared to a cell exposed to that signal or stimulus (e.g., a cell contacted with a ligand compared to a control cell not contacted with the ligand); and the like.
  • Biochemical embodiments of the library include a collection of nucleic acid molecules that have the sequences of the genes in the library, where the nucleic acids can correspond to the entire gene in the library or to a fragment thereof, as described in greater detail below.
  • the nucleic acid sequence information can be present in a variety of media.
  • the nucleic acid sequences of any of the polynucleotides shown in SEQ ID NOS.: 1 -209 and 419 - 627 can be recorded on computer readable media of a computer-based system, e.g., any medium that can be read and accessed directly by a computer.
  • a computer-based system e.g., any medium that can be read and accessed directly by a computer.
  • Any of the presently known computer readable mediums can be used to create a manufacture comprising a recording of the present sequence information. Any convenient data storage structure can be chosen, based on the means used to access the stored information.
  • a variety of data processor programs and formats can be used for storage, e.g., word processing text file, database format, etc.
  • electronic versions of the libraries of the invention can be provided in conjunction or connection with other computer-readable information and/or other types of computer-based files (e.g., searchable files, executable files, etc, including, but not limited to, for example, search program software, etc.).
  • nucleotide sequence By providing the nucleotide sequence in computer readable form in a computer-based system, the information can be accessed for a variety of purposes.
  • Computer software to access sequence information is publicly available.
  • Conventional bioinformatics tools can be utilized to analyze sequences to determine sequence identity, sequence similarity, and gap information.
  • the gapped BLAST Altschul et al., 1990, Altschul et al., 1997), and BLAZE (Brutlag et al., 1993) search algorithms on a Sybase system, or the TeraBLAST (TimeLogic, Crystal Bay, Nevada) program optionally running on a specialized computer platform available from TimeLogic, can be used to identify open reading frames (ORFs) within the genome that contain homology to ORFs from other organisms.
  • ORFs open reading frames
  • Homology between sequences of interest can be determined using the local homology algorithm of Smith and Waterman, 1981, as well as the BestFit program (Rechid et al., 1989), and the FastDB algorithm (FastDB, 1988; described in Current Methods in Sequence Comparison and Analysis, Macromolecule Sequencing and Synthesis, Selected Methods and Applications, pp. 127-149, 1988, Alan R. Liss, Inc).
  • Alignment programs that permit gaps in the sequence include Clustalw (Thompson et al, 1994), FASTA3 (Pearson, 2000) AlignO (Myers and Miller, 1988), and TCoffee (Notredame et al, 2000).
  • Other methods for comparing and aligning nucleotide and protein sequences include, for example, BLASTX (NCBI), the Wise package (Birney and Durbin, 2000), and FASTX (Pearson, 2000). These algorithms determine sequence homology between nucleotide and protein sequences without translating the nucleotide sequences into protein sequences.
  • Sequence similarity is calculated based on a reference sequence, which may be a subset of a larger sequence, such as a conserved motif, coding region, flanking region, etc.
  • the reference sequence is usually at least about 18 nt long, at least about 30 nt long, or may extend to the complete sequence that is being compared.
  • One parameter for determining percent sequence identity is the percentage of the alignment in the region of strongest alignment between a target and a query sequence. Methods for determining this percentage involve, for example, counting the number of aligned bases of a query sequence in the region of strongest alignment and dividing this number by the total number of bases in the region. For example, 10 matches divided by 11 total residues gives a percent sequence identity of approximately 90.9%.
  • the length of the aligned region is typically at least about 55% ⁇ , at least about 58%>, or at least about 60%) of the total sequence length, and can be as great as about 62%>, as great as about 64%>, and even as great as about 66%> of the total sequence length.
  • the present invention includes human and mouse polynucleotide and polypeptide sequences that are at least about 95%>, at least about 96%>, at least about 97%), at least about 98%>, or at least about 99% homologous to the sequences in the Sequence Listing, based on using the method of determining sequence identity with the insertion of gaps to detect the maximum degree of sequence identity. In other embodiments of interest, homology will be at least about 80%>, at least about 85%, or as high as about 90%o.
  • a variety of structural formats for the input and output means can be used to input and output the information in the computer-based systems of the present invention.
  • One format for an output means ranks the relative expression levels of different polynucleotides. Such presentation provides a skilled artisan with a ranking of relative expression levels to determine a gene expression profile.
  • the library of the invention also encompasses biochemical libraries of the polynucleotides shown in SEQ ID NOS.: 1 - 209 and 419 - 627, e.g., collections of nucleic acids representing the provided polynucleotides.
  • the biochemical libraries can take a variety of forms, e.g., a solution of cDNAs, a pattern of probe nucleic acids stably associated with a surface of a solid support (i.e., an array) and the like.
  • nucleic acid arrays in which one or more of the polynucleotide sequences shown in SEQ ID NOS.: 1 - 209 and 419 - 627 is represented on the array.
  • arrays of the subject invention find use in a variety of applications, including gene expression analysis, drug screening, mutation analysis, and the like, as disclosed in the herein-listed exemplary patent documents.
  • analogous libraries of polypeptides are also provided, where the polypeptides of the library will represent at least a portion of the polypeptides encoded by a gene corresponding to one or more of the sequences shown in SEQ ID NOS.: 1 -209 and 419 - 627.
  • analogous libraries of antibodies are also provided, where the libraries comprise antibodies or fragments thereof that specifically bind to at least a portion of at least one of the subject polypeptides.
  • antibody libraries may comprise antibodies or fragments thereof that specifically inhibit binding of a subject polypeptide to its ligand or substrate, or that specifically inhibit binding of a subject polypeptide as a subsfrate to another molecule.
  • corresponding nucleic acid libraries are also provided, comprising polynucleotide sequences that encode the antibodies or antibody fragments described above.
  • This invention provides novel polypeptides, and related polypeptide compositions.
  • the novel polypeptides of the invention encompass proteins with amino acid sequences as shown in SEQ ID NOS.: 210 - 418, or encoded by the nucleic acids having nucleotide sequences shown in SEQ ID NOS.: 1 -209 and 419 - 627.
  • the subject polypeptides are human polypeptides, fragments thereof, variants (such as splice variants), homologs from other species, and derivatives thereof.
  • a polypeptide of the invention has an amino acid sequence substantially identical to the sequence of any polypeptide encoded by a polynucleotide sequence shown in SEQ ID NOS.: 1 -209 and 419 - 627.
  • polypeptides may reside within the cell, or extracellularly. They may be secreted from the cell, reside in the cytoplasm, in the membranes, or in any of the intracellular organelles, including the nucleus, mitochondria, ribosomes, or storage granules.
  • a novel polypeptide of the invention functions as a secreted protein, a single-transmembrane protein, a multiple-transmembrane protein, a kinase, a protein kinase, a ligase, a nuclear hormone receptor, a phosphatase, a protease, a phosphodiesterase, a kinesin, an immunoglobulin, a T-cell receptor, or a glycosylphosphatidylinositol anchor.
  • a novel polypeptide of the invention can also possess one or more of the following functions or properties: (1) an activator functioning to regulate one or more genes by increasing the rate of transcription, (2) an activator functioning to positively modulate an allosteric enzyme, (3) an adaptor functioning to sort cargo molecules into transport vesicles, (4) an adaptor functioning to form a clathrin-coated vesicle, (5) an adhesion molecule functioning to mediate the adhesion of cells with other cells and/or the exfracellular matrix, (6) an ATPase functioning to move ions or small molecules across a membrane against a chemical concentration gradient or electrical potential, (7) an ATPase functioning to translocate nucleotides across membranes, (8) a breakpoint- related sequence functioning as an oncoprotein, (9) a breakpoint-related sequence functioning as a tumor-specific antigen, (10) a channel functioning as a water channel, (11) a chamiel functioning as an ion channel, (12) a checkpoint-related sequence functioning
  • the present novel polypeptide modulates the cells or tissues of animals, particularly humans, such as, for example, by stimulating, enhancing or inhibiting T or B cell function or the function of other hematopoeitic cells or bone marrow cells; modulates adult or embryonic stem cell or precursor cell growth or differentiation; modulates cell function or activity of neuronal cells or other cells of the CNS, heart cells, liver cells, kidney cells, lung cells, pancreatic cells, gastrointestinal cells, spleen cells, breast cells, prostate cells, ovarian cells, and the like.
  • a subject polypeptide is present as a multimer.
  • Multimers include homodimers, homotrimers, homoteframers, and multimers that include more than four monomeric units.
  • Multimers also include heteromultimers, e.g., heterodimers, heterotrimers, heterotetramers, etc. where the subject polypeptide is present in a complex with proteins other than the subject polypeptide.
  • the multimer is a heteromultimer
  • the subject polypeptide can be present in a 1 : 1 ratio, a 1 :2 ratio, a 2:1 ratio, or other ratio, with the other protein(s).
  • polypeptides from other species are also provided, including mammals, such as: primates, rodents, e.g., mice, rats, hamsters, guinea pigs; domestic animals, e.g., sheep, pig, horse, cow, goat, rabbit, dog, cat; and humans, as well as non-mammalian species, e.g., avian, reptile and amphibian, insect, crustacean, fish, plant, fungus, and protozoa.
  • mammals such as: primates, rodents, e.g., mice, rats, hamsters, guinea pigs; domestic animals, e.g., sheep, pig, horse, cow, goat, rabbit, dog, cat; and humans, as well as non-mammalian species, e.g., avian, reptile and amphibian, insect, crustacean, fish, plant, fungus, and protozoa.
  • homolog is meant a protein having at least about 35 %, at least about 40%), at least about 60%), at least about 70%, at least about 75%>, at least about 80%), at least about 85%, at least about 90%, or at least about 95%, or higher, amino acid sequence identity to the reference polypeptide, as measured with the "GAP" program (part of the Wisconsin Sequence Analysis Package available through the Genetics Computer Group, Inc. (Madison WI)), where the parameters are: Gap weight: 12; length weight:4.
  • GAP Wisconsin Sequence Analysis Package available through the Genetics Computer Group, Inc.
  • homology will be at least about 75%, at least about 80%o, or at least 85%>, where in certain embodiments of interest, homology will be as high as about 90%).
  • polypeptides that are substantially identical to the at least one amino acid sequence shown in the Sequence Listing, or a fragment thereof, whereby substantially identical is meant that the protein has an amino acid sequence identity to the reference sequence of at least about 75%>, at least about 80%, at least about 85%o, at least about 90%, at least about 95%, at least about 97%, at least about 98%, or at least about 99%.
  • the proteins of the subject invention e.g., polypeptides encoded by the nucleotide sequences shown in SEQ ID NOS.: 1 - 209 and 419 - 627, and polypeptide sequences shown in SEQ ID NOS.: 210 - 418) have been separated from their naturally occurring environment and are present in a non-naturally occurring environment.
  • the proteins are present in a composition where they are more concentrated than in their naturally occurring environment. For example, purified polypeptides are provided.
  • Fusion proteins can comprise a subject polypeptide, or fragment thereof, and a polypeptide other than a subject polypeptide ("the fusion partner") fused in-frame at the N-terminus and/or C-terminus of the subject polypeptide, or internally to the subject polypeptide.
  • Fusion partners can also be those that are able to stabilize the present polypeptide, such as polyethylene glycol ("PEG") and a fragment of an immunoglobulin, such as the Fc fragment of IgG, IgE, IgA, IgM, and/or IgD.
  • PEG polyethylene glycol
  • an immunoglobulin such as the Fc fragment of IgG, IgE, IgA, IgM, and/or IgD.
  • Detection methods are chosen based on the detectable fusion partner.
  • the fusion partner provides an immunologically recognizable epitope
  • an epitope-specific antibody can be used to quantitatively detect the level of polypeptide.
  • the fusion partner provides a detectable signal
  • the detection method is chosen based on the type of signal generated by the fusion partner. For example, where the fusion partner is a fluorescent protein, fluorescence is measured.
  • the fusion partner is an enzyme that yields a detectable product, the product can be detected using an appropriate means.
  • ⁇ - galactosidase can, depending on the substrate, yield a colored product that can be detected with a spectrophotometer, and the fluorescent protein luciferase can yield a luminescent product detectable with a luminometer.
  • a polypeptide of the invention comprises at least about 5, at least about 8, at least about 10, at least about 15, at least about 18, at least about 20, at least about 25, at least about 30, at least about 50, at least about 75, at least about 100, at least about 150, at least about 200, at least about 250, at least about 300, at least about 350, at least about 400, at least about 450, at least about 500, at least about 550, at least about 600, at least about 650, at least about 700, at least about 750, at least about 800, at least about 850, at least about 900, at least about 950, or at least about 1000 contiguous amino acid residues of at least one of the sequences according to SEQ ID NOS.: 210 - 418, up to and including the entire amino acid sequence.
  • Fragments of the subject polypeptides, as well as polypeptides comprising such fragments, are also provided. Fragments of polypeptides of interest will typically be at least about 5, at least about 8, at least about 10, at least about 15, at least about 18, at least about 20, at least about 25, at least about 30, at least about 50, at least about 75, at least about 100, at least about 150, at least about 200, at least about 250, or at least 300 aa in length or longer, where the fragment will have a sfretch of amino acids that is identical to the subject protein of at least about 5, at least about 8, at least about 10, at least about 15, at least about 18, at least about 20, at least about 25, at least about 30, or at least about 50 aa in length.
  • fragments exhibit one or more activities associated with a corresponding naturally occurring polypeptide. Fragments find utility in generating antibodies to the full-length polypeptide; and in methods of screening for candidate agents that bind to and/or modulate polypeptide activity. Specific fragments of interest include those with enzymatic activity, those with biological activity including the ability to serve as an epitope or immunogen, and fragments that bind to other proteins or to nucleic acids.
  • the invention provides polypeptides comprising such fragments, including, e.g., fusion polypeptides comprising a subject polypeptide fragment fused in frame (directly or indirectly) to another protein (the "fusion partner"), such as the signal peptide of one protein being fused to the mature polypeptide of another protein.
  • fusion proteins are typically made by linking the encoding polynucleotides together in a vector or cassette.
  • Fusion partners can also be those that are able to stabilize the present polypeptide, such as polyethylene glycol ("PEG") and a fragment of an immunoglobulin, such as the Fc fragment of IgG, IgE, IgA, IgM, and/or IgD.
  • PEG polyethylene glycol
  • an immunoglobulin such as the Fc fragment of IgG, IgE, IgA, IgM, and/or IgD.
  • Polypeptides of the invention can be obtained from naturally- occurring sources or produced synthetically.
  • the sources of naturally occurring polypeptides will generally depend on the species from which the protein is to be derived, i.e., the proteins will be derived from biological sources that express the proteins.
  • the subject proteins can also be derived from synthetic means, e.g., by expressing a recombinant gene encoding a protein of interest in a suitable system or host or enhancing endogenous expression, as described in more detail above. Further, small peptides can be synthesized in the laboratory by techniques well known in the art.
  • the product can be recovered by any appropriate means known in the art.
  • convenient protein purification procedures can be employed (e.g., see Guide to Protein Purification. Deuthscher et al., 1990). That is, a lysate can be prepared from the original source, (e.g., a cell expressing endogenous polypeptide, or a cell comprising the expression vector expressing the polypeptide(s)), and purified using HPLC, exclusion chromatography, gel electrophoresis, or affinity chromatography, and the like.
  • the invention thus also provides methods of producing polypeptides.
  • the methods generally involve introducing a nucleic acid constract into a host cell in vitro and culturing the host cell under conditions suitable for expression, then harvesting the polypeptide, either from the culture medium or from the host cell, (e.g., by disrupting the host cell), or both, as described in detail above.
  • the invention also provides methods of producing a polypeptide using cell-free in vitro transcription/translation methods, which are well known in the art, also as provided above
  • polypeptides including polypeptide fragments, as targets for therapeutic intervention, including use in screening assays, for identifying agents that modulate polypeptide level and/or activity, and as targets for antibody and small molecule therapeutics, for example, in the treatment of disorders.
  • the present invention provides methods of producing a subject polypeptide and provides antibodies that specifically bind to a subject polypeptide.
  • the present invention further provides screening methods for identifying agents that modulate a level or an activity of a subject polypeptide or polynucleotide.
  • the present invention thus also provides agents that modulate a level or an activity of a subject polypeptide or polynucleotide, as well as compositions, including pharmaceutical compositions, comprising a subject agent.
  • the present invention further provides methods for treating disorders such as, for example, cancer and other proliferative disorders, inflammatory and immune disorders, metabolic disorders or conditions, and bacterial or viral disorders or conditions.
  • disorders such as, for example, cancer and other proliferative disorders, inflammatory and immune disorders, metabolic disorders or conditions, and bacterial or viral disorders or conditions.
  • Formation of a binding complex between a subject polypeptide and an interacting polypeptide or other macromolecule can be detected using any known method. Suitable methods include: a yeast two-hybrid system (Zhu et al., 1997; Fields and Song, 1989; U.S. Pat. No. 5,283,173; Chien et al.
  • FRET fluorescence resonance energy transfer
  • BRET bioluminescence resonance energy transfer
  • fluorescence quenching assay fluorescence quenching assay
  • fluorescence anisofropy assay Jameson and Sawyer, 1995
  • an immunological assay and an assay involving binding of a detectably labeled protein to an immobilized protein.
  • Immunological assays, and assays involving binding of a detectably labeled protein to an immobilized protein can be performed in a variety of ways.
  • immunoprecipitation assays can be designed such that the complex of protein and an interacting polypeptide is detected by precipitation with an antibody specific for either the protein or the interacting polypeptide.
  • FRET detects formation of a binding complex between a subj ect polypeptide and an interacting polypeptide. It involves the transfer of energy from a donor fluorophore in an excited state to a nearby acceptor fluorophore. For this transfer to take place, the donor and acceptor molecules must be in close proximity (e.g., less than 10 nanometers apart, usually between 10 and 100 A apart), and the emission spectra of the donor fluorophore must overlap the excitation spectra of the acceptor fluorophore.
  • a fluorescently labeled subject protein serves as a donor and/or acceptor in combination with a second fluorescent protein or dye.
  • Fluorescent proteins can be produced by generating a constract comprising a protein and a fluorescent fusion partner.
  • GFP green fluorescent protein
  • Fluorescent subject proteins can also be generated by producing the subject protein in an auxofrophic strain of bacteria which requires addition of one or more amino acids in the medium for growth.
  • a subject protein-encoding construct that provides for expression in bacterial cells is introduced into the auxofrophic sfrain, and the bacteria are cultured in the presence of a fluorescent amino acid, which is incorporated into the subject protein produced by the bacterium.
  • the subject protein is then purified from the bacterial culture using standard methods for protein purification.
  • BRET is a protein-protein interaction assay based on energy transfer from a bioluminescent donor to a fluorescent acceptor protein.
  • the BRET signal is measured by the ratio of the amount of light emitted by the acceptor to the amount of light emitted by the donor. The ratio of these two values increases as the two proteins are brought into proximity.
  • the BRET assay has been described in the literature (U.S. Patent Nos. 6,020,192; 5,968,750; 5,874,304; Xu, et al. 1999).
  • BRET assays can be performed by analyzing transfer between a bioluminescent donor protein and a fluorescent acceptor protein. Interaction between the donor and acceptor proteins can be monitored by a change in the ratio of light emitted by the bioluminescent and fluorescent proteins.
  • the subject protein serves as donor and/or acceptor protein.
  • Fluorescence anisotropy is a measurement of the rotational mobility of a multi-molecular complex. It can be used to generate information about the binding of one molecule to another, including the affinity and specificity of binding sites. It can be applied to polypeptides or nucleic acids of the present invention.
  • Fluorescence quenching measurements are useful in detecting protein multimerization, such as where the subject protein interacts with at least a second protein and, for example, where multimerization interaction is affected by a test agent.
  • multimerization refers to formation of dimers, trimers, tetramers, and higher multimers of the subject protein. Whether a subject protein forms a complex with one or more additional protein molecules can be determined using any known assay, including assays as described above for interacting proteins. Formation of multimers can also be detected using non-denaturing gel electrophoresis, where multimerized subject protein migrates more slowly than monomeric subject protein. Formation of multimers can also be detected using fluorescence quenching techniques.
  • Formation of multimers can also be detected by analytical ultracentrifugation, for example through glycerol or sucrose gradients, and subsequent visualization of a subject protein in gradient fractions by Western blotting or staining of SDS-polyacrylamide gels. Multimers are expected to sediment at defined positions in such gradients. Formation of multimers can also be detected using analytical gel filtration, e.g., in HPLC or FPLC systems, e.g., on columns such as Superdex 200 (Pharmacia Amersham Inc.). Multimers run at defined positions on these columns, and fractions can be analyzed as above. The columns are highly reproducible, allowing one to relate the number and position of peaks directly to the multimerization status of the protein.
  • the present invention provides methods for detecting the presence of mRNA in a biological sample.
  • the methods can be used, for example, to assess whether a test compound affects gene expression, either directly or indirectly.
  • the present invention provides diagnostic methods to compare the abundance of a nucleic acid with that of a control value, either qualitatively or quantitatively, and to relate the value to a normal or abnormal expression pattern.
  • Methods of measuring mRNA levels are known in the art (Pietu, 1996; Zhao, 1995; Soares, 1997; Raval, 1994; Chalifour, 1994; Stolz, 1996; Hong, 1982; McGraw, 1984; WO 97/27317). These methods generally comprise contacting a sample with a polynucleotide of the invention under conditions that allow hybridization and detecting hybridization, if any, as an indication of the presence of the polynucleotide of interest.
  • Appropriate controls include the use of a sample lacking the polynucleotide mRNA of interest, or the use of a labeled polynucleotide of the same "sense" as a polynucleotide mRNA of interest.
  • Detection can be accomplished by any known method, including, but not limited to, in situ hybridization, PCR, RT-PCR, and "Northern” or RNA blotting, or combinations of such techniques, using a suitably labeled subject polynucleotide.
  • a variety of labels and labeling methods for polynucleotides are known in the art and can be used in the assay methods of the invention.
  • a common method employed is use of microarrays which can be purchased or customized, for example, through conventional vendors such as Affymetrix.
  • the methods involve generating a cDNA copy of an mRNA molecule in a biological sample, and amplifying the cDNA using an . isolated primer pairs as described above, i.e., a set of two nucleic acid molecules that serve as forward and reverse primers in an amplification reaction (e.g., a polymerase chain reaction).
  • the primer pairs are chosen to specifically amplify a cDNA copy of an mRNA encoding a polypeptide.
  • a detectable label can be included in the amplification reaction, as provided above.
  • Methods using PCR amplification can be performed on the DNA from a single cell, although it is convenient to use at least about 10 5 cells.
  • the present invention provides methods for monitoring gene expression. Changes in a promoter or enhancer sequence that can affect gene expression can be examined in light of expression levels of the normal allele by various methods known in the art. Methods for determining promoter or enhancer strength include quantifying the expressed natural protein, and inserting the variant control element into a vector with a quantitative reporter gene such as ⁇ -galactosidase, luciferase, or chloramphenicol acetylfransferase (CAT).
  • a quantitative reporter gene such as ⁇ -galactosidase, luciferase, or chloramphenicol acetylfransferase (CAT).
  • Biochemical studies can determine whether a sequence polymorphism in a coding region or confrol region is associated with disease.
  • Disease-associated polymorphisms can include deletion or truncation of the gene, mutations that alter expression level, or mutations that affect protein function, etc.
  • a number of methods are available to analyze nucleic acids for the presence of a specific sequence, e.g., a disease associated polymorphism.
  • Genomic DNA can be used when large amounts of DNA are available.
  • the region of interest is cloned into a suitable vector and grown in sufficient quantity for analysis.
  • Cells that express the gene provide a source of mRNA, which can be assayed directly or reverse transcribed into cDNA for analysis.
  • the nucleic acid can be amplified by conventional techniques, i.e., PCR, to provide sufficient amounts for analysis. (Saiki et al., 1988; Sambrook et al., 1989, pp.14.2-14.33). Alternatively, various methods are known in the art that utilize oligonucleotide ligation as a means of detecting polymorphisms (Riley et al., 1990; Delahunty et al., 1996). [0473] The sample nucleic acid, e.g., an amplified or cloned fragment, is analyzed by one of a number of methods known in the art.
  • the nucleic acid can be sequenced by dideoxy nucleotide sequencing, or other methods, and the sequence of bases compared to a wild-type sequence. Hybridization with the variant sequence can also be used to determine its presence, e.g., by Southern blots, dot blots, etc.
  • the hybridization pattern of a control and variant sequence to an array of oligonucleotide probes immobilized on a solid support, as described in US Pat. No. 5,445,934, or WO 95/35505, can also be used as a means of detecting the presence of variant sequences.
  • Single strand conformational polymorphism (SSCP) analysis, denaturing gradient gel electrophoresis (DGGE), and heteroduplex analysis in gel matrices can detect variation as alterations in elecfrophoretic mobility resulting from conformational changes created by DNA sequence alterations.
  • SSCP Single strand conformational polymorphism
  • DGGE denaturing gradient gel electrophoresis
  • heteroduplex analysis in gel matrices can detect variation as alterations in elecfrophoretic mobility resulting from conformational changes created by DNA sequence alterations.
  • the sample can be digested with that endonuclease, and the products fractionated according to their size to determine whether the fragment was digested. Fractionation can be performed by gel or capillary electrophoresis, for example with acrylamide or agarose gels.
  • Screening for mutations in a gene can be based on the functional or antigenic characteristics of the protein. Protein truncation assays are useful in detecting deletions that might affect the biological activity of the protein. Various immunoassays designed to detect polymorphisms in proteins can be used in screening. Where many diverse genetic mutations lead to a particular disease phenotype, functional protein assays have proven to be effective screening tools. The activity of the encoded protein can be determined by comparison with the wild-type protein.
  • the present invention provides methods for detecting the presence and/or biological activity of a subject polypeptide in a biological sample.
  • the assay used will be appropriate to the biological activity of the particular polypeptide.
  • the method will involve contacting the sample with an appropriate subsfrate, and detecting the product of the enzymatic reaction on the subsfrate.
  • the assay detects protein-protein binding, protein-DNA binding, protein-carbohydrate binding, or protein-lipid binding, as appropriate, using well known assays.
  • an appropriate assay is used, such as measurement of intracellular calcium ion concentration, measurement of membrane conductance changes, or measurement of infracellular potassium ion concentration.
  • the present invention also provides methods for detecting the presence or measuring the level of a normal or abnormal polypeptide in a biological sample using a specific antibody.
  • the methods generally comprise contacting the sample with a specific antibody and detecting binding between the antibody and molecules of the sample. Specific antibody binding, when compared to a suitable control, is an indication that a polypeptide of interest is present in the sample.
  • Suitable controls include a sample known not to contain the polypeptide, and a sample contacted with a non-specific antibody, e.g., an anti-idiotype antibody.
  • a variety of methods to detect specific antibody-antigen interactions are known in the art, e.g., standard immunohistological methods, immunoprecipitation, enzyme immunoassay, and radioimmunoassay.
  • the specific antibody can be detectably labeled, either directly or indirectly, as described at length herein, and cells are permeabilized to stain cytoplasmic molecules. Briefly, antibodies are added to a cell sample, and incubated for a period of time sufficient to allow binding to the epitope, usually at least about 10 minutes.
  • the antibody may be labeled with radioisotopes, enzymes, fluorescers, chemiluminescers, or other labels for direct detection..
  • specific-binding pairs may be used, involving, e.g., a second stage antibody or reagent that is detectably-labeled, as described above. Such reagents and their methods of use are well known in the art
  • a biological sample can be brought into contact with an immobilized antibody on a solid support or carrier, such as nitrocellulose, that is capable of immobilizing cells, cell particles, or soluble proteins.
  • the antibody can be attached (coupled) to an insoluble support, such as a polystyrene plate or a bead.
  • an insoluble support such as a polystyrene plate or a bead.
  • the support can then be washed with suitable buffers, followed by contacting with a detectably-labeled specific antibody.
  • Detection methods are known in the art and will be chosen as appropriate to the signal emitted by the detectable label. Detection is generally accomplished in comparison to suitable controls, and to appropriate standards.
  • the present invention further provides methods for detecting the presence and/or levels of enzymatic activity of a subject polypeptide in a biological sample.
  • the methods generally involve contacting the sample with a substrate that yields a detectable product upon being acted upon by a subject polypeptide, and detecting a product of the enzymatic reaction.
  • polypeptides that are subsets of the complete sequences of the subject proteins may be used to identify and investigate parts of the protein important for function.
  • the present invention further includes methods for monitoring activity of a polypeptide through observation of phenotypic changes in a cell containing such polypeptide, such as growth or differentiation, or the ability of such a cell to secrete a molecule that can be detected, such as through chemical methods or through its effect on another cell, such as cell activation.
  • the present invention provides screening methods for identifying agents that modulate the level of a mRNA molecule of the invention, agents that modulate the level of a polypeptide of the invention, and agents that modulate the biological activity of a polypeptide of the invention.
  • the assay is cell-free; in others, it is cell-based.
  • the screening assay is a binding assay, one or more of the molecules can be joined to a label, where the label can directly or indirectly provide a detectable signal.
  • the invention encompasses endogenous polynucleotides of the invention that encode mRNA and/or polypeptides of interest. Again as discussed previously, the invention also encompasses exogenous polynucleotides that encode mRNA or polypeptides of the invention.
  • the polynucleotide can reside within a recombinant vector which is introduced into the cell.
  • a recombinant vector can comprise an isolated transcriptional regulatory sequence which is associated in nature with a nucleic acid, such as a promoter sequence operably linked to sequences coding for a polypeptide of the invention; or the transcriptional control sequences can be operably linked to coding sequences for a polypeptide fusion protein comprising a polypeptide of the invention fused to a polypeptide that facilitates detection.
  • the candidate agent is combined with a cell possessing a polynucleotide transcriptional regulatory element operably linked to a polypeptide-coding sequence of interest, e.g., a subject cDNA or its genomic component; and determining the agent's effect on polynucleotide expression, as measured, for example by the level of mRNA, polypeptide, or fusion polypeptide
  • a recombinant vector can comprise an isolated polynucleotide transcriptional regulatory sequence, such as a promoter sequence, operably linked to a reporter gene (e.g., ⁇ -galactosidase, CAT, luciferase, or other gene that can be easily assayed for expression).
  • a reporter gene e.g., ⁇ -galactosidase, CAT, luciferase, or other gene that can be easily assayed for expression.
  • the method for identifying an agent that modulates a level of expression of a polynucleotide in a cell comprises combining a candidate agent with a cell comprising a transcriptional regulatory element operably linked to a reporter gene; and determining the effect of said agent on reporter gene expression.
  • agents that modulate mRNA levels can be used to identify agents that modulate mRNA levels, including, but not limited to, PCR with detectably-labeled primers.
  • agents that modulate polypeptide levels can be identified using standard methods for determining polypeptide levels, including, but not limited to an immunoassay such as ELISA with detectably-labeled antibodies.
  • a wide variety of cell-based assays can also be used to identify agents that modulate eukaryotic or prokaryotic mRNA and/or polypeptide levels. Examples include transformed cells that over-express a cDNA constract and cells transformed with a polynucleotide of interest associated with an endogenously- associated promoter operably linked to a reporter gene.
  • a control sample would comprise, for example, the same cell lacking the candidate agent. Expression levels are measured and compared in the test and control samples.
  • the cells used in the assay are usually mammalian cells, including, but not limited to, rodent cells and human cells.
  • the cells can be primary cell cultures or can be immortalized cell lines.
  • Cell-based assays generally comprise the steps of contacting the cell with a test agent, forming a test sample, and, after a suitable time, assessing the agent's effect on macromolecule expression. That is, the mammalian cell line is transformed or transfected with a construct that results in expression of the polynucleotide, the cell is contacted with a test agent, and then mRNA or polypeptide levels are detected and measured using conventional assays
  • a suitable period of time for contacting the agent with the cell can be determined empirically, and is generally a time sufficient to allow entry of the agent into the cell and to allow the agent to have a measurable effect on subject mRNA and/or polypeptide levels. Generally, a suitable time is between about 10 minutes and about 24 hours, including about 1 to about 8 hours. Alternatively, incubation periods may be between about 0.1 and about 1 hour, selected for example for optimum activity or to facilitate rapid high-throughput screening. Where the polypeptide is expressed on the cell surface, however, a shorter length of time may be sufficient. Incubations are performed at any suitable temperature, i.e., between about 4°C and about 40°C. The contact and incubation steps can be followed by a washing step to remove unbound components, i.e., a label that would give rise to a background signal during subsequent detection of specifically-bound complexes.
  • one of the components can be bound to a solid support, and the remaining components contacted with the support bound component. Remaining components may be added at different times or at substantially the same time. Further, where the interacting protein is a second subject protein, the effect of the test agent on binding can be determined by determining the effect on multimization of the subject protein.
  • the present invention further provides methods of identifying agents that modulate a biological activity of a polypeptide of the invention.
  • the method generally comprises contacting a test agent with a sample containing a subject polypeptide and assaying a biological activity of the subject polypeptide in the presence of the test agent.
  • An increase or a decrease in the assayed biological activity in comparison to the activity in a suitable confrol e.g., a sample comprising a subject polypeptide in the absence of the test agent
  • the mixture of components is added in any order that provides for the requisite interaction..
  • External and internal processes that can affect modulation of a macromolecule of the invention include, but are not limited to, infection of a cell by a microorganism, including, but not limited to, a bacterium (e.g., Mycobacterium spp., Shigella, or Chlamydia), a protozoan (e.g., Trypanosoma spp., Plasmodium spp., or Toxoplasma spp.), a fungus, a yeast (e.g., Candida spp.), or a virus (including viruses that infect mammalian cells, such as human immunodeficiency virus, foot and mouth disease virus, Epstein-Barr virus, and viruses that infect plant cells); change in pH of the medium in which a cell is maintained or a change in internal pH; excessive heat relative to the normal range for the cell or the multicellular organism; excessive cold relative to the normal range for the cell or the multicellular organism; an effector molecule such as a hormone
  • a variety of other reagents can be included in the screening assay. These include salts, neutral proteins, e.g., albumin, detergents, and other compounds that facilitate optimal binding and/or reduce non-specific or background interactions. Reagents that improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, or anti-microbial agents, etc., can be used.
  • the present invention provides a method for identifying an agent, particularly a biologically active agent that modulates the level of expression of a nucleic acid in a cell, the method comprising: combining a candidate agent to be tested with a cell comprising a nucleic acid that encodes a polypeptide, and determining the agent's effect on polypeptide expression.
  • Some embodiments will detect agents that decrease the biological activity of a molecule of the invention. Maximal inhibition of the activity is not always necessary, or even desired, in every instance to achieve a therapeutic effect. Agents that decrease a biological activity can find use in treating disorders associated with the biological activity of the molecule. Alternatively, some embodiments will detect agents that increase a biological activity. Agents that increase a biological activity of a molecule of the invention can find use in treating disorders associated with a deficiency in the biological activity. Agents that increase or decrease a biological activity of a molecule of the invention can be selected for further study, and assessed for physiological attributes, i.e., cellular availability, cytotoxicity, or biocompatibility, and optimized as required.
  • physiological attributes i.e., cellular availability, cytotoxicity, or biocompatibility
  • a candidate agent is assessed for any cytotoxic activity it may exhibit toward the cell used in the assay using well-known assays, such as trypan blue dye exclusion, an MTT ([3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl-2 H-tetrazolium bromide]) assay, and the like.
  • well-known assays such as trypan blue dye exclusion, an MTT ([3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl-2 H-tetrazolium bromide]) assay, and the like.
  • Candidate agents encompass numerous chemical classes, as described above.
  • Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. Numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides. For example, random peptide libraries obtained by yeast two-hybrid screens (Xu et al., 1997), phage libraries (Hoogenboom et al., 1998), or chemically generated libraries.
  • libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced, including antibodies produced upon immunization of an animal with subject polypeptides, or fragments thereof, or with the encoding polynucleotides.
  • natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and can be used to produce combinatorial libraries.
  • known pharmacological agents can be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, and amidification, etc, to produce structural analogs.
  • the present invention provides methods for diagnosing disease states based on the detected presence and/or level of polynucleotide or polypeptide in a biological sample, and/or the detected presence and/or level of biological activity of the polynucleotide or polypeptide. These detection methods can be provided as part of a kit. Thus, the invention further provides kits for detecting the presence and/or a level of a polynucleotide or polypeptide in a biological sample and/or or the detected presence and/or level of biological activity of the polynucleotide or polypeptide. Procedures using these kits can be performed by clinical laboratories, experimental laboratories, medical practitioners, or private individuals.
  • kits of the invention will comprise a molecule of the invention.
  • the kits for detecting a polynucleotide will also comprise a moiety that specifically hybridizes to a polynucleotide of the invention.
  • the polynucleotide molecule can be of any length. For example, it can comprise a polynucleotide of at least 6, at least 7, at least 8, or at least 9 contiguous nucleotides of a molecule of the invention.
  • Kits of the invention for detecting a subject polypeptide will comprise a moiety that specifically binds to a polypeptide of the invention; the moiety includes, but is not limited to, a polypeptide-specific antibody.
  • the kits are useful in diagnostic applications. For example, the kit is useful to determine whether a given DNA sample isolated from an individual comprises an expressed nucleic acid, a polymorphism, or other variant.
  • Kits for detecting polynucleotides comprise a pair of nucleic acids in a suitable storage medium, e.g., a buffered solution, in a suitable container.
  • the pair of isolated nucleic acid molecules serve as primers in an amplification reaction (e.g., a polymerase chain reaction).
  • the kit can further include additional buffers, reagents for polymerase chain reaction (e.g., deoxynucleotide triphosphates (dNTP), a thermostable DNA polymerase, a solution containing Mg 2+ ions (e.g., MgCl 2 ), and other components well known to those skilled in the art for carrying out a polymerase chain reaction).
  • dNTP deoxynucleotide triphosphates
  • MgCl 2 MgCl 2
  • the kit can further include instructions for use, which may be provided in a variety of forms, e.g., printed information, or compact disc, and the like.
  • the kit may further include reagents necessary to extract DNA from a biological sample and reagents for generating a cDNA copy of an mRNA.
  • the kit may optionally provide additional useful components, including, but not limited to, buffers, developing reagents, labels, reacting surfaces, means for detections, control samples, standards, and interpretive information.
  • kits of the invention for detecting a polynucleotide, such as an mRNA encoding a polypeptide comprises a pair of nucleic acids that function as "forward" and “reverse” primers that specifically amplify a cDNA copy of the mRNA.
  • the "forward" and “reverse” primers are provided as a pair of isolated nucleic acid molecules, each from about 10 to about 200 nucleotides in length, the first nucleic acid molecule of the pair comprising a sequence of at least about 10 contiguous nucleotides having 100% sequence identity to a nucleic acid sequence shown in from SEQ ID NOS.: 1 - 209 and 419 - 627, and the second nucleic acid molecule of the pair comprising a sequence of at least about 10 contiguous nucleotides having 100%> sequence identity to the reverse complement of a nucleic acid sequence shown in SEQ ID NOS.: 1 - 209 and 419 - 627 , wherein the sequence of the second nucleic acid molecule is located 3 'of the nucleic acid sequence of the first nucleic acid molecule.
  • the primer nucleic acids are prepared using any known method, e.g., automated synthesis.
  • one or both members of the pair of nucleic acid molecules comprise a detectable
  • the kit provides for polypeptide detection,. it can include one or more specific antibodies.
  • the antibody specific to the polypeptide is detectably labeled.
  • the antibody specific to the polypeptide is not labeled; instead, a second, detectably-labeled antibody is provided that binds to the specific antibody.
  • the kit may further include blocking reagents, buffers, and reagents for developing and/or detecting the detectable marker.
  • the kit may further include instructions for use, controls, and interpretive information.
  • the kit provides for detecting enzymatic activity, it includes a subsfrate that provides for a detectable product when acted upon by a polypeptide of interest.
  • the kit may further include reagents necessary to detect and develop the detectable marker.
  • kits with unit doses of an active agent These agents are described in more detail below.
  • the agent is provided in oral or injectable doses.
  • kits will comprise containers containing the unit doses and an informational package insert describing the use and attendant benefits of the drugs in treating a condition of interest.
  • the invention further provides agents identified using a screening assay of the invention, and compositions comprising the agents, subject polypeptides, subject polynucleotides, recombinant vectors, and/or host cells, including pharmaceutical compositions for therapeutic administration.
  • the subject compositions can be formulated using well-known reagents and methods. These compositions can include a buffer, which is selected according to the desired use of the agent, polypeptide, polynucleotide, recombinant vector, or host cell, and can also include other substances appropriate to the intended use. Those skilled in the art can readily select an appropriate buffer, a wide variety of which are known in the art, suitable for an intended use.
  • compositions are provided in formulation with pharmaceutically acceptable excipients, a wide variety of which are known in the art (Gennaro, 2000; Ansel et al, 1999; Kibbe et al., 2000).
  • pharmaceutically acceptable excipients such as vehicles, adjuvants, carriers or diluents, are readily available to the public.
  • pharmaceutically acceptable auxiliary substances such as pH adjusting and buffering agents, tonicity adjusting agents, stabilizers, wetting agents and the like, are readily available to the public.
  • compositions of the invention can be administered in the form of their pharmaceutically acceptable salts, or they can also be used alone or in appropriate association, as well as in combination, with other pharmaceutically active compounds.
  • the subject compositions are formulated in accordance to the mode of potential administration. Administration of the agents can be achieved in various ways, including oral, buccal, nasal, rectal, parenteral, intraperitoneal, intradermal, fransdermal, subcutaneous, intravenous, infra-arterial, intracardiac, intraventricular, intracranial, infratracheal, and intrathecal adminisfration, etc., or otherwise by implantation or inhalation.
  • compositions can be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants and aerosols.
  • solid, semi-solid, liquid or gaseous forms such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants and aerosols.
  • the agents, polynucleotides, and polypeptides can be used alone or in combination with appropriate additives to make tablets, powders, granules or capsules, for example, with conventional additives, such as lactose, mannitol, corn starch, or potato starch; with binders, such as crystalline cellulose, cellulose derivatives, acacia, corn starch, or gelatins; with disintegrators, such as corn starch, potato starch, or sodium carboxymethylcellulose; with lubricants, such as talc or magnesium stearate; and if desired, with diluents, buffering agents, moistening agents, preservatives, and flavoring agents.
  • conventional additives such as lactose, mannitol, corn starch, or potato starch
  • binders such as crystalline cellulose, cellulose derivatives, acacia, corn starch, or gelatins
  • disintegrators such as corn starch, potato starch, or sodium carboxymethylcellulose
  • Suitable excipient vehicles are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof.
  • the vehicle can contain minor amounts of auxiliary substances such as wetting or emulsifying agents or pH buffering agents. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in the art (Remington, 1985).
  • the composition or formulation to be administered will, in any event, contain a quantity of the agent adequate to achieve the desired state in the subject being treated.
  • the agents, polynucleotides, and polypeptides can be formulated into preparations for injection by dissolving, suspending or emulsifying them in an aqueous or nonaqueous solvent, such as vegetable or other similar oils, synthetic aliphatic acid glycerides, esters of higher aliphatic acids or propylene glycol; and if desired, with conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives.
  • an aqueous or nonaqueous solvent such as vegetable or other similar oils, synthetic aliphatic acid glycerides, esters of higher aliphatic acids or propylene glycol
  • solubilizers isotonic agents
  • suspending agents emulsifying agents
  • stabilizers and preservatives preservatives.
  • Other formulations for oral or parenteral delivery can also be used, as conventional in the art
  • the agents, polynucleotides, and polypeptides can be utilized in aerosol formulation to be administered via inhalation.
  • the compounds of the present invention can be formulated into pressurized acceptable propellants such as dichlorodifluoromethane, propane, nitrogen, and the like.
  • the agent, polynucleotides, or polypeptide composition may be converted to powder form for administration intranasally or by inhalation, as conventional in the art.
  • the agents can be made into suppositories by mixing with a variety of bases such as emulsifying bases or water-soluble bases.
  • bases such as emulsifying bases or water-soluble bases.
  • the compounds of the present invention can be administered rectally via a suppository.
  • the suppository can include vehicles such as cocoa butter, carbowaxes and polyethylene glycols, which melt at body temperature, yet are solidified at room temperature.
  • a polynucleotide, polypeptide, or other modulator can also be introduced into tissues or host cells by other routes, such as viral infection, microinjection, or vesicle fusion.
  • expression vectors can be used to introduce nucleic acid compositions into a cell as described above.
  • jet injection can be used for intramuscular administration (Furth et al., 1992).
  • the DNA can be coated onto gold microparticles, and delivered intradermally by a particle bombardment device, or "gene gun” as described in the literature (Tang et al., 1992), where gold microprojectiles are coated with the DNA, then bombarded into skin cells.
  • Unit dosage forms for oral or rectal administration such as syrups, elixirs, and suspensions can be provided wherein each dosage unit, for example, teaspoonful, tablespoonful, tablet, or suppository, contains a predetermined amount of the composition containing one or more agents.
  • unit dosage forms for injection or intravenous administration can comprise the agent(s) in a composition as a solution in sterile water, normal saline or another pharmaceutically acceptable carrier.
  • nucleic acid, polypeptide, and modulator compositions of the subject invention find use as therapeutic agents in situations where one wishes to modulate an activity of a subject polypeptide in a host, particularly the activity of the subject polypeptides, or to provide or inhibit the activity at a particular anatomical site.
  • the compositions are useful in treating disorders associated with an activity of a subject polypeptide.
  • active agents of the present invention The following provides further details of active agents of the present invention.
  • the active agent is an agent that modulates, and generally decreases or down regulates, the expression of a gene encoding a target protein in a host, i.e., antisense molecules.
  • Anti-sense reagents include antisense oligonucleotides (ODN), i.e., synthetic ODN having chemical modifications from native nucleic acids, or nucleic acid constructs that express such anti-sense molecules as RNA.
  • ODN antisense oligonucleotides
  • the antisense sequence is complementary to the mRNA of the targeted gene, and inhibits expression of the targeted gene products.
  • Antisense molecules inhibit gene expression through various mechanisms, e.g., by reducing the amount of mRNA available for translation, through activation of RNase H, or steric hindrance.
  • One or a combination of antisense molecules can be administered, where a combination can comprise multiple different sequences.
  • Antisense molecules can be produced by expression of all or a part of the target gene sequence in an appropriate vector, where the transcriptional initiation is oriented such that an antisense strand is produced as an RNA molecule.
  • the antisense molecule is a synthetic oligonucleotide.
  • Antisense oligonucleotides can be chemically synthesized by methods known in the art (Wagner et al., 1993; Milligan et al., 1993) Oligonucleotides can be chemically modified from the native phosphodiester structure to increase their intracellular stability and binding affinity, for example, as described in detail above.
  • Antisense oligonucleotides will generally be at least about 7, at least about 12, or at least about 20 nucleotides in length, and not more than about 500, not more than about 50, or not more than about 35 nucleotides in length, where the length is governed by efficiency of inhibition, and specificity, including absence of cross-reactivity, and the like. Short oligonucleotides, of from about 7 to about 8 bases in length, can be strong and selective inhibitors of gene expression (Wagner et al., 1996).
  • a specific region or regions of the endogenous sense strand mRNA sequence is chosen to be complemented by the antisense sequence. Selection of a specific sequence for the oligonucleotide can use an empirical method, where several candidate sequences are assayed for inhibition of expression of the target gene in an in vitro or animal model. A combination of sequences can also be used, where several regions of the mRNA sequence are selected for antisense complementation.
  • catalytic nucleic acid compounds e.g., ribozymes, or anti-sense conjugates can be used to inhibit gene expression.
  • Ribozymes can be synthesized in vitro and administered to the patient, or can be encoded in an expression vector, from which the ribozyme is synthesized in the targeted cell (WO 9523225; Beigelman et al., 1995). Examples of oligonucleotides with catalytic activity are described in WO 9506764.
  • the active agent is an interfering RNA (RNAi), including dsRNAi.
  • RNA interference provides a method of silencing eukaryotic genes. Double sfranded RNA can induce the homology-dependent degradation of its cognate mRNA in C. elegans, fungi, plants, Drosophila, and mammals (Gaudilliere et al., 2002). Use of RNAi to reduce a level of a particular mRNA andor protein, is based on the interfering properties of double-stranded RNA derived from the coding regions of a gene.
  • RNAi can also help identify the biochemical mode of action of a drug and to identify other genes encoding products that can respond or interact with specific compounds.
  • complementary sense and antisense RNAs derived from a substantial portion of the subject polynucleotide are synthesized in vitro.
  • the resulting sense and antisense RNAs are annealed in an injection buffer, and the double-stranded RNA injected or otherwise introduced into the subject, i.e., in food or by immersion in buffer containing the RNA (Gaudilliere et al., 2002; O'Neil et al., 2001; WO99/32619).
  • dsRNA derived from a gene of the present invention is generated in vivo by simultaneously expressing both sense and antisense RNA from appropriately positioned promoters operably linked to coding sequences in both sense and antisense orientations.
  • the active agent is a peptide.
  • Suitable peptides include peptides of from about 3 amino acids to about 50, from about 5 to about 30, or from about 10 to about 25 amino acids in length.
  • a peptide has a sequence of from about 3 amino acids to about 50, from about 5 to about 30, or from about 10 to about 25 amino acids of corresponding naturally-occurring protein.
  • a peptide exhibits one or more of the following activities: inhibits binding of a subject polypeptide to an interacting protein or other molecule; inhibits subject polypeptide binding to a second polypeptide molecule; inhibits a signal transduction activity of a subject polypeptide; inhibits an enzymatic activity of a subject polypeptide; or inhibits a DNA binding activity of a subject polypeptide.
  • Peptides can include naturally-occurring and non-naturally occurring amino acids.
  • Peptides can comprise D-amino acids, a combination of D- and L-amino acids, and various "designer" amino acids (e.g., ⁇ -methyl amino acids, C ⁇ -methyl amino acids, and N ⁇ -methyl amino acids, etc.) to convey special properties.
  • peptides can be cyclic.
  • Peptides can include non-classical amino acids in order to introduce particular conformational motifs. Any known non-classical amino acid can be used.
  • Non-classical amino acids include, but are not limited to, 1 ,2,3,4-tefrahydroisoquinoline-3-carboxylate; (2S,3S)-methylphenylalanine, (2S,3R)- methyl-phenylalanine, (2R,3S)-methyl-phenylalanine and (2R,3R)-methyl- phenylalanine; 2-aminotetrahydronaphthalene-2-carboxylic acid; hydroxy- 1,2,3, 4- tetrahydroisoquinoline-3-carboxylate; ⁇ -carboline (D and L); HIC (histidine isoquinoline carboxylic acid); and HIC (histidine cyclic urea).
  • Amino acid analogs and peptidomimetics can be incorporated into a peptide to induce or favor specific secondary structures, including, but not limited to, LL-Acp (LL-3-amino-2- propenidone-6-carboxylic acid), a ⁇ -turn inducing dipeptide analog; ⁇ -sheet inducing analogs; ⁇ -turn inducing analogs; ⁇ -helix inducing analogs; ⁇ -turn inducing analogs; Gly- Ala turn analogs; amide bond isostere; or tretrazol, and the like.
  • LL-Acp LL-3-amino-2- propenidone-6-carboxylic acid
  • a ⁇ -turn inducing dipeptide analog ⁇ -sheet inducing analogs
  • ⁇ -turn inducing analogs ⁇ -helix inducing analogs
  • ⁇ -turn inducing analogs Gly- Ala turn analogs
  • amide bond isostere or tretra
  • a peptide can be a depsipeptide, which can be linear or cyclic (Kuisle et al., 1999).
  • Linear depsipeptides can comprise rings formed through S-S bridges, or through an hydroxy or a mercapto group of an hydroxy-, or mercapto-amino acid and the carboxyl group of another amino- or hydroxy-acid but do not comprise rings formed only through peptide or ester links derived from hydroxy carboxylic acids.
  • Cyclic depsipeptides contain at least one ring formed only through peptide or ester links, derived from hydroxy carboxylic acids.
  • Peptides can be cyclic or bicyclic.
  • the C-terminal carboxyl group or a C-terminal ester can be induced to cyclize by internal displacement of the -OH or the ester (-OR) of the carboxyl group or ester respectively with the N-terminal amino group to form a cyclic peptide.
  • the free acid is converted to an activated ester by an appropriate carboxyl group activator such as dicyclohexylcarbodiimide (DCC) in solution, for example, in methylene chloride (CH 2 C1 2 ), dimethyl formamide (DMF) mixtures.
  • DCC dicyclohexylcarbodiimide
  • the cyclic peptide is then formed by internal displacement of the activated ester with the N-terminal amine. Internal cyclization as opposed to polymerization can be enhanced by use of very dilute solutions. Methods for making cyclic peptides are well known in the art.
  • a desamino or descarboxy residue can be incorporated at the terminal ends of the peptide, so that there is no terminal amino or carboxyl group, to decrease susceptibility to proteases or to restrict conformation.
  • C-terminal functional groups include amide, amide lower alkyl, amide di (lower alkyl), lower alkoxy, hydroxy, and carboxy, and the lower ester derivatives thereof, and the pharmaceutically acceptable salts thereof.
  • a peptide or peptidomimetic can be modified with or covalently coupled to one or more of a variety of hydrophilic polymers to increase solubility and circulation half- life of the peptide.
  • Suitable nonproteinaceous hydrophilic polymers for coupling to a peptide include, but are not limited to, polyalkylethers as exemplified by polyethylene glycol and polypropylene glycol, polylactic acid, polyglycolic acid, polyoxyalkenes, polyvinylalcohol, polyvinylpyrrolidone, cellulose and cellulose derivatives, dextran, and dextran derivatives.
  • hydrophilic polymers have an average molecular weight ranging from about 500 to about 100,000 daltons, from about 2,000 to about 40,000 daltons, or from about 5,000 to about 20,000 daltons.
  • the peptide can be derivatized with or coupled to such polymers using any of the methods set forth in Zallipsky, 1995; Monfardini et al, 1995; U.S. Pat. Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192; 4,179,337, or WO 95/34326. d) Antibodies
  • the invention provides antibodies that specifically recognize a particular polypeptide.
  • Antibodies are obtained by immunizing a host animal with peptides, polynucleotides encoding polypeptides, or cells, each comprising all or a portion of the target protein ("immunogen").
  • Suitable host animals include rodents (e.g., mouse, rat, guinea pig, hamster), cattle (e.g., sheep, pig, cow, horse, goat), cat, dog, chicken, primate, monkey, and rabbit.
  • the origin of the protein immunogen can be any species, including mouse, human, rat, monkey, avian, insect, reptile, or crustacean.
  • the host animal will generally be a different species than the immunogen, e.g., a human protein used to immunize mice. Methods of antibody production are well known in the art (Howard and Bethell, 2000; Harlow et al., 1998; Harlow and Lane, 1988).
  • the immunogen can comprise the complete protein, or fragments and derivatives thereof, or proteins expressed on cell surfaces. Immunogens comprise all or a part of one of the subject proteins, where these amino acids contain post- translational modifications, such as glycosylation, found on the native target protein. Immunogens comprising protein extracellular domains are produced in a variety of ways known in the art, e.g., expression of cloned genes using conventional recombinant methods, or isolation from tumor cell culture supernatants, etc. The immunogen can also be expressed in vivo from a polynucleotide encoding the immunogenic peptide introduced into the host animal.
  • Polyclonal antibodies are prepared by conventional techniques. These include immunizing the host animal in vivo with the target protein (or immunogen) in substantially pure form, for example, comprising less than about 1% contaminant.
  • the immunogen can comprise the complete target protein, fragments, or derivatives thereof.
  • the target protein can be combined with an adjuvant; suitable adjuvants include alum, dextran, sulfate, large polymeric anions, and oil & water emulsions, e.g., Freund's adjuvant (complete or incomplete).
  • the target protein can also be conjugated to synthetic carrier proteins or synthetic antigens.
  • the target protein is administered to the host, usually infradermally, with an initial dosage followed by one or more, usually at least two, additional booster dosages.
  • blood from the host will be collected, followed by separation of the serum from blood cells.
  • the immunoglobulin present in the resultant antiserum can be further fractionated using known methods, such as ammonium salt fractionation, or DEAE chromatography and the like.
  • the method of producing polyclonal antibodies can be varied in some embodiments of the present invention. For example, instead of using a single substantially isolated polypeptide as an immunogen, one may inject a number of different immunogens into one animal for simultaneous production of a variety of antibodies.
  • the immunogens can be nucleic acids (e.g., in the form of plasmids or vectors) that encode the proteins, with facilitating agents, such as liposomes, microspheres, etc, or without such agents, such as "naked" DNA.
  • Antibodies can also be prepared using a library approach. Briefly, mRNA is extracted from the spleens of immunized animals to isolate antibody- encoding sequences. The extracted mRNA may be used to make cDNA libraries. Such a cDNA library may be normalized and subtracted in a manner conventional in the art, for example, to subtract out cDNA hybridizing to mRNA of non-immunized animals. The remaining cDNA may be used to create proteins and for selection of antibody molecules or fragments that specifically bind to the immunogen. The cDNA clones of interest, or fragments thereof, can be introduced into an in vitro expression system to produce the desired antibodies, as described herein.
  • polyclonal antibodies can be prepared using phage display libraries, conventional in the art.
  • phage display libraries a collection of bacteriophages displaying antibody properties on their surfaces are made to contact subject polypeptides, or fragments thereof.
  • Bacteriophages displaying antibody properties that specifically recognize the subject polypeptides are selected, amplified, for example, in E. coli, and harvested. Such a method typically produces single chain antibodies
  • Monoclonal antibodies are also produced by conventional techniques, such as fusing an antibody-producing plasma cell with an immortal cell to produce hybridomas.
  • Suitable animals will be used, e.g., to raise antibodies against a mouse polypeptide of the invention, the host animal will generally be a hamster, guinea pig, goat, chicken, or rabbit, and the like.
  • the spleen and/or lymph nodes of an immunized host animal provide the source of plasma cells, which are immortalized by fusion with myeloma cells to produce hybridoma cells.
  • Culture supernatants from individual hybridomas are screened using standard techniques to identify clones producing antibodies with the desired specificity.
  • the antibody can be purified from the hybridoma cell supernatants or from ascites fluid present in the host by conventional techniques, e.g., affinity chromatography using antigen, e.g., the subject protein, bound to an insoluble support, i.e., protein A sepharose, etc.
  • the antibody can be produced as a single chain, instead of the normal multimeric structure of the immunoglobulin molecule. Single chain antibodies have been previously described (i.e., Jost et al., 1994).
  • DNA sequences encoding parts of the immunoglobulin, for example, the variable region of the heavy chain and the variable region of the light chain are ligated to a spacer, such as one encoding at least about four small neutral amino acids, i.e., glycine or serine.
  • the protein encoded by this fusion allows the assembly of a functional variable region that retains the specificity and affinity of the original antibody.
  • the invention also provides intrabodies that are intracellularly expressed single-chain antibody molecules designed to specifically bind and inactivate target molecules inside cells. Intrabodies have been used in cell assays and in whole organisms (Chen et al., 1994; Hassanzadeh et al., 1998). Inducible expression vectors can be constructed with intrabodies that react specifically with a protein of the invention. These vectors can be introduced into host cells and model organisms.
  • the invention also provides "artificial" antibodies, e.g., antibodies and antibody fragments produced and selected in vitro.
  • these antibodies are displayed on the surface of a bacteriophage or other viral particle, as described above.
  • artificial antibodies are present as fusion proteins with a viral or bacteriophage stractural protein, including, but not limited to, Ml 3 gene III protein. Methods of producing such artificial antibodies are well known in the art (U.S. Patent Nos. 5,516,637; 5,223,409; 5,658,727; 5,667,988; 5,498,538; 5,403,484; 5,571,698; and 5,625,033).
  • the artificial antibodies selected for example, on the basis of phage binding to selected antigens, can be fused to a Fc fragment of an immunoglobulin for use as a therapeutic, as described, for example, in US 5,116,964 or WO 99/61630.
  • Antibodies of the invention can be used to modulate biological activity of cells, either directly or indirectly.
  • a subject antibody can modulate the activity of a target cell, with which it has primary interaction, or it can modulate the activity of other cells by exerting secondary effects, i.e., when the primary targets interact or communicate with other cells.
  • the antibodies of the invention can be administered to mammals, and the present invention includes such adminisfration, particularly for therapeutic and/or diagnostic purposes in humans.
  • Antibodies may be administered by injection systemically, such as by intravenous injection; or by injection or application to the relevant site, such as by direct injection into a tumor, or direct application to the site when the site is exposed in surgery; or by topical application, such as if the disorder is on the skin, for example.
  • the antigenicity of the antibody For in vivo use, particularly for injection into humans, in some embodiments it is desirable to decrease the antigenicity of the antibody.
  • An immune response of a recipient against the antibody may potentially decrease the period of time that the therapy is effective.
  • Methods of humanizing antibodies are known in the art.
  • the humanized antibody can be the product of an animal having transgenic human immunoglobulin genes, e.g., constant region genes (e.g., Grosveld and Kolias, 1992; Murphy and Carter, 1993; Pinkert, 1994; and International Patent Applications WO 90/10077 and WO 90/04036).
  • the antibody of interest can be engineered by recombinant DNA techniques to substitute the CHI, CH2, CH3, hinge domains, and/or the framework domain with the corresponding human sequence (see, e.g., WO 92/02190).
  • Both polyclonal and monoclonal antibodies made in non-human animals may be "humanized" before administration to human subjects.
  • Chimeric immunoglobulin genes constructed with immunoglobulin cDNA are known in the art (Liu et al. 1987a; Liu et al. 1987b).
  • Messenger RNA is isolated from a hybridoma or other cell producing the antibody and used to produce cDNA.
  • the cDNA of interest can be amplified by the polymerase chain reaction using specific primers (U.S. Patent nos. 4,683,195 and 4,683,202).
  • a library is made and screened to isolate the sequence of interest.
  • the DNA sequence encoding the variable region of the antibody is then fused to human constant region sequences.
  • the sequences of human constant regions genes are known in the art (Kabat et al., 1991). Human C region genes are readily available from known clones.
  • IgGl, IgG3 and IgG4 isotypes and either of the kappa or lambda human light chain constant regions can be used.
  • the chimeric, humanized antibody is then expressed by conventional methods.
  • Consensus sequences of heavy (“H”) and light (“L”) J regions can be used to design oligonucleotides for use as primers to introduce useful restriction sites into the J region for subsequent linkage of V region segments to human C region segments.
  • C region cDNA can be modified by site directed mutagenesis to place a restriction site at the analogous position in the human sequence.
  • a convenient expression vector for producing antibodies is one that encodes a functionally complete human CH or CL immunoglobulin sequence, with appropriate restriction sites engineered so that any VH or VL sequence can be easily inserted and expressed, such as plasmids, refroviruses, YACs, or EBV derived episomes, and the like.
  • splicing usually occurs between the splice donor site in the inserted J region and the splice acceptor site preceding the human C region, and also at the splice regions that occur within the human CH exons. Polyadenylation and transcription termination occur at native chromosomal sites downstream of the coding regions.
  • the resulting chimeric antibody can be joined to any strong promoter, including retroviral LTRs, e.g., SV-40 early promoter, (Okayama, et al. 1983), Rous sarcoma virus LTR (Gorman et al. 1982), and Moloney murine leukemia virus LTR (Grosschedl et al. 1985), or native immunoglobulin promoters.
  • the antibodies can be fully human antibodies.
  • xenogenic antibodies which are produced in animals that are transgenic for human antibody genes, can be employed.
  • xenogenic human antibodies is meant antibodies that are fully human antibodies, with the exception that they are produced in a non-human host that has been genetically engineered to express human antibodies, (e.g., WO 98/50433; WO 98,24893 and WO 99/53049).
  • Antibody fragments such as Fv, F(ab')2 and Fab can be prepared by cleavage of the intact protein, e.g., by protease or chemical cleavage. These fragments can include heavy and light chain variable regions.
  • a trancated gene can be designed, e.g., a chimeric gene encoding a portion of the F(ab') 2 fragment that includes DNA sequences encoding the CHI domain and hinge region of the H chain, followed by a translational stop codon.
  • the antibodies of the present invention may be administered alone or in combination with other molecules for use as a therapeutic, for example, by linking the antibody to cytotoxic agent, as discussed above, or to a radioactive molecule.
  • Radioactive antibodies that are specific to a cancer cell, disease cell, or virus-infected cell may be able to deliver a sufficient dose of radioactivity to kill such cancer cell, disease cell, or virus-infected cell.
  • the antibodies of the present invention can also be used in assays for detection of the subject polypeptides.
  • the assay is a binding assay that detects binding of a polypeptide with an antibody specific for the polypeptide; the subject polypeptide or antibody can be immobilized, while the subject polypeptide and/or antibody can be detectably-labeled.
  • the antibody can be directly labeled or detected with a labeled secondary antibody. That is, suitable, detectable labels for antibodies include direct labels, which label the antibody to the protein of interest, and indirect labels, which label an antibody that recognizes the antibody to the protein of interest.
  • radioisotopes including, but not limited to 64 Cu, 67 Cu, 90 Y, 124 1, 125 1, 131 1, 137 Cs, 186 Re, 211 At, 212 Bi, 213 Bi, 223 Ra, 241 Am, and 244 Cm; enzymes having detectable products (e.g., luciferase, ⁇ -galactosidase, and the like); fluorescers and fluorescent labels, e.g., as provided herein; fluorescence emitting metals, e.g., 152 Eu, or others of the lanthanide series, attached to the antibody through metal chelating groups such as EDTA; chemiluminescent compounds, e.g., luminol, isoluminol, or acridinium salts; and bioluminescent compounds, e.g., luciferin, or aequorin (green fluorescent protein), specific binding molecules, e.g., magnetic particles, microspheres, nano
  • specific-binding pairs may be used, involving, e.g., a second stage antibody or reagent that is detectably-labeled and that can amplify the signal.
  • a primary antibody can be conjugated to biotin, and horseradish peroxidase-conjugated strepavidin added as a second stage reagent.
  • Digoxin and antidigoxin provide another such pair.
  • the secondary antibody can be conjugated to an enzyme such as peroxidase in combination with a substrate that undergoes a color change in the presence of the peroxidase.
  • Peptide aptamers are peptides or small polypeptides that act as dominant inhibitors of protein function. Peptide aptamers specifically bind to target proteins, blocking their functional ability (Kolonin and Finley, 1998). Due to the highly selective nature of peptide aptamers, they can be used not only to target a specific protein, but also to target specific functions of a given protein (e.g., a signaling function). Further, peptide aptamers can be expressed in a controlled fashion by use of promoters which regulate expression in a temporal, spatial or inducible manner. Peptide aptamers act dominantly, therefore, they can be used to analyze proteins for which loss-of-function mutants are not available.
  • Peptide aptamers that bind with high affinity and specificity to a target protein can be isolated by a variety of techniques known in the art. Peptide aptamers can be isolated from random peptide libraries by yeast two-hybrid screens (Xu et al., 1997). They can also be isolated from phage libraries (Hoogenboom et al., 1998) or chemically generated peptides/libraries.
  • the instant invention provides various therapeutic methods.
  • methods of modulating, including increasing and inhibiting, a biological activity of a subject protein are provided.
  • methods of modulating an enzymatic activity of a subject protein are provided.
  • methods of increasing the level of enzymatically active subject protein are provided, while in some embodiments, methods of decreasing a level of enzymatically active subject protein are provided.
  • methods of modulating enzymatic activity of a subject protein are provided.
  • methods of modulating a signal transduction activity of a subject protein are provided.
  • methods of modulating interaction of a subject protein with another, interacting protein or other macromolecule e.g., DNA, carbohydrate, lipid
  • methods of modulating transport activity of a subject protein are provided.
  • methods of modulating phopholipase activity of a subject protein are provided.
  • methods of modulating polymerase activity of a subject protein are provided.
  • methods of modulating nuclease activity of a subj ect protein are provided.
  • an effective amount of the active agent e.g., small molecule, antibody specific for a subject polypeptide, a subject polypeptide, or a subject polynucleotide
  • effective amount means a dosage sufficient to produce a desired effect or result.
  • the desired result is at least a reduction in a given biological activity of a subject polypeptide as compared to a confrol, for example, a decreased level of enzymatically active subject protein in the individual, or in a localized anatomical site in the individual.
  • the desired result is at least an increase in a biological activity of a subject polypeptide as compared to a confrol, for example an increased level of enzymatically active subject protein in the individual, or in a localized anatomical site in the individual.
  • compositions of the instant invention will contain from less than about 1%> to about 95% of the active ingredient, about 10%) to about 50%. Generally, between about 100 mg and about 500 mg will be administered to a child and between about 500 mg and about 5 grams will be administered to an adult.
  • the active agent(s) can be administered to the host via any convenient means capable of resulting in the desired result. Administration is generally by injection and often by injection to a localized area. The frequency of administration will be determined by the care given based on patient responsiveness. For example, the agents may be administered daily, weekly, or as conventionally determined appropriate.
  • the host, or patient may be from any animal species, and will generally be mammalian, e.g., primate sp., e.g., monkeys, chimpanzees, and particularly humans; rodents, including mice, rats and hamsters, guinea pig; rabbits; cattle, including equines, bovines, pig, sheep, goat, canines; felines; etc. Animal models are of interest for experimental investigations, providing a model for treatment of human disease.
  • primate sp. e.g., monkeys, chimpanzees, and particularly humans
  • rodents including mice, rats and hamsters, guinea pig
  • rabbits including cattle, including equines, bovines, pig, sheep, goat, canines; felines; etc.
  • Animal models are of interest for experimental investigations, providing a model for treatment of human disease.
  • a protein of the present invention is involved in the control of cell proliferation, and an agent of the invention inhibits undesirable cell proliferation.
  • agents are useful for treating disorders that involve abnormal cell proliferation, including, but not limited to, cancer, psoriasis, and scleroderma.
  • Whether a particular agent and/or therapeutic regimen of the invention is effective in reducing unwanted cellular proliferation, e.g., in the context of treating cancer can be determined using standard methods. For example, the number of cancer cells in a biological sample (e.g., blood, a biopsy sample, and the like), can be determined. The tumor mass can be determined using standard radiological or biochemical methods.
  • Tumors that can be treated using the methods of the instant invention include carcinomas, e.g., colorectal, prostate, breast, bone, kidney, skin, melanoma, ductal, endometrial, stomach or other organ of the gastrointestinal tract, pancreatic, mesothelioma, dysplastic oral mucosa, invasive oral cancer, non-small cell lung carcinoma ("NSCL"), transitional and squamous cell urinary carcinoma; brain cancer and neurological malignancies, e.g., neuroblastoma, glioblastoma, astrocytoma, and gliomas; lymphomas and leukemias such as myeloid leukemia, myelogenous leukemia, hematological malignancies, such as childhood acute leukemia, non- Hodgkin's lymphomas, chronic lymphocytic leukemia, malignant cutaneous T-cell lymphoma, mycosis fungoides, non-MF cutaneous T-cell lymphoma
  • the polynucleotides, polypeptides, and modulators of the present invention find use in immunotherapy of hyperproliferative disorders, including cancer, neoplastic, and paraneoplastic disorders. That is, the subject molecules can correspond to tumor antigens, of which 1770 have been identified to date (Yu and Restifo, 2002). Immunotherapeutic approaches include passive immunotherapy and vaccine therapy and can accomplish both generic and antigen-specific cancer immunotherapy.
  • Passive immunity approaches involve antibodies of the invention that are directed toward specific tumor-associated antigens. Such antibodies can eradicate systemic tumors at multiple sites, without eradicating normal cells.
  • the antibodies are combined with radioactive components, as provided above, for example, combining the antibody's ability to sjpecifically target tumors with the added lethality of the radioisotope to the tumor DNA.
  • Useful antibodies comprise a discrete epitope or a combination of nested epitopes, i.e., a 10-mer epitope and associated peptide multimers incorporating all potential 8-mers and 9-mers, or overlapping epitopes (Dutoit et al., 2002).
  • a single antibody can interact with one or more epitopes.
  • the antibody can be used alone or in combination with different antibodies, that all recognize either a single or multiple epitopes.
  • Neutralizing antibodies can provide therapy for cancer and proliferative disorders.
  • Neutralizing antibodies that specifically recognize a secreted protein or peptide of the invention can bind to the secreted protein or peptide, e.g., in a bodily fluid or the extracellular space, thereby modulating the biological activity of the secreted protein or peptide.
  • neutralizing antibodies specific for secreted proteins or peptides that play a role in stimulating the growth of cancer cells can be useful in modulating the growth of cancer cells.
  • neutralizing antibodies specific for secreted proteins or peptides that play a role in the differentiation of cancer cells can be useful in modulating the differentiation of cancer cells.
  • Vaccine therapy involves the use of polynucleotides, polypeptides, or agents of the invention as immunogens for tumor antigens (Machiels et al., 2002).
  • peptide-based vaccines of the invention include unmodified subject polypeptides, fragments thereof, and MHC class I and class Il-restricted peptide (Knutson et al., 2001), comprising, for example, the disclosed sequences with universal, nonspecific MHC class Il-restricted epitopes.
  • Peptide-based vaccines comprising a tumor antigen can be given directly, either alone or in conjunction with other molecules.
  • the vaccines can also be delivered orally by producing the antigens in transgenic plants that can be subsequently ingested (U.S. Patent No. 6,395,964).
  • antibodies themselves can be used as antigens in anti-idiotype vaccines. That is, administering an antibody to a tumor antigen stimulates B cells to make antibodies to that antibody, which in turn recognize the tumor cells
  • Nucleic acid-based vaccines can deliver tumor antigens as polynucleotide constructs encoding the antigen.
  • Vaccines comprising genetic material, such as DNA or RNA, can be given directly, either alone or in conjunction with other molecules.
  • nucleic acid-based vaccines encode subject antibodies.
  • the vaccines e.g., DNA vaccines
  • the vaccines can include post-transcriptional regulatory elements, such as the post-transcriptional regulatory acting RNA element (WPRE) derived from Woodchuck Hepatitis Virus. These post- transcriptional regulatory elements can be used to target the antibody, or a fusion protein comprising the antibody and a co-stimulatory molecule, to the tumor microenvironment (Pertl et al., 2003).
  • WPRE post-transcriptional regulatory acting RNA element
  • vaccines of the invention can also induce cellular responses, including stimulating T-cells that recognize and kill tumor cells directly.
  • nucleotide-based vaccines of the invention encoding tumor antigens can be used to activate the CD8 + cytotoxic T lymphocyte arm of the immune system.
  • the vaccines activate T-cells directly, and in others they enlist antigen-presenting cells to activate T-cells.
  • Killer T-cells are primed, in part, by interacting with antigen-presenting cells, i.e., dendritic cells.
  • plasmids comprising the nucleic acid molecules of the invention enter antigen-presenting cells, which in turn display the encoded tumor-antigens that contribute to killer T-cell activation.
  • the tumor antigens can be delivered as plasmid DNA constructs, either alone or with other molecules.
  • RNA can be used.
  • dendritic cells can be transfected with RNA encoding tumor antigens (Heiser et al., 2002; Mitchell and Nair, 2000). This approach overcomes the limitations of obtaining sufficient quantities of tumor material, extending therapy to patients otherwise excluded from clinical trials.
  • a subject RNA molecule isolated from tumors can be amplified using RT-PCR.
  • the RNA molecule of the invention is directly isolated from tumors and transfected into dendritic cells with no intervening cloning steps.
  • the molecules of the invention are altered such that the peptide antigens are more highly antigenic than in their native state. These embodiments address the need in the art to overcome the poor in vivo immunogenicity of most tumor antigens by enhancing tumor antigen immunogenicity via modification of epitope sequences (Yu and Restifo, 2002).
  • Another recognized problem of cancer vaccines is the presence of preexisting neutralizing antibodies.
  • Some embodiments of the present invention overcome this problem by using viral vectors from non-mammalian natural hosts, i.e., avian pox viruses.
  • Alternative embodiments that also circumvent preexisting neutralizing antibodies include genetically engineered influenza viruses, and the use of "naked" plasmid DNA vaccines that contain DNA with no associated protein. (Yu and Restifo, 2002).
  • immunogenic molecules can be combined with other molecules that have a variety of antiproliferative effects, or with additional substances that help stimulate the immune response, i.e., adjuvants or cytokines.
  • nucleic acid vaccines encode an alphaviral replicase enzyme, in addition to tumor antigens. This recently discovered approach to vaccine therapy successfully combines therapeutic antigen production with the induction of the apoptotic death of the tumor cell (Yu and Restifo, 2002).
  • a DNA or RNA vaccine of the present invention can also be directed against the production of blood vessels in the vicinity of the tumor, a process called antiangiogenesis, thereby depriving the cancer cells of nutrients.
  • antiangiogenic molecules angiostatin (a fragment of plasminogen), endostatin (a fragment of collagen XVIII), interferon- ⁇ , interferon- ⁇ inducible protein 10, interleukin 12, thrombospondin, platelet factor-4, calreticulin, or its protein fragment vasostatin can be used to treat tumors by suppressing neovascularization and thereby inhibiting growth (Cheng et al., 2001).
  • the antiangiogenesis approach can be used alone, or in conjunction with molecules directed to tumor antigens.
  • adjuvants can be used in conjunction with the antibodies and vaccines disclosed herein.
  • Adjuvants help boost the general immune response, for example, concentrating immune cells to the specific area where they are needed. They can be added to a cancer vaccine itself or administered separately, and in some embodiments, a viral vector can be engineered to display adjuvant proteins on its surface.
  • Cytokines can also be used to help stimulate immune response. Cytokines act as chemical messengers, recruiting immune cells that help the killer T- cells to the site of attack. An example of a cytokine is granulocyte-macrophage colony-stimulating factor (GM-CSF), which stimulates the proliferation of antigen- presenting cells, thus boosting an organism's response to a cancer vaccine. As with adjuvants, cytokines can be used in conjunction with the antibodies and vaccines disclosed herein. For example, they can be incorporated into the antigen-encoding plasmid or introduced via a separate plasmid, and in some embodiments, a viral vector can be engineered to display cytokines on its surface.
  • GM-CSF granulocyte-macrophage colony-stimulating factor
  • the invention provides agents for treating such inflammation or immune disorders.
  • Disease states that are treatable using formulations of the invention include various types of arthritis such as rheumatoid arthritis and osteoarthritis, autoimmune thyroiditis, various chronic inflammatory conditions of the skin, such as psoriasis, the intestine, such as inflammatory bowel disease (IBD), insulin-dependent diabetes, autoimmune diseases such as multiple sclerosis (MS), intestinal immune disorders and systemic lupus erythematosis (SLE), allergic diseases, transplant rejections, adult respiratory distress syndrome, atherosclerosis, ischemic diseases due to closure of the peripheral vasculature, cardiac vasculature, and vasculature in the central nervous system (CNS).
  • arthritis such as rheumatoid arthritis and osteoarthritis
  • autoimmune thyroiditis various chronic inflammatory conditions of the skin, such as psoriasis, the intestine, such as inflammatory bowel disease (IBD), insulin-dependent diabetes, autoimmune diseases such as multiple
  • Neutralizing antibodies can provide immunosuppressive therapy for inflammatory and autoimmune disorders.
  • Neutralizing antibodies can be used to treat disorders such as, for example, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, transplant rejection, and psoriasis.
  • Neutralizing antibodies that specifically recognize a secreted protein or peptide of the invention can bind to the secreted protein or peptide, e.g., in a bodily fluid or the extracellular space, thereby modulating the biological activity of the secreted protein or peptide.
  • neutralizing antibodies specific for secreted proteins or peptides that play a role in activating immune cells are useful as immunosuppressants.
  • an agent of the invention is useful for treating disorders relating to cell death (e.g., DNA damage, cell death, apoptosis).
  • Cell death-related indications that can be treated using the methods of the invention to reduce cell death in a eukaryotic cell, include, but are not limited to, cell death associated with Alzheimer's disease, Parkinson's disease, rheumatoid arthritis, autoimmune thyroiditis, septic shock, sepsis, stroke, central nervous system inflammation, intestinal inflammation, osteoporosis, ischemia, reperfusion injury, cardiac muscle cell death associated with cardiovascular disease, polycystic kidney disease, cell death of endothelial cells in cardiovascular disease, degenerative liver disease, multiple sclerosis, amyotropic lateral sclerosis, cerebellar degeneration, ischemic injury, cerebral infarction, myocardial infarction, acquired immunodeficiency syndrome (AIDS), myelodysplastic syndromes, aplastic an
  • hypoxic or anoxic conditions e.g., conditions relating to or resulting from ischemia, myocardial infarction, cerebral infarction, stroke, bypass heart surgery, organ transplantation, and neuronal damage, etc.
  • DNA damage can be detected using any known method, including, but not limited to, a Comet assay (commercially available from Trevigen, Inc.), which is based on alkaline lysis of labile DNA at sites of damage; and immunological assays using antibodies specific for aberrant DNA structures, e.g., 8-OHdG.
  • a Comet assay commercially available from Trevigen, Inc.
  • immunological assays using antibodies specific for aberrant DNA structures, e.g., 8-OHdG.
  • Cell death can be measured using any known method, and is generally measured using any of a variety of known methods for measuring cell viability. Such assays are generally based on entry into the cell of a detectable compound (or a compound that becomes detectable upon interacting with, or being acted on by, an intracellular component) that would normally be excluded from a normal, living cell by its structurally and functionally intact cell membrane.
  • Such compounds include substrates for intracellular enzymes, including, but not limited to, a fluorescent substrate for esterase; dyes that are excluded from living cells, including, but not limited to, trypan blue; and DNA-binding compounds, including, but not limited to, an ethidium compound such as ethidium bromide and ethidium homodimer, and propidium iodide.
  • substrates for intracellular enzymes including, but not limited to, a fluorescent substrate for esterase
  • dyes that are excluded from living cells including, but not limited to, trypan blue
  • DNA-binding compounds including, but not limited to, an ethidium compound such as ethidium bromide and ethidium homodimer, and propidium iodide.
  • Apoptosis or programmed cell death, is a regulated process leading to cell death via a series of well-defined morphological changes.
  • Programmed cell death provides a balance for cell growth and multiplication, eliminating unnecessary cells. The default state of the cell is to remain alive.
  • a cell enters the apoptotic pathway when an essential factor is removed from the exfracellular environment or when an internal signal is activated.
  • Genes and proteins of the invention that suppress the growth of tumors by activating cell death provide the basis for treatment strategies for hyperproliferative disorders and conditions.
  • Apoptosis can be assayed using any known method. Assays can be conducted on cell populations or an individual cell, and include morphological assays and biochemical assays. A non-limiting example of a method of determining the level of apoptosis in a cell population is TUNEL (TdT-mediated dUTP nick-end labeling) labeling of the 3 -OH free end of DNA fragments produced during apoptosis (Gavrieli et al., 1992).
  • TUNEL TdT-mediated dUTP nick-end labeling
  • the TUNEL method consists of catalytically adding a nucleotide, which has been conjugated to a chromogen system, a fluorescent tag, or the 3 -OH end of the 180-bp (base pair) oligomer DNA fragments, in order to detect the fragments.
  • the presence of a DNA ladder of 180-bp oligomers is indicative of apoptosis.
  • Procedures to detect cell death based on the TUNEL method are available commercially, e.g., from Boehringer Mannheim (Cell Death Kit) and Oncor (Apoptag Plus).
  • annexin Another marker that is currently available is annexin, sold under the trademark APOPTESTTM. This marker is used in the "Apoptosis Detection Kit,” which is also commercially available, e.g., from R&D Systems. During apoptosis, a cell membrane's phospholipid asymmetry changes such that the phospholipids are exposed on the outer membrane. Annexins are a homologous group of proteins that bind phospholipids in the presence of calcium. A second reagent, propidium iodide (PI), is a DNA binding fluorochrome.
  • PI propidium iodide
  • AIDS acquired immunodeficiency syndrome
  • angiogenesis angiogenesis
  • metastasis metabolic disorders
  • metabolic disorders such as diabetes and obesity
  • cardiovascular disorders such as congestive heart failure and stroke
  • male erectile dysfunction and the disorders described throughout the specification.
  • HG1001229N0_160000_gene_predictionl and HG1001264N0 _160000_gene_ predictionl are expressed in brain.
  • HG1000591N0 _160000_genejpredictionl is expressed in several tissues and highly expressed in the spleen and lymph nodes.
  • HG1001192N0_160000_genejpredictionl is expressed in the brain, heart, prostate, and lung.
  • HG1001417N0_1000_gene_predictionl is expressed in fetal liver, brain, muscle and pancreas.
  • HG1001052N0_0_gene_predictionl may be secreted and/or be a STM protein.
  • HG1000365N0_20000_gene_predictionl is present in the nucleus.
  • HG1000382N0_160000_gene_predictionl is a TM protein.
  • HG1000591N0_ 160000_gene_predictionl is found in and/or on the plasma membrane.
  • HG1000365N0_20000_gene_predictionl is useful for treating cancer.
  • HG1000904N0_160000_gene_predictionl, HG1000904N0_40000 _gene_predictionl, HG1000904N0_160000_gene_prediction2, HG1000904N0 _40000_gene_predictionl, and HG1000904N0_160000 _gene_prediction2 are useful in biotechnology. They can be used in gene cloning, directed evolution, genetic engineering, generation of recombinant DNA, and the generation of transgenic, knock-out and/or chimeric organisms.
  • HG1000382N0 _160000_gene_predictionl is useful in the treatment of disorders of hematopoeisis, development, and neuronal disorders.
  • HG1000591N0_ 160000_gene_predictionl is useful in the understanding of the pathogenesis of atherosclerosis, and its diagnosis and treatment.
  • HG1000379N0 _160000_gene_predictionl is useful in the diagnosis and freatment of hemophilia.
  • the subject nucleic acid compositions find use in a variety of different investigative applications.
  • Applications of interest include identifying genomic DNA sequence using molecules of the invention, identifying homologs of molecules of the invention, creating a source of novel promoter elements, identifying expression regulatory factors, creating a source of probes and primers for hybridization applications, identifying expression patterns in biological specimens; preparing cell or animal models to investigate the function of the molecules of the invention, and preparing in vitro models to investigate the function of the molecules of the invention.
  • Human genomic polynucleotide sequences corresponding to molecules of the present invention are identified by conventional means, such as, for example, by probing a genomic DNA library with all or a portion of the polynucleotide sequences.
  • Homologs are identified by any of a number of methods.
  • probes particularly labeled probes of DNA sequences
  • a fragment of the provided cDNA can be used as a hybridization probe against a cDNA library from the target organism of interest, under various stringency conditions, e.g., low stringency conditions.
  • the probe can be a large fragment, or one or more short degenerate primers, and is typically labeled.
  • Sequence identity can be determined by hybridization under stringent conditions, as described in detail above. Nucleic acids having a region of substantial identity or sequence similarity to the provided nucleic acid sequences, for example allelic variants, related genes, or genetically altered versions of the gene, bind to the provided sequences under less stringent hybridization conditions.
  • the sequence of the 5' flanking region can be utilized as promoter elements, including enhancer binding sites that provide for tissue-specific expression and developmental regulation in tissues where the subject genes are expressed, providing promoters that mimic the native pattern of expression.
  • Naturally occurring polymorphisms in the promoter region are useful for determining natural variations in expression, particularly those that may be associated with disease.
  • Promoters or enhancers that regulate the transcription of the polynucleotides of the present invention are obtainable by use of PCR techniques using human tissues, and one or more of the present primers.
  • mutations can be introduced into the promoter region to determine the effect of altering expression in experimentally defined systems.
  • the regulatory sequences can be used to identify cis acting sequences required for transcriptional or translational regulation of expression, especially in different tissues or stages of development, and to identify cis acting sequences and tr ⁇ r ⁇ -acting factors that regulate or mediate expression.
  • Such franscription or translational control regions can be operably linked to a gene in order to promote expression of wild type genes or of proteins of interest in cultured cells, embryonic, fetal or adult tissues, and for gene therapy (Hooper, 1993).
  • RNA fragments are useful as primers for reactions that involve nucleic acid hybridization, as described in detail above. Briefly, pairs of primers will be used in amplification reactions, such as PCR. Amplification primers hybridize to complementary strands of DNA, for example, under stringent conditions, and will prime towards each other. In some embodiments a pair of primers will generate an amplification product of at least about 50 nt, or at least about 100 nt. Algorithms for the selection of primer sequences are generally known, and are available in commercial software packages.
  • the nucleotides can also be used as probes to identify genomic DNA or gene expression in a biological specimen, as described above and as is well established in the art. Briefly, DNA or mRNA is isolated from a cell sample. Detection of mRNA hybridizing to the subject sequence is indicative of gene expression in the sample. The mRNA can be amplified by RT-PCR, using reverse transcriptase to form a complementary DNA strand, followed by polymerase chain reaction amplification using primers specific for the subject DNA sequences.
  • the mRNA sample is separated by gel electrophoresis, transferred to a suitable support, e.g., nitrocellulose, nylon, etc., and then probed with a fragment of the subject nucleotides as a probe.
  • a suitable support e.g., nitrocellulose, nylon, etc.
  • Other techniques such as oligonucleotide ligation assays, in situ hybridizations, and hybridization to probes arrayed on a solid chip may also find use.
  • sequence of a gene according to the subject invention can be mutated in various ways known in the art to generate targeted changes, i.e., changes in promoter strength, or sequence of the encoded protein, etc.
  • the DNA sequence or protein product of such a mutation will usually be substantially similar to the sequences provided herein.
  • the sequence changes can be substitutions, insertions, deletions, or a combination thereof. Deletions can further include larger changes, such as deletions of a domain or exon.
  • the subject nucleic acids can be used to generate transgenic, non- human animals and/or site-specific gene modifications in cell lines; suitable methods are known in the art (Grosveld and Kollias, 1992; Hooper, 1993; Murphy and Carter, 1993; Pinkert, 1994).
  • the invention provides a non- human transgenic animal comprising, as a transgene integrated into the genome of the animal, a nucleic acid molecule comprising a sequence encoding a subject polypeptide in operable linkage with a promoter, such that the subject polypeptide- encoding nucleic acid molecule is expressed in a cell of the animal. Either a complete or partial sequence of a gene native to the host can be introduced.
  • a complete or partial sequence of a gene exogenous to the host animal e.g., a human sequence of the subject invention
  • Transgenic animals can be made through homologous recombination, where the endogenous locus is altered.
  • DNA constructs for homologous recombination will comprise at least a portion of the human gene or of a gene native to the species of the host animal, wherein the gene has the desired genetic modification(s), and includes regions of homology to the target locus.
  • nucleic acid construct is randomly integrated into the genome.
  • Vectors for stable integration include plasmids, refroviruses and other animal viruses, and YACs.
  • DNA constructs for random integration need not include regions of homology to mediate recombination.
  • markers for positive and negative selection are included.
  • a detectable marker such as lac Z can be introduced into a locus at which up-regulation of expression will result in a detectable change in phenotype.
  • Transformed ES or embryonic cells can be used to produce transgenic animals.
  • An embryonic stem (ES) cell line can be a source of embryonic stem cells, or they can be newly obtained from a host animal, e.g., a mouse, rat, or guinea pig.
  • the cells are grown on an appropriate fibroblast-feeder layer or in the presence of leukemia inhibiting factor (LIF).
  • LIF leukemia inhibiting factor
  • the cells are plated for growth onto a feeder layer in an appropriate medium.
  • Cells containing the relevant construct can be detected by employing a selective medium and analyzing them for the occurrence of homologous recombination or integration of the constract. Positive colonies can be used for embryo manipulation and blastocyst injection.
  • Blastocysts are obtained from 4 to 6 week old super-ovulated females.
  • the ES cells are trypsinized, and the modified cells are injected into the blastocoel of the blastocyst. After injection, the blastocysts are returned to each uterine horn of pseudopregnant female animals that proceed to term. The resulting offspring are screened for the constract.
  • chimeric progeny can be readily detected.
  • the chimeric animals are screened for the presence of the modified gene and males and females having the modification are mated to produce homozygous progeny. If the gene alterations cause lethality at some point in development, tissues or organs can be maintained as allogeneic or congenic grafts or transplants, or in in vitro culture.
  • the transgenic animals can be any non-human mammal.
  • the modified cells or animals are useful in the study of gene function and regulation. For example, a series of small deletions and/or substitutions can be made in the host's native gene to determine the role of different exons in biological processes such as oncogenesis or signal transduction. Of interest is the use of genes to constract transgenic animal models for cancer, where expression of the subject protein is specifically reduced or absent. Specific constructs of interest include anti-sense constructs, which will block expression, expression of dominant negative mutations, and gene over-expression.
  • transgenic animals can also be used in functional studies, for example drug screening, to determine the effect of a candidate drag on a biological activity of a subject polypeptide.
  • HG1000026N0 20000_genej ⁇ rediction member 12 Abc-mitochondrial erythroid [Mus 1 musculus] gi
  • HG1000276N0_1000_gene jpredictionl musculus gi
  • HG1000173N0_20000_gene jprediction gi
  • HG1000084N0_10000_gene jprediction protein kinase mitogen activated, kinase 1, p45 1 [Mus musculus]

Abstract

L'invention concerne de nouveaux polynucléotides, des polypeptides associés, des compositions d'acides nucléiques et de polypeptides associées et des modulateurs associés, tels que des anticorps et des modulateurs de petites molécules. L'invention concerne également des méthodes permettant de fabriquer et d'utiliser ces polynucléotides, ces polypeptides, ces compositions associées et ces modulateurs. Ces méthodes sont destinées à des applications diagnostiques, prophylactiques et thérapeutiques. Les compositions et les méthodes selon l'invention sont utiles pour le traitement de troubles prolifératifs, par exemple, les cancers et les troubles inflammatoires, immunitaires, bactériens et viraux.
PCT/US2003/026864 2002-08-29 2003-08-28 Methodes d'utilisation de nouveaux polypeptides humains codes par des polynucleotides WO2004020591A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003265787A AU2003265787A1 (en) 2002-08-29 2003-08-28 Methods of use for novel human polypeptides encoded by polynucleotides

Applications Claiming Priority (68)

Application Number Priority Date Filing Date Title
US40664202P 2002-08-29 2002-08-29
US40665302P 2002-08-29 2002-08-29
US40664602P 2002-08-29 2002-08-29
US40658802P 2002-08-29 2002-08-29
US40658502P 2002-08-29 2002-08-29
US40660802P 2002-08-29 2002-08-29
US40657902P 2002-08-29 2002-08-29
US60/406,646 2002-08-29
US60/406,585 2002-08-29
US60/406,653 2002-08-29
US60/406,642 2002-08-29
US60/406,579 2002-08-29
US60/406,608 2002-08-29
US60/406,588 2002-08-29
US41102302P 2002-09-17 2002-09-17
US41103502P 2002-09-17 2002-09-17
US41104102P 2002-09-17 2002-09-17
US41094802P 2002-09-17 2002-09-17
US41104502P 2002-09-17 2002-09-17
US41095802P 2002-09-17 2002-09-17
US41095902P 2002-09-17 2002-09-17
US41107302P 2002-09-17 2002-09-17
US41105502P 2002-09-17 2002-09-17
US41096102P 2002-09-17 2002-09-17
US41104802P 2002-09-17 2002-09-17
US41110102P 2002-09-17 2002-09-17
US41094902P 2002-09-17 2002-09-17
US41094702P 2002-09-17 2002-09-17
US60/411,045 2002-09-17
US60/410,947 2002-09-17
US60/411,101 2002-09-17
US60/411,055 2002-09-17
US60/410,948 2002-09-17
US60/410,961 2002-09-17
US60/411,048 2002-09-17
US60/411,023 2002-09-17
US60/411,035 2002-09-17
US60/410,958 2002-09-17
US60/411,041 2002-09-17
US60/410,959 2002-09-17
US60/411,073 2002-09-17
US60/410,949 2002-09-17
US46371603P 2003-04-18 2003-04-18
US46370803P 2003-04-18 2003-04-18
US60/463,708 2003-04-18
US60/463,716 2003-04-18
US46720103P 2003-05-02 2003-05-02
US46719903P 2003-05-02 2003-05-02
US60/467,201 2003-05-02
US60/467,199 2003-05-02
US47133603P 2003-05-19 2003-05-19
US60/471,336 2003-05-19
US47243003P 2003-05-22 2003-05-22
US60/472,430 2003-05-22
US47664103P 2003-06-09 2003-06-09
US60/476,641 2003-06-09
US48522403P 2003-07-08 2003-07-08
US48521803P 2003-07-08 2003-07-08
US60/485,218 2003-07-08
US60/485,224 2003-07-08
US48644603P 2003-07-14 2003-07-14
US60/486,446 2003-07-14
US48689103P 2003-07-15 2003-07-15
US60/486,891 2003-07-15
US49334103P 2003-08-08 2003-08-08
US49357703P 2003-08-08 2003-08-08
US60/493,577 2003-08-08
US60/493,341 2003-08-08

Publications (2)

Publication Number Publication Date
WO2004020591A2 true WO2004020591A2 (fr) 2004-03-11
WO2004020591A3 WO2004020591A3 (fr) 2005-03-24

Family

ID=34317894

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/026864 WO2004020591A2 (fr) 2002-08-29 2003-08-28 Methodes d'utilisation de nouveaux polypeptides humains codes par des polynucleotides

Country Status (2)

Country Link
AU (1) AU2003265787A1 (fr)
WO (1) WO2004020591A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US9000127B2 (en) 2012-02-15 2015-04-07 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
US9273111B2 (en) 2004-11-29 2016-03-01 Universite De Lorraine Therapeutic TREM-1 peptides
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
US9663568B2 (en) 2012-02-15 2017-05-30 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
US10179814B2 (en) 2014-07-17 2019-01-15 Novo Nordisk A/S Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity
US11155618B2 (en) 2018-04-02 2021-10-26 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010025098A1 (en) * 1998-03-13 2001-09-27 Incyte Pharmaceuticals, Inc. Human membrane-spanning proteins
US6555654B1 (en) * 1997-04-15 2003-04-29 The Wellcome Trust Limited As Trustee For The Wellcome Trust LDL-receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555654B1 (en) * 1997-04-15 2003-04-29 The Wellcome Trust Limited As Trustee For The Wellcome Trust LDL-receptor
US20010025098A1 (en) * 1998-03-13 2001-09-27 Incyte Pharmaceuticals, Inc. Human membrane-spanning proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BROWN ET AL.: 'Isolation and characterization of LRP6, a novel member of the low density lipoprotein receptor gene family' BIOCHEMICAL AND BIPHYSICAL RESEARCH COMMUNICATIONS vol. 248, no. 3, July 1998, pages 879 - 888, XP002249367 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US10603357B2 (en) 2004-11-29 2020-03-31 Bristol-Myers Squibb Company Therapeutic TREM-1 peptides
US9273111B2 (en) 2004-11-29 2016-03-01 Universite De Lorraine Therapeutic TREM-1 peptides
US10906965B2 (en) 2012-02-15 2021-02-02 Novo Nordisk A/S Methods of treating autoimmune disease or chronic inflammation wtih antibodies that bind peptidoglycan recognition protein 1
US9663568B2 (en) 2012-02-15 2017-05-30 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
US10150809B2 (en) 2012-02-15 2018-12-11 Bristol-Myers Squibb Company Antibodies that bind peptidoglycan recognition protein 1
US10189904B2 (en) 2012-02-15 2019-01-29 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
US9000127B2 (en) 2012-02-15 2015-04-07 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
US10906975B2 (en) 2012-02-15 2021-02-02 Novo Nordisk A/S Methods of treating autoimmune disease or chronic inflammation with antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
US10179814B2 (en) 2014-07-17 2019-01-15 Novo Nordisk A/S Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity
US11072654B2 (en) 2014-07-17 2021-07-27 Novo Nordisk A/S Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity
US11155618B2 (en) 2018-04-02 2021-10-26 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof
US11919954B2 (en) 2018-04-02 2024-03-05 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof
US11952420B2 (en) 2018-04-02 2024-04-09 Bristol-Myers Squibb Company Nucleic acids encoding anti-TREM-1 antibodies

Also Published As

Publication number Publication date
WO2004020591A3 (fr) 2005-03-24
AU2003265787A1 (en) 2004-03-19
AU2003265787A8 (en) 2004-03-19

Similar Documents

Publication Publication Date Title
WO2004020595A2 (fr) Nouveaux polypeptides humains codes par des polynucleotides
WO2004035732A2 (fr) Polypeptides humains codes par des polynucleotides et procedes d'utilisation de ces polypeptides
US7256010B2 (en) Nucleic acid sequences encoding melanoma associated antigen molecules, aminotransferase molecules, ATPase molecules, acyltransferase molecules, pyridoxal-phosphate dependant enzyme molecules and uses therefor
US7745173B2 (en) Histone deacetylase and methods of use thereof
WO2004093804A2 (fr) Polypeptides humains codes par des polynucleotides et methodes d'utilisation associees
US20090239219A1 (en) Telomerase expression repressor proteins and methods of using the same
JP2005503112A (ja) 脂質結合分子
EP2621944A2 (fr) Peptides chimériques comprenant un peptide de pénétration et un domaine de liaison de la sous-unité catalytique de la pp2a à la capsase 9
US20090286954A1 (en) Human cDNA Clones Comprising Polynucleotides Encoding Polypeptides and Methods of Their Use
WO2004020591A2 (fr) Methodes d'utilisation de nouveaux polypeptides humains codes par des polynucleotides
US20070258949A1 (en) Human Cdna Clones Comprising Polynucleotides Encoding Polypeptides and Methods of Their Use
JP4383170B2 (ja) ヒストン脱アセチル化酵素９
WO2004094651A2 (fr) Nouveaux polypeptides humains codes par des polynucleotides
US20220168402A1 (en) PIP4Ks SUPPRESS INSULIN SIGNALING AND ENHANCE IMMUNE FUNCTION THROUGH A CATALYTIC-INDEPENDENT MECHANISM
WO2004038003A2 (fr) Polypeptides humains codes par des polynucleotides et methodes d'utilisation
WO2004039952A2 (fr) Procedes d'utilisation de polypeptides humains codes par des polynucleotides
WO2004046310A2 (fr) Nouveaux polypeptides de souris codes par des polynucleotides et leurs procedes d'utilisation
US7211435B2 (en) Telomerase expression repressor proteins and methods of using the same
WO2005005597A2 (fr) Nouveaux polypeptides de souris codes par des polynucleotides et leurs procedes d'utilisation
WO2004039319A2 (fr) Nouveaux polypeptides humains codes par des polynucleotides
US20030130485A1 (en) Novel human genes and methods of use thereof
WO2004094598A2 (fr) Procedes d'utilisation pour de nouveaux polypeptides humains codes par des polynucleotides
CA2401660A1 (fr) Enzymes metabolisant les lipides
JP2002502264A (ja) サイクリン関連タンパク質
US20030113846A1 (en) Lipid metabolism enzymes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP